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Abstract 
In individuals with asthma, non-adherence to inhaled corticosteroids contributes to increased 
exacerbations, healthcare utilisation and mortality. Understanding the beliefs an individual holds 
about their medicines, illness and about the controllability of their health provides a promising way 
to better understand non-adherence in individuals with chronic conditions. Research to date has 
focussed on bivariate relationships between a specific set of beliefs and medication adherence. This 
approach simplifies the complex, multifaceted nature of medication adherence. I suggest that 
investigating how different beliefs associate with medication adherence in a multivariable model may 
improve understanding of adherence decisions.  
The aim of the thesis is to investigate the relationship between beliefs about medicines, illness 
perceptions and locus of control beliefs with self-reported medication adherence in individuals with 
asthma.  
The first part of the thesis was to identify whether beliefs about medicines, elicited through the Beliefs 
about Medicines Questionnaire (BMQ), were correlated to medication adherence on a population 
level. The BMQ consists of two scales that seek to elicit an individual’s beliefs in the necessity and 
concerns of taking medication. Necessity beliefs reflect medicines being protective of current and 
future health and concern beliefs reflect beliefs about the negative effects of medicines. Beliefs about 
medicines are thought to play a key role in medication-taking, but inconsistent results across different 
conditions and different measures of adherence makes it difficult to conclude the size of the effect at 
a population level. A meta-analysis was conducted to identify whether beliefs in the necessity and 
concerns of medicines, were significantly correlated with medication adherence across different 
conditions. An electronic search was conducted for manuscripts comparing scores from the BMQ to 
measures of medication adherence. Studies were pooled using the random-effects model to produce 
a mean effect size correlation. Studies were stratified for condition, adherence measure, power and 
study design. Ninety-four papers were included and the overall effect size correlation was 0.17 for 
necessity and -0.18 for concerns (p<0.0001). Necessity and concerns beliefs were correlated with 
medication adherence on a population level and across the majority of included conditions. The effect 
sizes were small with a magnitude comparable to other predictors of adherence. Exploring the role of 
beliefs outside the Beliefs about Medicines Framework may improve prediction and understanding 
of medication adherence. 
A cross-sectional study was conducted to explore the relationship between measures of health beliefs 
and medication adherence in individuals with asthma. A total of 198 participants using a preventative 
asthma inhaler for three or more months were recruited from two community pharmacies and via 
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online advertisement. Each participant completed a survey of validated questionnaires consisting of: 
BMQ, Brief Illness Perception Questionnaire (B-IPQ) and the Multi-dimensional Health Locus of 
Control Scale (MHLCS). Medication adherence was elicited using the Medication Adherence Report 
Scale (MARS) and the Asthma Readiness to Change Questionnaire.  
There was a range of beliefs and medication-taking behaviours reported in this sample. We found that 
the mean scores on BMQ, B-IPQ and MHLCS subscales were different compared to studies 
conducted in other chronic conditions, suggesting that interventions to support medication adherence 
in asthma may need to be different to interventions used in other chronic conditions.  
Multivariable regression analysis with interaction effects was performed to discover the 
interrelationships between beliefs and the ways in which these interrelationships may better predict 
adherence behaviour. The identified regression model predicted 39% of the variance in MARS score 
(p<0.0001). Predictors of better medication adherence were: strong necessity beliefs and few 
concerns about medicines (BMQ); perceiving a shorter timeline of asthma (B-IPQ) and; believing 
the doctor to control asthma outcomes (MHLCS). The doctor (MHLCS) subscale was the strongest 
predictor and accounted for the most variance (12%) in adherence scores. There were two significant 
interactions between belief scales: concerns (BMQ) scale interacting with chance (MHLCS) scale 
and understanding (B-IPQ) scale with treatment control (B-IPQ) scale. The results of the regression 
model supports eliciting multiple beliefs and exploring interaction effects as beliefs about medicines, 
illness perception and locus of control beliefs all made unique contributions to model prediction and 
incorporating interaction effects improved prediction of medication adherence.  
To identify beliefs that may be amenable to an intervention to improve adherence, I explored the 
degree to which the regression model could be given a causal interpretation. Using an interventionist 
account of causation, I suggest that improving necessity beliefs about medicines and treatment control 
illness perceptions, reducing concern beliefs about medicines are a strategy to improve medication 
adherence. Doctor locus of control beliefs appear to be causally related to adherence, but these beliefs 
may difficult to intervene upon. 
In conclusion, this thesis contributes to the literature by determining the relationship between beliefs 
about medicines, illness perceptions and locus of control beliefs with medication adherence in 
individuals with asthma. Exploring the causal relationship between beliefs and medication adherence 
has provided hypotheses that can be tested in the future.  
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 INTRODUCTION AND LITERATURE REVIEW 
 Introduction to Medication Adherence in Asthma 
Australia has the highest prevalence of asthma worldwide, with approximately two million 
Australians having a diagnosis of asthma.1-3 Asthma is characterised by chronic airway inflammation 
which commonly presents as symptoms of wheeze, shortness of breath and cough.4 Fortunately, 
significant advances in medicine mean that asthma can be successfully managed through medication, 
which is the cornerstone of therapy.3,4 For most individuals, a long-term inhaled corticosteroid (ICS) 
± long-acting beta2 agonist (LABA), known as a preventer is the mainstay of treatment.
3,5 The aim of 
treatment is to gain full control of symptoms, prevent asthma exacerbations and maintain normal lung 
function.3,6,7 Short-acting beta2 agonists (SABA) or “relievers”, acting as bronchodilators are used 
intermittently for quick acting relief of asthma symptoms (e.g. shortness of breath).5 Current 
guidelines recommend minimal use of SABAs and the need for frequent use (≥ 3 times per week) is 
generally a sign of poorly controlled asthma.5 Because SABAs mask, rather than treat underlying 
inflammation, overuse can increase the likelihood of potentially life-threatening exacerbations.5 A 
large study conducted across 11 different countries (including Australia), found that many individuals 
with asthma overuse their SABA and underuse their ICS.8 A total of 74% of 3415 participants 
prescribed an ICS reported that they used their SABA every day in the week preceding the study 
questionnaire. Only 45% of participants reported being adherent to their ICS.8 Compared to ICS, 
SABAs are inexpensive and easily accessible, being able to be purchased at a pharmacy without a 
prescription in Australia. 
Approximately 50% of adults and children with asthma do not use their ICS regularly, despite strong 
international and national evidence recommending regular use.3,4,9 This contributes to increased 
symptoms, healthcare utilisation and mortality.3,10-12 The majority of asthma morbidity and its 
associated costs in Australia is due to non-adherence.1 Williams and colleagues reported that up to 
60% of all asthma-related hospital admissions could be attributed to less-than-perfect adherence,9 
while Suissa et al. demonstrated that discontinuation of an ICS is detrimental to a patient’s health.11 
In 2003, the World Health Organisation (WHO) reported that medication non-adherence in asthma 
presents a significant threat to the improvements in health outcomes.13 Over a decade later, asthma 
still remains susceptible to non-adherence.3 With such serious consequences, the importance of 
supporting patients in using their ICS is critical.  
Across many chronic conditions including asthma, the beliefs and perceptions a patient holds about 
their medicines, illness and the health care system are considered a central reason for non-
adherence.13-16 Models of health behaviour are useful for describing the beliefs that may affect 
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medication-taking behaviour. Well established models of health behaviour that have been applied to 
medication adherence are the Health Belief Model,17 Common Sense Model,18 Locus of Control,19 
and Stages of Change.20 Each model proposes that the specific beliefs that an individual holds will 
influence the individual’s decision to perform (or not perform) certain health behaviours. This review 
will explore the relationship between theoretically-derived health beliefs and medication adherence, 
to better understand medication-taking in asthma. 
 Medication Adherence  
The WHO defines adherence as: “the extent to which a person’s behaviour —  taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from 
a health care provider”.13 While adherence is the preferred terminology used in the literature, other 
terms include compliance and concordance.21,22 “Compliance” is defined as the extent to which an 
individual follows their prescriber’s instructions, whereas “concordance” represents a shared decision 
made between the patient and prescriber to follow a given treatment regimen.23,24 
Medication adherence is reported as a dichotomous or continuous variable in the literature. 
Dichotomising adherence based on a specific cut-off (e.g. 80%) results in the patient being labelled 
adherent or non-adherent and can be useful for identifying individuals who may benefit from 
adherence support.25-27 However, dichotomising adherence does not differentiate between the 
different types of non-adherence.25 In terms of an individual’s medication-taking, medication non-
adherence is more commonly measured as a continuous variable on a predefined scale, with 
individuals using their medicines in many different ways, varying the dose and/or frequency of 
administration on a daily basis.28  
 Dynamic Nature of Medication Adherence 
Adherence is dynamic in nature and can change over time. Two adherence taxonomies have been 
described by Vrijens et al.29 and Gearing et al.30 and are helpful for understanding the complexity of 
medication-taking behaviour at different stages in the treatment cycle. 
Vrijens and colleagues considers medication adherence as three unique stages of medication-taking: 
initiation, implementation and discontinuation.29 Initiation begins when the patient takes the first dose 
of the medication and continues with the implementation of the dosing regimen. A patient may be 
non-adherent in the initiation stage by choosing not to fill their original prescription. It is estimated 
that 22% of new prescriptions are never filled.31 This is known as non-initiation29 or primary non-
adherence.32 The factors associated with non-initiation in asthma are not well understood as there has 
been very little work conducted in this area.15 When a medication is discontinued after 
implementation, without agreement with the prescribing doctor, this is known as discontinuation.29 
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The time between initiation and immediately preceding discontinuation is labelled medication 
persistence.29 
Gearing et al. conceptualises adherence by defining medication-taking into six dynamic phases.30 
Treatment initiation, similarly described by Vrijens et al.29 begins with a choice to accept or decline 
the treatment.30 Some individuals fill their first prescription and begin a treatment trial, but choose 
to discontinue before the next refill. This is considered immediate non-adherence.30 Rather than 
completely discontinuing medication, many individuals choose to only partially accept treatment, 
filling their prescriptions but altering their dose or dosage regimen and display sup-optimal 
implementation.29,30 Another form of non-adherence behaviour is intermittent treatment adoption, 
where individuals take their medication exactly as agreed upon with their doctor, but their adherence 
is episodic.30 This type of non-adherence behaviour may be particularly relevant to individuals with 
asthma, who may stop their ICS when they have no symptoms and restart when they experience 
exacerbations. Premature discontinuation following treatment adoption occurs when a patient is fully 
adherent but chooses to discontinue their medication prematurely.30 The last phase occurs when the 
patient is fully adherent, taking their medication in the way they agreed upon with their doctor 100% 
of the time.30  
These taxonomies provide a useful and detailed description of adherence behaviour and allows for 
more precise reporting in research. This thesis will use the term ‘medication adherence’ as it has been 
identified as the most relevant and inclusive term and reflects the WHO definition that medication 
adherence is an agreement between the patient and prescribing physician.13,33  
 Magnitude of Medication Non-Adherence in Chronic Conditions 
Medication non-adherence is a global challenge.13 It is estimated that up to half of the patients 
prescribed a medication for a chronic condition do not take it in the way they agreed upon with their 
doctor.13,34 Non-adherence to medication is the main cause of avoidable healthcare costs worldwide 
and it is estimated that a total of 4.6% of global healthcare costs (or $US 269 billion) could be saved 
if people adhered to their medicine regimen.35  
A meta-analysis reported that good medication adherence across a number of different chronic 
conditions was associated with lower mortality.36 Most studies included defined ‘good’ adherence as 
above 75% or 80% adherence. In cardiovascular conditions and breast cancer, less than 80% 
adherence has been associated with higher rates of mortality.37,38 A higher cut-off of 95% was 
generally required in studies of individuals with Human Immunodeficiency Virus (HIV).36 Non-
adherence has also been associated with increased hospitalisations and emergency department use,39 
although the exact percentage of adherence required to prevent these outcomes is not well defined. 
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Further, adherence to medication may be an indicator of overall healthy behaviour. Adherence to 
placebo has been associated with lower rates of mortality compared to non-adherence.36 This suggests 
that those that adhere to their medication are likely to adopt other healthy behaviours that may lead 
to lower rates of morbidity and mortality. Determining the exact contribution of medication non-
adherence to poor clinical outcomes remains difficult to extrapolate.  
In asthma, non-adherence has been linked to a number of poor health outcomes. Less-than-perfect 
(<100%) adherence has been shown to increase the risk of asthma-related hospitalisation.9 Adherence 
rates of less than 80% to an ICS have been associated with poor asthma control (nocturnal symptoms, 
exacerbations and limitation on physical activity)40,41 and the need for ventilation.42 Mortality rates 
have been shown to decrease by 50% in patients using more than 6 canisters of ICS (containing 200 
inhalations per canister) per year compared to those using no ICS.11 The level of adherence required 
to prevent poor health outcomes in a particular individual is likely to vary depending on a number of 
patient factors such as the severity of illness and the medication regimen.  
 Measuring Medication Adherence 
There are a number of measures of adherence that can be divided into direct and indirect methods. 
Opinions as to the best technique vary, each is recognised to have its advantages and limitations. The 
most commonly used measures of adherence are biological measures, pill counting, prescription 
refills and self-report.43,44 
Biological measures include measuring drug concentrations in the body and adding biological 
markers to drugs so that their presence can be detected.43,44 While this technique is objective, it is the 
least acceptable method to patients and only provides a snap shot of adherence in the weeks preceding 
the test.43 This method is rarely used as routine measurement of adherence in clinical practice.  
Medication Event Monitoring Systems (MEMS) are a pill counting device that records the number 
of times a patient opens a medication bottle.45 Similar systems are also available for medication 
blisters packs46 inhalers47 and eye drops.48 MEMS provides continuous and reliable data about the 
timing and frequency of patients opening the MEMS container.49 While there is no guarantee that the 
medication is actually ingested, it would take a committed consumer to “game” the results. 
Prescription refills use pharmacy records to measure how often an individual fills their prescription, 
but face the same challenge as MEMS being unable to determine whether the medicine is actually 
taken.43,44 Using prescription refills to estimate medication adherence can be an affordable method 
for researchers but can often be difficult to accurately measure when patients attend multiple 
pharmacies and with a healthcare system that does not have linkage of prescription records.  
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A relatively new method of measuring adherence is using wirelessly observed therapy.50 This method 
uses an ingestible sensor inside medication to wirelessly feed to an external sensor to confirm 
whether, when and how many doses of prescribed medication were taken by the patient. Currently 
costs limit its use in everyday practice, however this may become the gold standard for measuring 
medication adherence in research as it will be able to confirm whether a dose has been ingested. 
Self-report methods include questionnaires or interviews to elicit a patient’s medication adherence. 
This method is a practical and affordable approach that is used in both the research and clinical 
environment. There are many self-report methods used in the literature and are useful for identifying 
the possible reasons for and barriers to medication adherence.25 A number of different validated scales 
are available to use (e.g. Medication Adherence Report Scale,51 Morisky 4 scale52 and 8 scale53), with 
each having its advantages and limitations.25  
A common limitation of self-report methods is that they can lead a patient to answer in a socially 
desirable way to avoid possible disappointment or judgement from the interviewer.13,54 This means 
they can over estimate medication adherence. For this reason, self-completed questionnaires, posited 
in a non-judgemental manner, are preferred to face-to-face interviews.  
Overall, it is important to note the limitations of each technique and to interpret any results with this 
in mind. The choice of adherence measure used in research or practice is often based upon cost, 
patient acceptability and time taken to use. If possible, using multiple measures is recommended.13 
 Factors associated with Adherence 
There are many factors that have been shown to impact medication adherence in the literature. The 
WHO have categorised common barriers to adherence into five different dimensions.13 The five 
dimensions are: social and economic, health-system, therapy-related, condition-related and patient-
related factors. Factors within these dimensions are commonly identified through statistically 
significant bivariate relationships with a measure of medication adherence in one or more patient 
populations. As described below, these findings are not always consistent and no factor has been 
found to be a consistent, sole predictor of medication adherence.55 The following section will explore 
the commonly reported factors associated with medication adherence and describe some of the 
inconsistencies among these relationships.  
Social and Economic Factors 
Social and economic factors include age, gender, race and socioeconomic status. Age has been shown 
to have a “U-shaped” relationship with medication non-adherence, with non-adherence being more 
common in the young and old.56 This may be due to certain challenges faced at particular ages that 
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can increase the likelihood of non-adherence. For example, the elderly are more likely to have 
multiple chronic conditions that require complex medication regimens and may have more physical 
and cognitive challenges than their younger counterparts.57 On the other hand, adolescents can 
struggle with self-esteem and peer pressure, especially when they have a condition that can limit and 
invade on their lives (e.g. school, sports, dating). This can affect their medication adherence.58 
However, the literature is not consistent about the relationship between age and adherence and it has 
been suggested that age alone may not be an important predictor of adherence.13 Researchers should 
consider the obstacles and particular patient characteristics that can come with certain age groups and 
address these, instead of assuming all patients at a particular age will struggle with medication 
adherence.13  
A review on the impact of race on medication adherence to cholesterol lowering medication found 
that non-white patients generally had lower adherence rates.59 In individuals with heart failure, there 
was no consistent relationship.60 This relationship may be better explained by the beliefs people hold, 
rather than simply race alone.61-63 Exploring the beliefs and attitudes people hold in different races, 
such as trust in the health care system and belief in the use of western medicine may provide a more 
detailed understanding of the reasons behind the observed relationship between race and medication 
adherence. 
The impact of socioeconomic status, and particularly income, often varies depending on the cost of 
medication in different countries.64 The extent that cost impacts medication adherence appears less 
in countries such as Australia where medication is subsidised.64 Generally, increasing the amount the 
patient pays compared to the healthcare system (in Australia, the Pharmaceutical Benefits Scheme) 
is associated with poorer medication adherence.65 A meta-analysis of studies assessing adherence to 
antihypertensive medicines suggested that there is not a reliable relationship between socioeconomic 
status and adherence.66 Similar findings have been reported in asthma.15  
Overall, the literature suggests social and economic factors are not reliable predictors of 
adherence.16,44,67,68  
Health-System Factors 
A number of health-system factors have been shown to influence adherence.55 Poor physician 
communication,16,69 the physician-patient relationship16,44 and lack of trust in doctors and the 
healthcare system70,71 have been associated with non-adherence. Patients want to be involved in their 
health and incorporating their views and requests into the decision often leads to better medication 
adherence.44,72 When patients are involved in their treatment plan it enables them to discuss their 
beliefs about their medicines and illness.73 Physicians should encourage patients to discuss their 
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concerns and perceptions about their condition and treatment.16 In doing so, a patient is able to have 
an informed collaborative choice, which echoes with the WHO definition of adherence and gives the 
patient input into the decision around treatment choice.  
Therapy and Condition Related Factors 
The characteristics of some therapies and conditions appear to put some individuals at a higher risk 
of non-adherence.13,56 Key therapy-related and condition-related predictors of non-adherence include 
side effects of medication (or perceived side effects of medications), complexity of the medication 
regimen and asymptomatic conditions.44,55 Side effects are commonly reported in individuals with 
asthma, with 64% of participants reporting one or more side effects from their ICS in one study.74 
These individuals reported stronger concerns about their medicines and this was correlated to poor 
medication adherence.74 Chapman and colleagues found that adherence rates to antihypertensives and 
lipid lowering medication were lowest in individuals taking the greatest number of other 
medications.75 Overall, across a number of different conditions, those who experience side effects 
from their medication and require multiple daily dosing of their medication are more likely to be non-
adherent.16,73,76-78 However, reducing side effects can be difficult to achieve and simplifying treatment 
alone does not guarantee adherence.79  
Individuals with asymptomatic conditions such as hypertension can have reduced motivation to take 
their medicines.55 Non-adherent patients generally feel no different when stopping their medication 
and this can lead to the misbelief that their medication is not necessary and that there will be no 
serious consequences.80 Believing medication is necessary appears important in asymptomatic 
conditions.80 Recognising that individuals with asymptomatic conditions are more likely to be non-
adherent is an important factor for health professionals to consider. Reinforcing the importance and 
reason behind taking medicine may be one way to support a patient in adhering to their medicines.  
Patient-Related Factors 
Patient-related factors represent the knowledge, beliefs, attitudes, perceptions, expectations and 
resources of the patient.13 These include the patient’s beliefs and perceptions about their treatment, 
illness and the healthcare system, the expectations they hold about the outcomes of treatment and 
their motivation to manage their condition. The relationship between patient-related factors and 
medication adherence has been widely investigated across a number of conditions including asthma,15 
patients taking lipid-lowering medication81 antihypertensives,73 and in older patients with multiple 
comorbidities.14 A patient’s beliefs accounted for the largest amount of variance in adherence in 
patients taking lipid-lowering medication81 and were the most consistent predictor of medication 
adherence in patients with asthma.15  
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Individuals are actively engaging with their medicines, making decisions about modifying their 
regimen to suit their needs; whether that is taking medication only when they have symptoms, altering 
their dose to reduce side effects or using their medication sparingly for financial reasons.82 A patient’s 
beliefs are likely to influence all of these decisions, making them an important factor to consider 
when understanding the reasons behind a patient’s medication-taking behaviour.  
Summary of factors impacting adherence 
The five different dimensions described by WHO are useful for categorising the many factors 
associated with medication adherence. Within these dimensions, there are non-modifiable and 
potentially modifiable factors. This is an important distinction when using this information to inform 
adherence interventions. Steiner suggests it may be harmful to patients to continue to focus on the 
relationship between non-modifiable factors and adherence as we risk imposing stereotypes of the 
typical ‘non-adherer’.68 These stereotypes could influence therapeutic decisions and the physician 
may deny certain medication on the basis of anticipated non-adherence.68 Research should focus on 
modifiable factors to be able to provide potential targets for interventions to support medication 
adherence. 
It is important to highlight that most of the factors discussed are not consistently associated with 
medication adherence. One reason for this is that researchers examine bivariate relationships between 
variables, rather than exploring the way different variables interact to influence medication 
adherence. Although factors associated with medication adherence are separated into different 
dimensions, they are also likely to interact.13 In particular, beliefs are likely to influence behaviour 
across all the dimensions described by WHO. Health beliefs have been found to be important in 
determining the relationship between adherence and: age,80,83 minority status,84 race,85 cost86 and 
health literacy.85 Aikens and colleagues found that patients who do not hold strong beliefs about the 
benefits of their medicines are more likely to be influenced by medication costs,87 while Federman et 
al. reported that those who have poor health literacy are less likely to believe that their asthma is a 
chronic illness and hold more concerns about their asthma controller medicines.85 This suggests that 
it is important to consider non-modifiable factors associated with non-adherence in the broader 
context of an individual’s beliefs about their medicines and the treatment of their condition. Better 
understanding the beliefs and perceptions patients hold about their medicines and illness may inform 
better strategies of supporting medication-taking behaviour.  
 Intentional and Unintentional Non-Adherence 
Medication adherence is often labelled as either an intentional or unintentional decision.88 
Researchers describe intentional non-adherence as a cognitive decision made by the patient to alter 
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their treatment regimen.88 This decision is thought to be influenced by an individual’s beliefs.88,89 In 
contrast, unintentional non-adherence is thought to be related to a patient’s ability or capacity to take 
their medication.88 Individuals who forget to take their dose or refill their repeat prescription, are 
unable to remove medication from packaging and/or cannot afford their medication are labelled 
unintentionally non-adherent.88 The elderly are described to be at greater risk of unintentional non-
adherence.88  
More recently, unintentional non-adherence has also been associated with beliefs in the necessity86,90-
92 and concerns of medicines86,91,93 and perceived affordability of medicines.92 Therefore, 
unintentional non-adherence may not always be ‘accidental’ or ‘random’, as there is considerable 
overlap with the factors associated with intentional non-adherence.94 These studies suggest that 
individuals who do not perceive a need for medication or hold strong concerns about taking their 
medication are more likely to forget to take their medication, be careless with their medication or 
place less importance on refilling their prescription before running out of medication.  
 Medication Adherence Interventions 
A number of reviews have evaluated the effectiveness of various interventions to improve medication 
adherence in chronic conditions.95-100 Adherence interventions vary widely and include simplified 
dosing, behavioural counselling, feedback systems, reminder systems and educational 
interventions.101 A common recurring characteristic among successful interventions is that they are 
complex.98,101 Complex interventions are likely to address a greater number of potential problems, 
but because the separate effects are often not assessed, it is not clear whether all components are 
necessary. 
A common reason interventions fail is that they are not targeted or tailored to the individual.101 
Targeting only individuals who require an intervention (i.e. only non-adherent participants) results in 
greater improvements in medication adherence.102,103 When studies include both adherent and non-
adherent participants they often lack the power required to show a change in adherence or clinical 
outcome.104 The most successful intervention is not going to be able to improve adherence any further 
in completely adherent individuals.  
Interventions that do not tailor the intervention to the participant’s needs may miss the origins for 
non-adherence. As discussed in Section 1.2.4 and 1.2.5, there are many reasons individuals may be 
non-adherent and this may be an intentional or unintentional decision. Complex interventions may be 
more successful because they target more problems. However; a simpler approach may be successful 
if the intervention is tailored to the specific reasons for non-adherence in the individual.101 For 
example, if a patient is non-adherent to their medication due to negative beliefs around the side effects 
10 
 
of medication, using a reminder device or untargeted education is unlikely to improve medication 
adherence. 
Understanding how different factors associate with medication adherence is important to tailor 
interventions for individuals requiring adherence support. Exploring the way different types of beliefs 
associate with medication adherence may be one way to inform tailored interventions for individuals 
with belief-related non-adherence.  
 Section Summary 
This section has described the many reasons why people do not take their medicines in the way they 
agreed upon with their doctor. Across the five dimensions described by WHO, the beliefs a patient 
holds play a central role. Although beliefs most clearly influence adherence when medication non-
adherence is intentional, beliefs can also play a role in unintentional decisions, such as when using 
medicines sparingly because of financial reasons.  
To support individuals with asthma in taking their medicines, a better understanding of the role of 
beliefs in medication-taking behaviour in chronic illness is needed. One approach to this is to explore 
different models of health behaviour. Models of health behaviour provide a theoretical framework for 
describing beliefs that may influence medication adherence.  
 Models of Health Behaviour 
Models of health behaviour attempt to explain cause-effect relationships in health, and as such have 
been used to predict many different behaviours and behaviour changes. Specifically, models of health 
behaviour appear useful for understanding the relationship between beliefs and medication-taking 
behaviour in chronic illness.18,105-107 
Beliefs form an integral part of an individual’s decision-making and are thought to be one of the most 
central and modifiable factors affecting medication adherence.16,108,109 Importantly, changing beliefs 
improves health outcomes.110,111  
The beliefs an individual holds are derived from their experiences, background and culture and are 
grounded in the social and economic context they live in.112 The term ‘belief’ is used in a range of 
ways in the literature. In this thesis, “beliefs” denote a type of attitude a person has towards a 
proposition.113 A proposition is a statement or sentence that says something about the world. 
Propositions are typically either true or false (though, in some circumstances it may not be possible 
to determine whether a proposition is true or false). Examples include “my preventer has side effects” 
and “aspirin thins the blood”. Some examples of health beliefs towards propositions are “I believe 
my medicine is necessary for my health”, “I believe my medicine will cause side effects”, “I believe 
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aspirin thins my blood” and “I believe I got asthma by chance”. The more confidence a person has in 
a proposition to be true, the more likely they are to depend on it in their behaviour.113 Beliefs may 
also have an emotional aspect that can influence behaviour. The belief “I believe my heart medicine 
causes side effects” may influence behaviour differently depending on the emotional connection they 
have, which may be “I worry about the side effects” or “I am not worried about the side effects”. 
Behaviour can be described as the result of the interaction between “what we believe and how feel”.114  
There are a number of models of health behaviour that identify different types of beliefs as key 
determinants of health behaviour, such as adhering to medicine. Commonly applied models of health 
behaviour are: The Health Belief Model,115 The Common Sense Model,116 The Locus of Control 
Model,19 and Stages of Change.20 These models have been used to better understand medication-
taking behaviour in patients with chronic conditions. The Health Belief Model, Common Sense 
Model and Locus of Control Model describe how beliefs may affect behaviour whereas the Stages of 
Change describes how behaviour change occurs. Health behaviour models do not deny that other 
factors (e.g. demographic and cultural factors) may also influence behaviour but rather assume these 
factors are largely mediated through beliefs and attitudes.117 
There are other models of health behaviour that may be relevant for understanding the relationship 
between beliefs and medication-taking behaviour but currently do not have widely used, validated 
tools that could elicit the constructs important in these theories. Other models of health behaviour 
include the Theory of Reasoned Action/Theory of Planned Behaviour118,119 and Self-Efficacy 
Theory.120 These models are yet to be broadly applied to adherence research. 
While there is some overlap between health behaviour models, they offer the opportunity to identify 
different kinds of beliefs that may be related to adherence (or non-adherence). To date, research in 
this area has focused on a single model of health behaviour and how well it predicts medication 
adherence. It is currently not clear whether using multiple models may help us better predict and/or 
understand medication-taking behaviour. 
The following section will describe the theoretical background behind The Health Belief Model, 
Common Sense Model, Locus of Control and Stages of change and present the research investigating 
the relationship between beliefs derived from these theoretical models and medication adherence. As 
there has been limited work conducted in asthma, it was important to broaden the search and explore 
the relationship between beliefs and medication adherence across different chronic conditions. 
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 Health Belief Model  
The Health Belief Model has been used since the 1950’s and is the most widely applied model in 
health psychology.17,121,122 While the Health Belief Model was specifically designed to predict 
preventative health behaviours, it has been applied to many different behaviours, including 
medication adherence.17,106,107,115,123,124 The Health Belief Model assumes that health behaviour 
occurs through a logically ordered thought process, where given the risks, benefits and consequences 
of different behaviours, individuals will choose a behaviour that will improve or maintain their 
health.18 For an individual to modify their current behaviour, they must first perceive that their illness 
is a “health threat”, that they are susceptible to the illness and that becoming ill could have severe 
physical, social and/or emotional consequences.17 These components have a strong cognitive 
component and are said to be at least partly reliant on knowledge and understanding.17 Once a health 
threat has been perceived, the decision to adopt or reject a behaviour (e.g. adhere to medication) 
occurs through a cost-benefit analysis, where the perceived benefits are weighed up against the 
perceived costs (the term cost may be in relation to financial costs or other risks).18  
In applying the Health Belief Model to understanding medication-taking behaviour, the Beliefs about 
Medicines Framework was developed and has been widely applied in the adherence literature.125 The 
Beliefs about Medicines Framework proposes that individuals make decisions about adhering to their 
medication through a cost-benefit analysis, where beliefs in the perceived necessity of a medicine are 
weighed up against beliefs in the perceived concerns of a medicine.17,109,126 Necessity beliefs reflect 
medicines being protective of current and future health (e.g. improved quality of life, reduction in 
symptoms).107 Concern beliefs reflect beliefs about the negative effects of medicines (e.g. disruption 
to daily life, side effects).107  
Importantly, how a patient weighs up the necessity and concerns of their medicines can be very 
different to a health professional.112,115 For example, a doctor may instruct an individual to take 
cholesterol-lowering medication believing it will benefit the patient’s future health and this would 
outweigh any perceived costs such as side effects. However, the patient may see that taking this 
medicine is unnecessary as they have no symptoms and are not seeing any immediate benefits. For 
the patient, a very different cost-benefit analysis is constructed that is not necessarily based solely on 
knowledge but rather the beliefs and perceptions they hold.  
The Beliefs about Medicines Framework is operationalised through the Beliefs about Medicines 
Questionnaire (BMQ).127 The BMQ is widely used, validated and easy to administer. The BMQ 
consists of two subscales that seek to elicit an individual’s beliefs in the necessity and concerns of 
medicines.127 Individuals who believe their medication is necessary for current and long-term health 
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are more likely to adhere to their medication than those who do not endorse these beliefs.109 
Individuals who perceive fewer concerns about their medication, such as believing their medicines 
cause little or no disruptions to daily life, are also more likely to adhere to their medication.109 
Subtracting the necessity subscale score from the concern subscale score generates the necessity-
concerns differential.109 The necessity-concerns differential is said to reflect the cost-benefit analysis 
proposed by the Health Belief Model.109 As individuals may hold both strong necessity and concern 
beliefs at once, the differential can provide a way of determining which belief is the most 
dominant.107,109 A positive score indicates that the individual has higher scores on the necessity 
subscale than the concern subscale. Conversely, a negative score indicates the individual has higher 
scores on the concern subscale than the necessity subscale. When beliefs in the necessity of 
medication outweigh concerns (i.e. a positive differential), the individual is likely to be adherent to 
their medication.109 A limitation of the differential is that it cannot describe the strength of necessity 
or concern beliefs (i.e. whether both are relatively high or low scores on the scale) and is generally 
not used on its own. 
 Relationship between Beliefs about Medicines and Medication Adherence 
Beliefs about medicines have been widely explored in the adherence literature and are thought to play 
a key role in medication adherence.15,107,109 Researchers have investigated the relationship between 
beliefs and medication adherence across many different conditions, including asthma,128-133 
cardiovascular disease,80,134-138 mental illness26,87,139,140 and cancer.141-143 However, some studies have 
found that both necessity and concern beliefs are not predictive of adherence. A number of papers 
have reported that only necessity beliefs were associated with medication adherence131,133,134,144-147 
whereas others have found only concern beliefs to be associated with adherence.139,148-152 In some 
studies, the necessity-concerns differential had a stronger correlation with adherence than necessity 
or concern beliefs alone.109,132,153,154 
To clarify whether both necessity and concerns were correlated to medication adherence on a 
population level, a meta-analysis was conduted and this is described in Chapter 2. The meta-analysis 
found that both necessity and concern beliefs and the necessity-concerns differential were 
significantly correlated to medication adherence across the majority of conditions included in the 
analysis.155 These findings were supported by another meta-analysis published on the topic.156 
 Common Sense Model 
The Common Sense Model of illness is centred on the assumption that people hold beliefs about their 
illness that can impact the decision to adopt certain health behaviours.116,157 The Common Sense 
Model proposes that individuals are goal directed and will take action against anything that may 
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interfere with that goal.18 Similar to the Health Belief Model, individuals are thought to make rational 
decisions in order to close the gap between their current and goal state (i.e. improved health).18 
However; instead of weighing up the perceived benefits and costs, the Common Sense Model 
proposes the way an individual approaches a health threat depends on the cognitive and emotional 
beliefs they hold about their illness, known as illness perceptions.18 People form illness perceptions 
to make sense of their illness and its associated symptoms.107 Individuals use their illness perceptions 
to make ‘common sense’ decisions about their health as a method of coping with the health threat.107 
 An individual may see non-adherence to medication as a common sense behaviour if they do not 
understand the relationship between their illness, their symptoms and the doctor’s instructions. For 
example “Why take my medication when I don’t have any symptoms and I feel fine?” Illness 
perceptions can have both cognitive and emotional aspects that can be triggered by stimuli in the 
environment (e.g. media, family), from within (e.g. symptoms) as well as being based on previous 
illness experiences.18 An individual’s illness perceptions may change over time with new information, 
changes in health status (e.g. when symptoms appear or disappear) and in evaluating the chosen 
behaviour.107,157-159  
The Common Sense Model categorises illness perceptions into five different dimensions; identity, 
timeline, consequences, cause and cure and/or control.157 Identity reflects the amount of symptoms 
perceived to be associated with an illness. Timeline describes the expected duration of the illness 
(acute compared to chronic). Consequences reflect the perceived physical, social and economic 
impact the disease has on the individual. The perceived cause of illness can be gathered from personal 
experiences as well as outside sources such as health professionals, media and family.157 The final 
dimension, cure and/or control, reflects whether an individual believes their illness can be cured 
and/or controlled. This dimension was later divided into separate components; treatment cure/control 
and personal cure/control.128 This change occurred after researchers found that that treatment beliefs 
are likely play a role in certain health behaviours, including non-adherence to medication.107,128 
Treatment cure/control reflects an individual’s belief in their medicine or prescriber’s advice to 
control and/or cure the illness whereas personal cure/control reflects beliefs in one’s own ability to 
cure and/or control their illness.128 For chronic conditions, the focus is on beliefs around 
controllability, rather than cure of illness.  
The Illness Perception Questionnaire (IPQ) was developed to elicit an individual’s illness perceptions. 
160 The questionnaire has six dimensions: identity, timeline, consequences, cause and, treatment 
cure/control and personal cure/control.160 The more recent version, the Illness Perception 
Questionnaire Revised (IPQ-R) was developed to improve validity and reliability issues, include the 
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emotional representations theorised by the Common Sense Model and to evaluate a patients 
understanding of their illness known as “illness coherence”.128 The Brief Illness Perception 
Questionnaire (B-IPQ) is also available to allow a more efficient and practical method for health 
professionals to elicit illness perceptions, whilst maintaining the good psychometric properties seen 
in the extended version.161 A review identified that all three versions are widely used in the adherence 
literature.158 
 Relationship between Illness Perceptions and Medication Adherence 
Illness perceptions are predictive of a number of self-management behaviours in asthma.162,163 To 
examine the relationship between illness perceptions and medication adherence across different 
conditions, Table 1.1 describes the relationship observed in the published literature between each 
dimension and measures of medication adherence, using the IPQ (or one of its revisions). 
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Table 1.1: Reported relationship between each illness perception dimension and medication adherence 
Illness Author(s) 
Sample 
Size 
Questionnaire  
ILLNESS PERCEPTION DIMENSION 
Identity 
Amount of 
symptoms 
experienced 
from illness 
Timeline 
Duration of 
illness (acute 
vs chronic) 
Consequences 
Amount illness 
affects life 
Personal 
control 
Amount of 
control they 
have over 
illness 
Treatment 
control 
Amount 
treatment can 
control illness 
Emotional 
impact 
Amount 
emotionally 
affected/concer
ned about 
illness 
Asthma 
Jessop and 
Rutter164 
330 BAAQ + NS + + + + 
Byer and 
Myers131 
64 IPQ + + NS NS NS NA 
Horne and 
Weinman165 
100 IPQ NS NS -  NS NS NA 
Bipolar 
Disorder 
Hou et al.166 35 IPQ-R NA - -  NS NS NS 
Chronic Pain 
Nicklas et 
al.167 
217 IPQ-R NS + NS - NS NS 
Chronic 
Obstructive 
Pulmonary 
Disease 
Krauskopf et 
al.152 
188 B-IPQ NS NS NS NS NS - 
Cystic Fibrosis Bucks et al.83 38  IPQ-R NA + NS NS + NS 
Diabetes (Type 
2) 
Aflakseir168 102 IPQ-R NA + - NS NS NS 
Ashur et al.169 523 IPQ-R NS NS NS NS + NS 
Barnes et al.170 82 IPQ-R NA NS - NS NS NS 
Broadbent et 
al.171 
157 B-IPQ - NS - NS NS -  
Griva et al.172 64 IPQ - NS NS + + NA 
Searle et al.173 134 IPQ-R NS NS NS NS + NS 
Glaucoma Rees et al.90 131 B-IPQ NS NS NS NS NS NS 
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Illness Author(s) 
Sample 
Size 
Questionnaire  
ILLNESS PERCEPTION DIMENSION 
Identity 
Amount of 
symptoms 
experienced 
from illness 
Timeline 
Duration of 
illness (acute 
vs chronic) 
Consequences 
Amount illness 
affects life 
Personal 
control 
Amount of 
control they 
have over 
illness 
Treatment 
control 
Amount 
treatment can 
control illness 
Emotional 
impact 
Amount 
emotionally 
affected/concer
ned about 
illness 
Haemophilia 
Llewellyn et 
al.174 
65 IPQ + NS NS NS NS NA 
Heart Disease 
Mosleh and 
Almalik175 
254 B-IPQ NS NS NS + + + 
Fennessy et 
al.159 
93 IPQ-R NA + NS NS - NS 
Byrne et al.176 857 IPQ-R NS + NS NS NS NS 
Heart Failure Molloy et al.177 58 IPQ-R NA NS - NS NS NS 
Hypertension  
Chen et al.178 277 IPQ-R NS NS - + + NS 
Lo et al.179 195 IPQ-R NS NS NS NS + NS 
Morrison et 
al.180 
2595 B-IPQ NS NS + + + NS 
Ross et al.80 514 IPQ-R NA NS - - + - 
Zugelj et al.181 97 B-IPQ NS NS NS NS + - 
Inflammatory 
Bowel Disease 
Have et al.182 128 B-IPQ + NS NS NS NS - 
Renal disease 
Kim and 
Evangelista183 
151 IPQ-R NS NA NA NS NS NA 
Rheumatoid 
Arthritis 
Kumar et al.184 180 IPQ NS NS NS + NS NS 
Morgan et 
al.185 
329 IPQ-R NS NS NS NS + NS 
Systemic Lupus 
Daleboudt et 
al.64 
106 B-IPQ NS NS NS NS NS - 
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Illness Author(s) 
Sample 
Size 
Questionnaire  
ILLNESS PERCEPTION DIMENSION 
Identity 
Amount of 
symptoms 
experienced 
from illness 
Timeline 
Duration of 
illness (acute 
vs chronic) 
Consequences 
Amount illness 
affects life 
Personal 
control 
Amount of 
control they 
have over 
illness 
Treatment 
control 
Amount 
treatment can 
control illness 
Emotional 
impact 
Amount 
emotionally 
affected/concer
ned about 
illness 
Secondary 
stroke 
prevention 
Sjolander et 
al.136 
595 B-IPQ NS NS NS NS + NS 
Transplant 
patients 
Kung et al.186 326 B-IPQ - NS - NS + - 
+ indicates that a high score on the illness perception subscale was shown to be positively associated with medication adherence (promotes adherence) 
– indicates that a high score on the illness perception subscale was shown to be negatively associated with medication adherence (hinders adherence) 
NS indicates there was no significant relationship between illness perception subscale and medication adherence 
NA indicates there was no data on the illness perception subscale 
BAAQ: Beliefs About Asthma Questionnaire (based on IPQ)
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From this table, illness perceptions do not appear to have a consistent relationship with medication 
adherence across different conditions. It is important to highlight that study quality varied 
substantially. Sample sizes ranged from 35 to 2595 participants and most studies did not describe 
their power calculation. There were a number of different adherence measures used; most studies 
used a self-report measure.64,80,83,90,136,152,159,164-173,175,176,178-186 Other methods included prescription 
refills131 and measuring drug concentrations in the blood.177 In the study conducted in haemophilia, 
three different measures of medication-taking behaviour that were not been validated were used. In 
comparison, some studies used the Morisky scale80,166,175,179,180 which is well validated and widely 
used.25 Because difference measures of adherence use different cut-offs and are likely to measure 
different medication-taking behaviours, this may be one reason for the differences in the relationships 
reported. Statistical analyses also varied, from comparing means between groups, correlation analysis 
and more complex structural equation modelling. For consistency, we chose to report statistically 
significant relationships reported from bivariate analysis, where possible (see for example, Horne et 
al.165 who reported both correlations and a structural equation model). These differences in study 
design and study quality limits our ability to make any inferences or comparisons about the 
relationship between illness perceptions with medication adherence across different conditions.  
Type 2 diabetes, hypertension, heart disease and asthma were the most commonly studied conditions 
in papers exploring the relationship between illness perceptions and medication adherence. 
In type 2 diabetes, the identity, consequence and treatment control subscales had the most consistent 
evidence. Individuals who perceived their diabetes to have few symptoms (identity) and consequences 
and believed in the treatment (in this instance, medication) to control their condition were more likely 
to be adherent. The negative associations between medication adherence and the identity and 
consequences subscales are unexpected as the Common Sense Model and Health Belief Model both 
suggest if an individual believes their illness can have severe consequences then it would be expected 
that the take actions to reduce this threat, such as adhering to their medicine.17,158,165 A prospective 
study is needed to confirm the direction of the relationship between identity and consequence illness 
perception subscales with medication adherence in type 2 diabetes. A possible explanation is that 
cross-sectional studies are picking up the result of adherence.165 Those who are adherent are more 
likely to experience fewer symptoms, feel better and therefore perceive less consequences than those 
who are non-adherent and possibly more symptomatic.165  
There were some differences in the specific illness perception subscales that were associated with 
medication adherence in individuals with hypertension and heart disease. In hypertension, the 
treatment control subscale was positively associated to medication adherence in all five studies.80,178-
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181 This association may be due to the asymptomatic nature of the disease, making it critical to 
recognise that the condition requires ongoing medication adherence to prevent long-term 
consequences and the ability of being able to use a blood pressure monitor to assess the effectiveness 
of medication. These perceptions would be expected to closely align with necessity beliefs from the 
BMQ as they both appear to relate to beliefs in treatment. In two of the studies conducted in 
individuals with heart disease, perceiving illness to have a chronic timeline was associated with better 
adherence.159,176 This suggests that an individual recognising that heart disease is a long-term, chronic 
condition rather than having an acute or episodic timeline, is more likely to be adherent.  
In studies in asthma there were mixed findings. For two of the three studies, the identity subscale had 
a significant positive relationship with adherence.131,164 Perceiving more asthma-related symptoms 
was associated with better adherence. Individuals often hold the belief that “no symptoms means no 
asthma” and this is associated with poor medication adherence.187 As described by both the Common 
Sense Model and Health Belief Model, the presence of symptoms (which may also indicate more 
severe asthma) may provide motivation to act to avoid the health threat. In this situation, the 
appropriate behaviour is to take their medication.  
Some illness perception dimensions were not widely reported in the literature. These were perceived 
understanding (illness coherence) and perceived cause of illness. In the latest versions of the illness 
perception questionnaires, a perceived understanding subscale was introduced.128 This is not a 
distinct dimension of the Common Sense Model; however, it aims to provide insight into how well 
an individual believes they understand their illness. In transplant patients, patients taking 
antihypertensives and those with rheumatoid arthritis who believed they had a poor understanding 
about their illness had poor adherence.180,184-186 Other findings suggest there is not a strong 
relationship between the understanding subscale and adherence.64,158,167,169 The cause subscale is 
usually analysed as a categorical variable. The perceived cause of illness is generally categorised into 
different factors (e.g. environmental, hereditary) and is thought to be most important in affecting 
behaviour in early stages of an illness.158 Individuals who have lived with their illness for some time 
are less likely to associate the cause of their illness with their health actions.158 Most researchers do 
not investigate the relationship between perceived cause and medication adherence.  
Across different conditions, there is no consistent relationship between illness perceptions and 
medication adherence. A meta-analysis found that illness perceptions alone are not a strong predictor 
of medication adherence within or across different conditions.188 This is not completely surprising as 
the Common Sense Model suggests that for an individual to undertake a positive health behaviour it 
must make ‘common sense’ to them given their illness perceptions.157 Compared to beliefs about 
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medicines, illness perceptions may be more useful for understanding an individual’s adherence 
behaviour, rather than making population level prediction across different chronic conditions. The 
same illness perception may lead one individual to make the decision to adhere to their medication, 
while for another individual it may lead them to not adhere to their medication. This reflects the 
individual nature of non-adherent behaviour and the need to use a personalised approach when 
supporting adherence at the individual level.  
 Locus of Control Model 
Locus of Control is a major component of Social Learning Theory and refers to who or what an 
individual believes is in control of an outcome.19 There are two broad groups that locus of control 
beliefs fall under: internal and external. The belief that an outcome is directly due to one’s own 
behaviour is termed an internal locus of control.189 This is opposed to an external locus of control, 
which indicates the belief that goal attainment occurs because of external forces.189 External locus of 
control can be separated into powerful others (such as health professionals, family and friends) and 
chance or fate.190,191 Rotter proposes that the likelihood of an individual performing a particular 
behaviour depends on whether they hold internal or external locus of control beliefs and whether they 
view the outcome of the behaviour as desirable.19 Generally, if an individual views an outcome as not 
contingent upon their own behaviour (external locus of control), it will not increase the likelihood of 
that behaviour occurring as much as if the outcome was perceived to be due to their own behaviour 
(internal locus of control).19 
The Locus of Control model has been applied to health behaviour to describe who or what an 
individual believes is in control of their health or illness and enables researchers to conceptualise the 
relationship between responsibility/control and health behaviour.189 For example, an individual is 
more likely to exercise if they believe their exercise will contribute to improvements in health and 
the individual perceives the improvement as desirable. If the individual viewed the improved health 
as chance or fate, rather than because of their own exercising, this could lead the individual to believe 
that it is not their behaviour (exercise) that will lead to the outcome (improved health) and are 
therefore more likely to conclude that there is no need to exercise to improve their health. In chronic 
illness, a strong external locus of control is likely to reflect a reliance on the healthcare system or 
chance to control one’s illness whereas an individual with a high internal locus of control would be 
expected to exhibit better self-management.189,192 
The specific effects of locus of control beliefs on health behaviour were not explicitly stated in the 
original theory, however it has since been proposed that individuals with a high internal locus of 
control (belief that an outcome is directly due to one’s own behaviour) and a low external locus of 
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control (belief that an outcome is due to another person, chance or fate) are more likely to exhibit 
better self-management of illness.189 Adhering to prescribed medication can be seen as one way an 
individual might manage their illness. 
Locus of control beliefs have been suggested to be influenced by relatively permanent factors, such 
as demographics and personality traits, and some more modifiable social and cognitive factors.189 
Those with a strong internal locus of control are thought to be more competent, take responsibility 
for their actions and take steps to avoid unwanted events in their life compared to individuals who 
are externally orientated.189A sense of control of one’s health may therefore increase the likelihood 
of engaging in health promoting behaviour.193 This is important in chronic diseases, which generally 
require self-management and adherence to prescribed medication. For example, asthma patients are 
expected to self-manage exacerbations, monitor peak flow measurements and use inhaler devices to 
ensure optimal delivery of medications.194 
The Health Locus of Control scale was developed to elicit the degree an individual is internally and 
externally orientated in terms of health behaviours.195 It was further developed into the 
Multidimensional Health Locus of Control scale (MHLCS) to incorporate the distinction within the 
external control scale (powerful others and chance).191 The MHLCS has been used in the adherence 
literature in patients with chronic diseases.134,148,196,197 There are three variations of the MHLCS 
available: form A, B and C.191,198 Form A and B investigate beliefs about control of current health, 
whereas form C specifically looks at control of current illness and was created to assess disease 
specific locus of control beliefs.198,199 Form C also differentiates the powerful others external locus 
of control into doctor and other (powerful) people.198 This differentiation was due to individuals with 
chronic disease perceiving a difference in potential influence between medically-trained health 
professionals and other people (family, friends).198  
 Relationship between Locus of Control Beliefs and Adherence 
The relationship between locus of control subscales and medication adherence is not as widely 
examined in the adherence literature compared with beliefs about medicines and illness perceptions. 
Table 1.2 describes the result of studies that have explored the relationship between different locus 
of control subscales and medication adherence. Most of the studies do not differentiate between 
powerful others, which means there is very little data available on the relationship between the doctor 
locus of control subscale and medication adherence.  
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Table 1.2: Reported relationships between each locus of control dimension and medication adherence 
Illness Author(s) 
Sample 
Size 
Questionnaire  
LOCUS OF CONTROL DIMENSION 
Internal Doctor 
Other People/ 
Powerful Others 
Chance 
Asthma 
Ahmedani et al.200 1025 MHLCS NS + NS NS 
Apter et al.201 50 MHLCS NS NS NS NS 
Bipolar Disorder Sajatovic et al.202 140 MHLCS NS NA - NS 
Chronic Disease Craig and Wright203 65 MHLCS NS NA NS - 
Chronic Kidney 
Disease 
Theofilou204 168 MHLCS + + NS NS 
Cystic Fibrosis Abbott et al.205 60 HLCS NS NA + + 
Depression Voils et al.206 80 MHLCS NS NA NS NS 
Depressive disorders 
De Las Cuevas et 
al.207 
119 MHLCS NS + NS NS 
Diabetes (Type 2) 
O’hea et al.196 109 MHLCS + NS NS NS 
Morowatisharifabad208 120 Diabetes LCS + NA NS - 
Heart Disease Bane et al.148 122 MHLCS NS NA NS NS 
Heart Failure 
George and 
Shalansky209 
350 MHLCS NS NA NS NS 
 HIV 
Barclay et al.210 140 MHLCS + NA NS -* 
Do et al.211 615 MHLCS NA NA NA - 
Lynam et al.212 189 MHLCS NS NS NS NS 
Molassiotis et al.197 136 MHLCS + NA NS NS 
Hypercholesterolemia  Berglund et al.134 414 MHLCS NS NA NS NS 
Hypertension 
Hong et al.213 588 Modified HLCS + NA NS NA 
Kretchy et al.214 400 MHLCS + NS - NS 
Omeje and Nebo215 100 MHLCS + NS - NS 
Schizophrenia Combes and Ferai216 65 MHLCS + + NS NS 
Transplant recipients 
Lamba et al.217 237 Modified MHLCS NS NS NA NS 
Silva et al.218 88 MHLCS NS NA NS - 
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+ indicates that a high score on the locus of control subscale was shown to be positively associated with medication adherence (promotes adherence) 
– indicates that a high score on the locus of control subscale was shown to be negatively associated with medication adherence (hinders adherence) 
NS indicates there was no significant relationship between locus of control subscale and medication adherence 
NA indicates there was no data on the locus of control subscale 
MHLCS: Multidimensional Health Locus of Control Scale 
LCS: Locus of Control Scale 
HLCS: Health Locus of Control Scale 
*Only in subgroup of younger people (<50) 
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From examining Table 1.2, it can be seen that the internal locus of control subscale is associated with 
better medication adherence in studies conducted in individuals with diabetes,196,208 HIV,197,210 
hypertension,213-215 chronic kidney disease204 and schizophrenia.216 These studies support the theory 
that those with strong internal locus of control beliefs exhibit healthier behaviours by adhering to 
their medicine.  
There is limited evidence for the role of external locus of control beliefs in medication adherence. 
This may be due to a lack of consistency in examining this dimension and most researchers not using 
form C of the MHLCS. Because many studies did not differentiate between other (powerful) people 
such as family and friends, and doctors, we have limited data available on the role of doctor locus of 
control beliefs in medication adherence. These studies also differ substantially in sample size, 
adherence measure used and locus of control scale used.  
Four studies have reported a positive relationship between the doctor locus of control subscale and 
medication adherence.200,204,207,216 It is not clear whether the doctor subscale is eliciting beliefs around 
a particular physician/prescriber or if it represents health professionals in general.  
There were some negative associations reported between the chance locus of control subscale and 
medication adherence,203,208,210,211,218 suggesting that individuals who put their health outcomes down 
to chance or fate are more likely to be non-adherent to their medication. In this situation, individuals 
may see their illness and/or its progression as out of their control, which may lead them to question 
whether their medication is worthwhile.  
 Stages of Change  
Stages of Change is a key component of the Trans-Theoretical Model which was developed in the 
field of psychotherapy to understand the process of change.219 The Trans-Theoretical Model proposes 
that behaviour change occurs through a series of small steps, rather than an all or nothing approach.22 
Behaviour change can involve the initiation, cessation or modification of a particular behaviour.22 
Essentially, the Trans-Theoretical Model states that people change their behaviour by moving through 
different stages, known as Stages of Change.20 
The Stages of Change model proposes that change is a continuous cycle, where individuals may move 
back and forth through different stages several times before behaviour change occurs.220 Individuals 
may relapse at any stage and return to any of the earlier stages. There are five stages that describe an 
individual’s readiness to change: pre-contemplation, contemplation, preparation, action and 
maintenance. Those in the pre-contemplation stage are not intending to change their behaviour 
anytime soon; however, those in the contemplation stage are considering a change in their behaviour. 
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In the preparation stage, individuals are actively planning and preparing to change their behaviour, 
while those in the action and maintenance stage have changed their behaviour and have maintained 
this for at least six months (maintenance stage).219,221 The Stages of Change model suggests that some 
of the beliefs an individual holds will differ depending on which stage of change they are in, and to 
move to another stage, these beliefs must also change.222 An intervention will be most successful if it 
matches the individual’s stage of change and targets all the issues associated with not changing the 
behaviour.222,223 The specific factors that cause individuals to move from one stage to another are not 
well understood and are likely to vary depending on the behaviour that is being changed.222 
Although Stages of Change was developed for use in addictive behaviour, it has been successfully 
applied to non-addictive health behaviours such as dieting, exercise and adhering to 
medication.103,221,224-227 Medication-taking behaviour is thought to follow a stage of change pattern226 
and has been recognised as a potential model to assess an individual’s motivation to adhere to their 
medication.225 When an individual receives a new prescription they are adopting a new behaviour. 
The stage of change model suggests that individuals are in different stages based on their readiness 
to adopt this new behaviour. The Stages of Change model may be useful for assessing readiness to 
adhere as well as current adherence. 
Applying the stage of change theory to adherence interventions may improve understanding on the 
motivation of individuals to adhere to their medication. If the participant has no motivation to adhere 
to their medication it is less likely that an intervention to improve adherence will be effective unless 
it also influences the individual’s motivation. It is also important to note that there is likely to be links 
between an individual’s beliefs related to “stages of change” and the other health beliefs that the 
individual holds.  
 Relationship between Stages of Change and Adherence 
Stages of change has been used to determine individual’s readiness to adhere to their prescribed 
medication in HIV,227-229 asthma,226 depression230 and hypertension.227 
In a cohort of HIV patients, stages of change was predictive of medication adherence when the 
questionnaire was completed at 4 months after medication initiation.229 However, stages of change 
did not predict medication adherence when the instrument was completed at baseline (before 
medication initiation). Baseline stages of change scores may not have been associated with adherence 
because individuals had little experience with the medication and although they may believe they will 
be adherent (preparation or action stage) they will not have experienced any of the possible concerns 
of the treatment (e.g. side effects) which may cause them to be non-adherent.229 On the other hand, 
some individuals may have prior beliefs about the problems associated with treatment (pre-
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contemplation stage), and may intend on being non-adherent, however when the concerns do not 
arise, they continue taking their medication.  
In individuals with asthma, different stages of change were compared to airflow limitation and 
medication adherence.226 Individuals in the pre-contemplation stage lacked willingness to take their 
medicines, displayed little symptoms and minimal airway limitation. These characteristics prevented 
any internal prompts for a behaviour change.226 Individuals in the contemplation and preparation 
stage displayed more signs of airway limitation, which may explain their motivation to start thinking 
about adhering to their medicine. Finally, those in action and maintenance stage had minimal airway 
limitation and better adherence than those in the preparation stage.226 
 Limitations of Applying Models of Health Behaviour in Adherence Research 
There are limitations to using theoretical models to predict and understand medication adherence. 
This section describes two of the key challenges in applying and using health behaviour models to 
understand medication-taking behaviour.  
Inconsistent Prediction across Different Conditions 
Models of health behaviour are one way to describe, predict and/or explain medication-taking on a 
population level. The Health Belief Model, Common Sense Model, Locus of Control Model and 
Stages of Change assume that the behaviours of individuals can be accurately modelled as they are 
rational decision-makers, who make decisions through a deliberative and systematic process based 
on the beliefs or perceptions an individual’s holds. All individuals are expected to value their health 
and are aware of the consequences of their actions. This is particularly pertinent to the Locus of 
Control model which is thought to only be predictive of health behaviour when individuals value their 
health.231 In practice, individuals do not always act rationally and decisions can be based on impulse, 
habit and/or external stimuli.232  
For example, in a patient who has been taking their medication for many years, beliefs about their 
medicines or illness may not be predictive of behaviour because they are in an established routine. If 
medication-taking behaviour becomes habitual, the expected relationship between particular beliefs 
and medication adherence may be different.233,234 Habitual behaviour may be particularly influential 
when patients have been adherent/non-adherent to other medication in the past and therefore continue 
with the same habit, despite holding beliefs that predict adherence (e.g. strong necessity beliefs and 
weak concern beliefs). In this situation, individuals are not acting as rational decision makers and the 
health behaviour models may not accurately describe or predict medication-taking behaviour. 
As shown throughout Section 1.3, even when taking into account poorly powered studies, differences 
in measurement and analysis used, models of health behaviour are not consistently predictive of 
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medication-taking behaviour within and across different conditions. When considering an 
individual’s medication adherence, it seems important to consider the utility of models of health 
behaviour with regards to their particular condition and their previous illness and medication 
experience.    
Relying on a Single Health Behaviour Model 
To date, a significant shortcoming of the adherence literature is that many researchers have relied on 
a single model of health behaviour to explain medication-taking behaviour. Generally, a single model 
of health behaviour does not predict a large portion of variance in medication adherence.124,188 Most 
studies investigate how beliefs derived from one health behaviour model correlate to a measure of 
medication adherence. This has limited our ability to understand how different beliefs come together 
to influence medication-taking behaviour. Models of health behaviour are not all encompassing and 
it should not be expected that one model will completely describe adherence behaviour across 
different conditions and in different situations over time.  
Different models may be able to explain different facets of medication-taking behaviour. Using 
multiple health behaviour models may allow us to better predict and/or understand medication-taking 
behaviour, rather than relying on a single model to explain such a complex behaviour. Individuals 
hold many different beliefs that are all likely to interrelate to influence medication-taking behaviour. 
A systematic review found that no individual health behaviour model could explain more than a 
limited amount of variance in medication adherence.124  
A small number of researchers have investigated how different models of health behaviour predict 
medication adherence through exploring the relationship between beliefs derived from multiple 
models. The Health Belief Model and Common Sense Model have been used to predict adherence in 
asthma,164,165 chronic pain,167 diabetes168 and hypertension.80 The Health Belief Model and Locus of 
Control have predicted adherence in patients taking lipid-lowering medication.134 How the Health 
Belief Model, Common Sense Model and Locus of Control together predict medication adherence is 
yet to be examined. These papers suggest that meaningful relationships between beliefs exist and 
these are an important factor to consider in understanding medication adherence.  
Specifically, beliefs about medicines relate to illness perceptions and locus of control beliefs.134,165,167 
In participants with asthma165 and chronic pain,167 illness perceptions indirectly affected adherence 
through beliefs about medicines. In individuals taking lipid-lowering medication, external locus of 
control beliefs were significantly correlated to beliefs about medicines.134 A strong belief in powerful 
others (e.g. doctor) to control health outcomes was positively correlated with necessity and concern 
beliefs, with necessity having the strongest association.134 Chance locus of control beliefs were also 
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associated with more concern beliefs. The authors did not provide an explanation for why patients 
who believe strongly in doctors and chance to control their health outcomes are more likely to 
perceive more concerns about their medicines.  
In a study of individuals taking antihypertensives, the way beliefs about barriers of medication (e.g. 
side effects, forgetting to take medication) were associated with medication adherence depended on 
an individual’s locus of control beliefs.213 When participants reported having minimal medication 
barriers, those with a strong internal locus of control had better adherence than those who did not. 
However, when medication barriers were reported to be high, those with an internal locus of control 
had the worst adherence.213 The authors proposed that those with an internal locus of control prefer 
to be in control and when medication barriers are high, these individuals may become overwhelmed, 
fear they are losing control and therefore regain control by changing the way they take their 
medication.213  
These studies suggest that exploring relationships between different health beliefs identifies 
important relationships between beliefs and medication adherence. A limitation of the current 
literature is that the way beliefs about medicines, illness perceptions and locus of control beliefs 
interrelate has not been assessed in a single study. Further, these studies suggest causal associations, 
but are not explicit in their hypotheses. This makes it difficult to move forward. Exploring the way 
beliefs interrelate may not only improve prediction of medication adherence but also provide a better 
understanding of why individuals do not adhere to their medication to be able to better tailor 
interventions to improve medication adherence.   
 Evidence for the Effectiveness of Interventions Modifying Health Beliefs to Improve 
Medication Adherence 
While there is a large amount of literature exploring associations between measures of beliefs and 
medication adherence, only a small number of studies have investigated whether modifying beliefs 
results in improvements in medication adherence. 
Characteristics of successful interventions have been to tailor the intervention to the specific beliefs 
the individual holds, rather than a population level intervention. Interventions that only target non-
adherent interventions also appear more effective. In a parallel-group randomised controlled trial, 
individuals identified as non-adherent to their antihypertensive medication received either the 
intervention or control (usual care of monthly outpatient clinic visits).235 In addition to usual care, the 
intervention group received seven weekly sessions of adherence therapy [previously known as 
compliance therapy236], which uses motivational interviewing techniques to change the perceived 
benefits of treatment, modify beliefs and resolve ambivalence towards medication.235,236 The study 
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used the general subscale of the BMQ, which explores beliefs about medicines in general, to inform 
the adherence therapy sessions. At one month follow-up, the intervention had changed beliefs 
(reflected by changes in scores on BMQ), improved adherence (37% increase [pill counts]) and 
improved blood pressure control (23.1mmHg reduction in systolic blood pressure and 15.2mmHg 
reduction in diastolic blood pressure) compared to baseline measures.235 No significant changes were 
observed in the control group. The study was strengthened by using an objective measure of 
medication adherence (pill counts) and relating the intervention to a clinical outcome (blood 
pressure). However, the study was limited by its short follow-up, making it difficult to determine 
whether the improved adherence reflects the intensive time spent with the participants during the 
intervention and if the changes could be sustained long term.  
Another randomised controlled trial recruited only non-adherent individuals with asthma.111 The 
study aimed to modify both medication beliefs and illness perceptions to improve medication 
adherence. Specifically, the intervention group received individualised text messages that aimed to 
counteract beliefs that had previously been shown to be associated with non-adherence in asthma.111 
The type of text message sent depended on individual scores on the B-IPQ and a study specific 
questionnaire about medication beliefs. Eighteen weeks after the intervention, the intervention group 
had changed beliefs about timeline perceptions, personal control perceptions and necessity beliefs 
about medicine to reflect a more accurate medical representation, compared to baseline scores. The 
intervention group at follow up also had improved adherence compared to the control group. A 
limitation of this study was that the researchers did not used a validated tool to measure medication 
adherence. Instead, participants were interviewed and asked about the number of preventer doses 
prescribed by the doctor and the number they have actually taken. This may have led the participant 
to overestimate their adherence, which may have influenced the results of the study.  
Some studies do not measure baseline beliefs, making it difficult to conclude whether changes in 
adherence were because of changes in beliefs or other factors. In a study by Clifford et al., an 
intervention involving pharmacists delivering individualised advice and information to participants 
about the perceived benefits and concerns of taking their medication for their chronic condition via 
the telephone was assessed.237 The study reported that the intervention group (compared to the control 
group) had better self-reported adherence and more positive beliefs about their medicines (necessity 
beliefs), relative to concerns, compared to the control group at four weeks follow up.237 The study 
had a number of limitations, in particular that baseline adherence and beliefs were not measured, the 
study was underpowered due to a high dropout rate and more participants dropped out of the 
intervention group compared to control. 
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Interventions have also been designed around the Stages of Change model to identify an individual’s 
beliefs about wanting to change their behaviour and then to tailor an intervention to suit their stage 
of change.22,238 One approach that has been shown to be effective is using computer systems to tailor 
adherence advice and information based on an individual’s stage of change.221 Using decision rules 
and previously entered information, the system develops adherence interventions that match an 
individual’s stage of change. For example, in an individual in the pre-contemplation stage of change, 
the computer would provide tailored advice around the benefits of taking their medication to help the 
participant consider moving into the contemplation stage of change.221 This intervention essentially 
provides stage-matched guidance on medication adherence. This approach has been used in 
individuals taking cholesterol-lowering medication to move individuals from pre-action stage of 
change (pre-contemplations, contemplation and preparation) to action and maintenance stages of 
change.221 The intervention group also had significantly higher adherence compared to those that did 
not receive stage-matched guidance.221 This intervention has also been used in individuals taking 
antihypertensives to move patients through the stages of change and improve medication 
adherence.103 Unfortunately, the exact advice given is not clear and it is not known whether the 
movement through stages is directly due to changes in certain health beliefs or improving motivation 
due to being involved in an intervention study.  
These small number of studies suggest that modifying beliefs is achievable and can result in 
improvements in adherence. However, the current quality of studies is weak. Studies do not elicit 
multiple beliefs and some do not target non-adherent individuals or tailor the intervention to the cause 
of non-adherence. No study has targeted their intervention to only individuals with belief-related non-
adherent individuals. A better understanding of the way beliefs associate with medication adherence 
may help inform interventions to better address the specific beliefs of individuals with the belief-
related non-adherence.  
1.4 Summary 
Adhering to medication is a complex health behaviour that involves a number of different factors. 
This literature review has focused on exploring the relationship between an individual’s beliefs and 
their medication adherence.  
Models of health behaviour provide a theoretical background for research in medication adherence 
and guide the selection of the key beliefs to elicit from individuals. The Health Belief Model, 
Common Sense Model, Locus of Control Model and Stages of Change have all been used to describe 
the type of beliefs that influence medication-taking behaviour. From these theories, beliefs about 
medicines, illness perceptions and locus of control beliefs have been elicited using validated 
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questionnaires and associated with measures of medication adherence across a number of different 
chronic conditions, including asthma. Even when considering differences in study design, this review 
has highlighted that the way in which these beliefs correlate to adherence is not consistent across 
studies.  
Beliefs about medicines were found to have the most considerable evidence, but findings were not 
consistent across studies which makes it difficult to conclude the effect on a population level. Other 
beliefs explored were illness perceptions and locus of control beliefs. The role of these beliefs in 
medication adherence remains poorly understood, specifically when assessing how beliefs together 
associate with medication behaviour. There is limited literature describing how these beliefs together 
influence medication adherence as most researchers only examined bivariate relationships. The 
application of multiple health behaviour models may improve our understanding of the role of these 
health beliefs in medication-taking behaviour.  
1.5  Aim  
The aim of the thesis is to investigate the relationship between beliefs about medicines, illness 
perceptions and locus of control beliefs with self-reported medication adherence in individuals with 
asthma.  
1.6 Research Questions 
1. How do necessity and concern beliefs elicited by the BMQ correlate with medication 
adherence across multiple patient populations?  
2. What do individuals with asthma believe about their asthma medicines, asthma and the 
controllability of their health as measured by the BMQ, B-IPQ and MHLCS respectively?  
3. What are the bivariate relationships between measures of health beliefs (BMQ, B-IPQ and 
MHLCS) and self-reported medication adherence in a sample of individuals with asthma?  
4. What multivariable model best predicts the relationship between patient characteristics, 
measures of health beliefs (BMQ, B-IPQ and MHLCS) and self-reported medication 
adherence in a sample of individuals with asthma? 
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 META-ANALYSIS OF THE RELATIONSHIP BETWEEN 
BELIEFS ABOUT MEDICINES AND MEDICATION ADHERENCE  
Citation: Foot H, La Caze A, Gujral G, Cottrell N. The necessity-concerns framework predicts 
adherence to medication in multiple illness conditions: A meta-analysis. Patient Educ Couns 2015. 
DOI: 10.1016/j.pec.2015.11.004 
 Chapter Introduction 
This chapter presents a version of a published paper that was produced to address questions regarding 
the relationship between the subscales of the BMQ and measures of medication adherence. Studies 
assessing the relationship between the subscales of the BMQ and medication adherence differ in terms 
of disease, study design, measures of adherence, sample size and methods of analysis. While overall 
there appears to be a relationship between necessity and concern beliefs and medication adherence, 
this finding is not consistent across all studies. In some studies, only necessity beliefs were associated 
with medication adherence and in others only concern beliefs. This made it difficult to conclude 
whether necessity beliefs, concern beliefs and/or the necessity-concerns differential were associated 
with medication adherence in a similar way across different conditions (population level), if there is 
a different relationship between necessity, concerns and adherence in certain conditions, or if 
observed differences in the relationship can be explained by methodological factors (such as size of 
the study or adherence measure).  
This meta-analysis addresses research question one of the thesis: How do necessity and concern 
beliefs elicited by the BMQ correlate with medication adherence across multiple patient populations?  
 Introduction 
There is a large amount of literature suggesting some of the key factors that may be involved in 
medication adherence and these include the patient-physician relationship, condition-related factors 
and patient-related factors.13 Patient-related factors play a strong role and include the beliefs or 
perceptions individuals hold about their treatment, their illness and the health-care system.13,16,24 
Particular focus has been placed on the relationship between medication adherence and the beliefs 
that a person holds towards their medicines.16,109 Medication beliefs most clearly influence adherence 
when medication non-adherence is not accidental or random, but rather a decision made by the patient 
to take their medicines in a different way.92 Medication beliefs are also likely to play a role when 
there are other factors influencing the patient’s adherence, such as the symptoms the patient is 
experiencing, or when making decisions regarding altering their dose to reduce side effects or using 
their medicines sparingly because of financial reasons.112,239 
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The Beliefs about Medicines Framework is derived from the Health Belief Model, which describes 
how beliefs about medicines might affect medication-taking behaviour.109 The Health Belief Model 
proposes that an individual chooses a particular behaviour through a cost-benefit analysis where the 
perceived benefits (e.g. improvements in health) are balanced against the perceived costs (e.g. 
physical pain, loss of time).17,115,126 
A number of tools exist to elicit medication beliefs, including the Brief Medication Questionnaire,240 
The Adherence Estimator241 and the Beliefs and Behaviour Questionnaire.242 The most widely used 
tool is the BMQ which stems directly from the Beliefs about Medicines Framework.107,127. The BMQ 
has two subscale domains: necessity and concerns. A high score on the necessity subscale suggests 
an individual has strong beliefs in the necessity of their medicine and a high score on the concerns 
subscale suggests the individual has strong concerns about the negative effects of taking medicines.127 
Necessity beliefs were thought to promote adherence, while concern beliefs were thought to hinder 
adherence.109 
Another method of relating medication beliefs to medication adherence is by subtracting the BMQ 
concern score from the BMQ necessity score to generate a necessity-concerns differential. A positive 
score indicates the individual has stronger beliefs in the necessity of medication relative to 
concerns.109 The necessity-concerns differential is an important aspect of the Beliefs about Medicines 
Framework as it is a method of illustrating the cost-benefit analysis individuals make in their 
adherence-related decisions as described in the Health Belief Model.109 
As described in Chapter 1, Section 1.3.1.1, scores from the BMQ have been correlated to medication 
adherence across a number of different conditions including asthma,128-133 cardiovascular 
disease,80,134-138 mental illness26,87,139,140 and cancer.141-143 Of the papers correlating beliefs about 
medicines to a measure of medication adherence, some report only the necessity subscale is correlated 
to medication adherence131,133,134,144-147 while others have found only the concern subscale to be 
correlated to medication adherence.139,148-152 In some studies, the necessity-concerns differential was 
shown to have a stronger correlation with adherence than necessity or concerns alone.109,132,153,154 
From these findings, it is unclear whether each of these scales — necessity, concerns and the 
necessity-concern differential — correlate with adherence on a population level. A recently published 
meta-analysis by Horne and colleagues156 found the relationship between necessity and concern 
beliefs and medication adherence remained significant when stratified by country published, sample 
size and type of adherence measure used. It was not clear in their post-hoc analysis whether this 
relationship was different between patient conditions.  
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It is important to confirm whether in specific conditions the relationship between necessity and 
concern subscale and medication adherence is changed. Each condition has its unique set of 
challenges, which can be due to the use of different medicines, symptoms of the condition or 
treatment, expected or actual outcomes and how it affects an individual’s quality of life. All these 
factors can affect the way in which an individual conceptualises their condition, its associated 
symptoms, the treatment and treatment outcomes.18 Given these distinct differences between 
illnesses, it could be postulated that the way necessity, concerns and/or the necessity-concerns 
differential correlate to adherence is also different. The condition in itself may be one variable that 
influences how medication beliefs affect an individual’s adherence. By exploring whether the 
condition an individual has impacts the relationship between medication adherence and beliefs about 
medicines may improve understanding in this area.  
This meta-analysis investigated whether the necessity subscale, concern subscale and the necessity-
concerns differential are correlated with medication adherence. We also set out to assess whether the 
correlation between BMQ subscales and adherence varied across different conditions, measures of 
adherence, power and study design. This study also provides an opportunity to extend the findings 
presented by Horne and colleagues156 who did not assess the relationship between the necessity-
concerns differential and adherence. 
 Method 
This study was conducted and prepared in accordance with the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) statement.243 
 Eligibility Criteria  
Peer-reviewed manuscripts indexed in Web of Science, EMBASE, PubMed or CINAHL utilising the 
BMQ were included if they were full text original research published in English, participants were 
aged 18 years or older and the paper reported the relationship between any measure of adherence and 
beliefs about medicines. All study designs were included. Studies that changed, added or removed 
questions from the BMQ without evidence of questionnaire validation were excluded. We also 
excluded validation studies, protocols and conference abstracts. Results that could not be accurately 
converted to the common effect size by either calculation or through personal communication with 
the authors were also excluded.  
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 Search Strategy  
A systematic search of four electronic databases (Web of Science, EMBASE, PubMed and CINAHL) 
was conducted for manuscripts utilising the BMQ and comparing it to a measure of medication 
adherence. A date restriction was applied for all searches (1999-Present). The last search was 
conducted on the 17th March 2015. Additional papers were also selected from bibliographies of 
identified papers. Subject headings were used for adherence where available and truncation was used 
for the remaining keywords to include any synonyms and variations of the word. The Boolean 
operators “AND” or “OR” were also used. 
The following search terms were used in all databases: (adheren* OR complian* OR concordan*) 
AND (medication* OR medicine* OR treatment*) AND (belief* OR BMQ OR beliefs about 
medicine questionnaire).  
 Study Selection 
The first author (HF) screened all retrieved studies for eligibility. To ensure the screening process 
was accurate and reproducible, a second author (ALC) independently screened 10% of all retrieved 
studies.  
 Data Extraction  
The coding was undertaken using a structured table. The items extracted from the studies included: 
sample size, illness population, method of assessing adherence, study design, statistics used and 
reported findings. We contacted 28 authors for additional information. Eight authors did not reply 
and six authors could not provide any further unpublished information. 
 Meta-Analysis 
R Studio software version 3.1 was used for all statistical analyses in the review.244 The meta-analysis 
tested the association between medication adherence and three BMQ-related scales: 1) necessity 
subscale, 2) concerns subscale and 3) necessity-concern differential score. 
Pearson’s correlation (r) was chosen for the common effect size as it best represents the strength and 
direction of association between the two continuous variables. In some manuscripts, the correlation 
was not directly reported and needed to be estimated from other reported data using standard 
methods.245 If this was not possible, authors were contacted to obtain the appropriate data. Pearson’s 
correlation was transformed into Fisher’s z for each study before combining studies. This approach 
is recommended to give a more symmetrical data set.245 All results reported in the paper have been 
transformed back to r for ease of interpretation.  
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Some studies reported more than one effect size (e.g. effect size at two time points). To ensure that 
each effect size in the meta-analysis was independent of each other, only one effect size from each 
study was used. For papers that reported multiple time points, the baseline results were chosen to 
prevent the influence of the study intervention. In non-interventional longitudinal studies that 
included initiation of a medication the later time point was chosen. An individual’s response to the 
BMQ may be different at medication initiation compared to later time points. Including data from 
later time points for non-interventional longitudinal studies ensures that the included data is more 
comparable to the other studies included in the meta-analysis. If more than one adherence measure 
was used and there was no missing data from either measure, the mean correlation between the two 
was reported. This was done because all measures of adherence were deemed relevant to the study 
aim and most importantly, to avoid non-independence.245 If missing data existed, only the measure 
with full results was included in the analysis. If results were separated based on certain characteristics 
(e.g. gender), a weighted mean correlation was calculated to ensure that the subgroup with the larger 
sample size received more weighting. Lastly, when multiple subgroups were involved and individuals 
could be in more than one group (i.e. subgroups based on prescribed medicines and the individual 
was on more than one prescribed medicine), the group with the largest sample size was chosen.  
The random-effects model was used in the meta-analysis because of the expected heterogeneity 
between studies and to provide a more conservative approach.245 The random-effects model accounts 
for within-study variance and between-study variance (tau-squared [τ2]). Hedges Ԛ test was used to 
test for the existence of heterogeneity and the I2 index was used to evaluate the amount of 
heterogeneity between studies.245 
Funnel plots were examined visually and formally with Egger’s test to evaluate the effect of 
publication bias in the meta-analysis.246 
 Assessment of Risk of Bias within Studies 
The effect size was examined according to each of the following quality components: measure of 
adherence, power and study design. 
Measures of adherence were categorised as either objective (e.g. MEMS, prescription refills), 
validated self-report method or unvalidated self-report method. Measures of adherence that were 
categorised as ‘validated self-report method’ were questionnaires that had previously shown evidence 
of some form of validation, such as previously being compared to objective measures of adherence 
(e.g. Medication Adherence Questionnaire [MAQ]52). In comparison, measures categorised as 
‘unvalidated’ had no evidence of validation. These were often study-specific measures or had 
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added/removed questions of established questionnaires (e.g. adding questions to the MAQ). Studies 
that used more than one measure of adherence were classified as mix. 
Studies with 85 or more participants were categorised as having high power. Studies with less than 
85 participants were categorised as having low power. This sample size differentiation was based on 
the ability of the sample to detect a medium effect size correlation (0.3) with alpha value of 0.05 and 
80% power.  
Lastly, cross-sectional studies were compared to those with a longitudinal design.  
 Sub-Group Analysis 
To explore differences in effect size, the analysis was stratified by condition. Studies that used 
participants without a defined illness were excluded from the analysis. Differences in effect sizes 
between conditions were assessed by comparing 95% confidence intervals between each condition 
and with the overall effect size.  
 Results 
 Study Selection 
A total of 3607 records were identified through database searches. Eleven additional records were 
found through bibliographies of identified studies. 3206 records were excluded after removing 
duplicates and screening titles and abstracts of studies for relevance. This left 412 full-text records 
that were assessed for eligibility. Of these papers, 318 papers were excluded. Reasons for exclusion 
are provided in Figure 2.1. This left 94 papers published between 1999 and 2015 to be included in 
the meta-analysis. Of the 94 papers analysed, 91 were able to be included in the necessity meta-
analysis, 89 in the concerns meta-analysis and 25 papers in the necessity-concerns differential meta-
analysis.  
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Figure 2.1: Flow diagram illustrating different phases of data collection  
k, number of studies 
a Reasons for exclusion: did not use BMQ or modified BMQ without evidence of validation 
(k=130), conference abstract (k=72), did not investigate the relationship between individual’s 
medication beliefs and adherence to medicine (k=54), not a peer reviewed article (k=25), could not 
calculate an effect size through paper or communication with author (k=10), only investigated 
general subscales of BMQ (k=10), pilot study (k=5), not in English (k=4), protocol (k=4), used 
same participants of a previously published and included paper (k=4). 
 
Records identified through database searching (k =3607)
Records identified through bibliographies (k=11) 
Records remaining after duplicates removed 
(k=412)
Records included in meta-analysis (k=94)           
Necessity meta-analysis (k=91)   
Concerns meta-analysis (k=89)  
Necessity-Concerns Differential meta-analysis (k=25)
Records excluded (k= 318)a 
I Records excluded from screening 
title and abstract (k= 3206) 
 en taking my asthma 
medication as prescribed in 
the past month, and do not 
intend to do so in the next 
month. 
 I have not been taking my 
asthma medication as 
prescribed in the past 
month, but am thinking 
about doing so in the next 
month. 
 I have not been taking my 
sthma medication as 
prescribed in the past 
month, but plan do so in the 
next month. 
 I am taking my medication 
as prescribed. 
 I have been taking my 
asthma medication as 
prescribed in the past 
month, and plan to continue 
doing so in the next month.  
 
Here are some ways in 
which people have said 
that they use their 
medicines 
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 Study Characteristics 
Characteristics of the included studies are shown in Table 2.1. The studies differed substantially in 
sample size, patient population, study design and adherence measure. Sample sizes ranged from 33 
to 1871 participants (mean=256, median=181). The most common conditions studied were 
cardiovascular disease (k=16) and mental illness (k=14). Nine studies enrolled participants with a 
diverse range of chronic diseases and most of these patients had multiple co-morbidities. There were 
82 cross-sectional studies and 12 longitudinal studies included in the meta-analysis. Self-report was 
the main method of measuring adherence (k=87) with the Medication Adherence Report Scale 
(MARS)247 most commonly used (k=17). Other methods used to measure adherence were 
prescription refill data (k =6), drug concentrations in the body (k=3) and MEMS (k=3). Seventeen 
studies used more than one measure of adherence (as recommended by WHO13) Seven studies used 
an altered version of the BMQ that had previously been validated.  
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Table 2.1: Characteristics of studies included in meta-analysis  
Study Condition Study design N Adherence measure 
Effect size 
correlation 
Axelsson et al 2013248 Asthma Cross-sectional 516 MARS N: 0.41 C:-0.15 
Byer & Myers 2000131 Asthma Cross-sectional 64 
self-report (unknown number of 
items) + number of preventer 
prescriptions 
N: 0.44 
Emilsson et al 2011132 Asthma Cross-sectional 35 MARS 
N: 0.38 C:-0.16 
NCD: 0.42 
Horne & Weinman 2002128 Asthma Cross-sectional 100 9 item MARS N: 0.32 C:-0.43 
Menckeberg et al 2008130 Asthma Cross-sectional 233 MARS + prescription refills 
N: 0.36 C:-0.13 
NCD: 0.38 
Sofianou et al 2013129 Asthma Cross-sectional 242 10 item MARS N: 0.25 C:-0.24 
Van Steenis et al 2014133 Asthma Cross-sectional 90 
4 item self-report + prescription 
refills 
N: 0.13 C: 0.02 
Arriola et al. 2014143 Breast cancer Cross-sectional 200 MARS** N: 0.20 C:-0.32 
Grunfeld et al 2005142 Breast cancer Cross-sectional 110 1 item self-report N:0.26 
Bhattacharya et al 2012141 
Breast and colorectal 
cancer 
Cross-sectional 43 MARS 
N: 0.09 C:-0.15 
NCD: 0.18 
Bane et al 2006148 
Cardiovascular disease 
(mixed) 
Cross-sectional 122 4 item self-report 
N: 0.00 C:-0.18 
NCD: 0.18 
Byrne et al 2005176 
Cardiovascular disease 
(mixed) 
Cross-sectional 933 MARS N: 0.25 C:-0.11 
Allen LaPointe et al 2011249 
Cardiovascular disease 
(ACS) 
Longitudinal 973 2 item self-report 
N: 0.06 C:-0.13 
NCD: 0.13 
Sud et al 2005144 
Cardiovascular disease 
(ACS) 
Cross-sectional 208 MAQ N: 0.15 C:-0.06 
Khanderia et al 2008250 
Cardiovascular disease 
(Coronary artery bypass 
surgery) 
Cross-sectional 132 MAQ N: 0.01 C:-0.15 
De Smedt et al 2012137 
Cardiovascular disease 
(Heart Failure) 
Cross-sectional 250 
5 item self-report adherence 
scale of SECope questionnaire 
N: 0.03 C: -0.09 
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Study Condition Study design N Adherence measure 
Effect size 
correlation 
Percival et al 2012251 
Cardiovascular disease 
(Heart Failure) 
Longitudinal 43 MARS 
N: 0.34 C:-0.21 
NCD: 0.27 
George & Shalansky 2007209 
Cardiovascular disease 
(Heart Failure) 
Cross-sectional 350 Prescription refills N: 0.10 C:-0.01 
Berglund et al 2012134 
Cardiovascular disease 
(Hypercholesterolemia) 
Cross-sectional 414 MAQ N: 0.22 C: 0.08 
Unni & Farris 2011135 
Cardiovascular disease 
(Hypercholesterolemia) 
Cross-sectional 420 MAR scale N:-0.01 C:-0.31 
Maguire et al 2008252 
Cardiovascular disease 
(Hypertension) 
Cross-sectional 326 RAM              C:-0.14 
Rajpura and Nayak 2014138 
Cardiovascular disease 
(Hypertension) 
Cross-sectional 117 MAQ 
N: 0.25 C:-0.23 
NCD: 0.30 
Ross et al 200480 
Cardiovascular disease 
(Hypertension) 
Cross-sectional 514 MAQ N: 0.26 C:-0.12 
Ruppar et al 2012149 
Cardiovascular disease 
(Hypertension) 
Longitudinal 33 MEMS N: 0.04 C:-0.35 
O'Carrol et al 2011253 
Cardiovascular disease 
(Stroke) 
Cross-sectional 180 MARS N:-0.01 C:-0.40 
Sjolander et al 2013136 
Cardiovascular disease 
(Stroke) 
Cross-sectional 595 MARS N: 0.08 C: -0.14 
AlHewiti 2014254 Chronic disease Cross-sectional 408 MMAS N: 0.53 C:-0.67 
Clifford et al 200889 Chronic disease Longitudinal 181 1 item self-report 
N: 0.22 C:-0.23 
NCD: 0.29 
Horne & Weinman 1999109 Chronic disease Cross-sectional 324 4 item self-report 
N: 0.21 C:-0.33 
NCD: 0.41 
Iihara et al 2010255 Chronic disease Cross-sectional 151 2 item self-report N: 0.15 C:-0.09 
Jamous et al 2014256 Chronic disease Cross-sectional 187 MMAS N: 0.03 C: -0.02 
Mahler et al 2012257 Chronic disease Cross-sectional 348 MARS N: 0.20 C:-0.18 
Phatak and Thomas 2006258 Chronic disease Cross-sectional 250 MMAS N: 0.12 C:-0.39 
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Study Condition Study design N Adherence measure 
Effect size 
correlation 
Sirey et al 2013259 Chronic disease Cross-sectional 299 MAQ 
N: 0.04 C:-0.20 
NCD: 0.16 
Krauskopf et al 2014152 
Chronic Obstructive 
Pulmonary Disease 
(COPD) 
Cross-sectional 
(part of a 
longitudinal study) 
188 10 item MARS N: 0.03 C:-0.44 
Aflakseir 2012168 Diabetes (Type 2) Cross-sectional 102 MARS* N: 0.14 C:-0.44 
Barnes et al 2004170 Diabetes (Type 2) Cross-sectional 82 MARS* + 2 item self-report N: 0.36 C: 0.14 
de Vries et al 2014260 Diabetes (Type 2) Cross-sectional 133 MARS N:-0.08 C: -0.13 
French et al 2013261 Diabetes (Type 2) Longitudinal 453 MARS N: 0.07 C: -0.18 
Schoenthaler et al 2012262 Diabetes (Type 2) Cross-sectional 608 Prescription refills N: 0.08 C: 0.04 
Sweileh et al 2014263 Diabetes (Type 2) Cross-sectional 405 MMAS N: 0.13 C:-0.27 
Kemp et al 2007264 Epilepsy Cross-sectional 37 drug concentrations N:-0.22 C:-0.14 
Nakhutina et al 2011265 Epilepsy Cross-sectional 72 MAQ + 1 recall question N: 0.04 C:-0.18 
Rees et al 201090 Glaucoma Cross-sectional 131 RAM N: 0.18 
Rees et al 2014266 Glaucoma Cross-sectional 475 RAM N: 0.13 
Llewellyn et al 2003174 Haemophilia Cross-sectional 65 
3 measures: adherence to 
frequency of prophylactic 
infusion; adherence to 
recommended ‘on demand’ dose; 
adherence to recommended dosea 
N: 0.44 C:-0.14 
Brown et al 2013267 HIV Cross-sectional 116 VAS N: 0.22 
Cooper et al 2011268 HIV Longitudinal 234 MASRI N: 0.17 
Gauchet et al 2007147 HIV Cross-sectional 127 16 item self-report N: 0.31 C:-0.04 
Gonzalez et al 2007269 HIV Longitudinal 325 
ACTG questionnaire + MEMS + 
viral load 
N: 0.16 C:-0.22 
Horne et al 2004270 HIV Cross-sectional 114 1 item self-report 
N: 0.15 C:-0.18 
NCD:0.23 
Horne et al 2007271 HIV Longitudinal 136 VAS N: 0.23 C:-0.36 
Sumari-de Boer et al 2012272 HIV Cross-sectional 201 
Prescription refills + self-report 
(unknown number of items)b 
N:0.10 C:-0.07 
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Study Condition Study design N Adherence measure 
Effect size 
correlation 
Uuskula et al 2012273 HIV Cross-sectional 144 
Self-report 3-day recall of doses 
missed 
N: 0.08 C: -0.24 
Ediger et al 2007274 
Inflammatory Bowel 
Disease 
Cross-sectional 326 MARS N: 0.14 C: -0.08 
Horne et al 2009275 
Inflammatory Bowel 
Disease 
Cross-sectional 1871 4 item MARS N: 0.35 C:-0.22 
Selinger et al 2013276 
Inflammatory Bowel 
Disease 
Cross-sectional 356 4 item MARS N:0.29 C: -0.08 
Daleboudt et al 201164 Lupus Cross-sectional 106 
Part A of MASRI (5 item self-
report) + VAS + 4 item MARSc 
            C: -0.23 
Peters et al 2001277 Marfan syndrome II Cross-sectional 174 3 item self-report 
            C:-0.18  
NCD: 0.12 
Aakre et al 2012278 Mental Illness (mixed) Cross-sectional 44 BMQ N: 0.21 C:-0.06 
Lupattelli et al 2015279 
Mental Illness in pregnant 
women (mixed) 
Cross-sectional 160 MMAS 
N: 0.21 C:-0.21 
NCD: 0.28 
Clatworthy et al 200926 
Mental Illness (Bipolar 
Disorder) 
Cross-sectional 223 MARS N: 0.20 C:-0.26 
Hou et al 2010166 
Mental Illness (Bipolar 
Disorder) 
Cross-sectional 35 MAQ N:-0.04 C:-0.11 
Aikens and Klinkman 2012145 
Mental Illness 
(Depression) 
Longitudinal 163 
BMQ + STAR*D Medication 
Adherence Questionnaire 
N: 0.26 C:-0.08 
Aikens et al 200587 
Mental Illness 
(Depression) 
Cross-sectional 81 
3 items from BMQ to measure 
recent percentage of adherence + 
MAQ 
N: 0.25 C:-0.32 
Al Jumah et al 2014139 
Mental Illness 
(Depression) 
Cross-sectional 403 MMAS N: 0.008 C:-0.40 
Brown et al 2005280 
Mental Illness 
(Depression) 
Cross-sectional 
(baseline results of 
a longitudinal 
study) 
192 MAQ N: 0.08 C:-0.16 
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Study Condition Study design N Adherence measure 
Effect size 
correlation 
Fawzi et al 2012153 
Mental Illness 
(Depression) 
Cross-sectional 108 MARS** 
N: 0.34 C:-0.34 
NCD: 0.50 
Maidment et al 2002281 
Mental Illness 
(Depression) 
Cross-sectional 67 
1 item Global Adherence 
Measure assessed by interviewer 
N: 0.39 C:-0.36 
Russell and Kazantzis 2008140 
Mental Illness 
(Depression) 
Cross-sectional 85 MARS 
N:0.03 C:-0.34 
NCD:0.24 
De las Cuevas et al 2013282 
Mental Illness (Outpatients 
with mood disorders) 
Cross-sectional 140 MAQ N:-0.06 C:-0.19 
Beck et al 2011283 
Mental Illness 
(Schizophrenia) 
Cross-sectional 150 
Adherence section in SES + 
BARS (percent in last week) 
N: 0.23 C:-0.15 
Jonsdottir et al 2009284 
Mental Illness (Bipolar 
and Schizophrenia) 
Cross-sectional 280 VAS + drug concentrations N: 0.34 C:-0.15 
Hedenrud et al 2008285 Migraine Cross-sectional 174 MARS 
N:-0.08 C:-0.14 
NCD: 0.06 
Nicklas et al 2009167 
Non-malignant chronic 
pain 
Cross-sectional 217 
5 item MARS + 1 study-specific 
item 
N: 0.19 C:-0.12 
Unni and Farris 201193 Older adults 
Cross-sectional 
(two time points) 
1061 MAQ N: 0.04 C:-0.22 
Kendler et al 2014286 Osteoporosis Longitudinal 250 
MEMS + received Denosumab 
injection by nurse 
N: -0.06 C:-0.07 
NCD: 0.00 
Vytrisalova et al 2015287 Osteoporosis Cross-sectional 363 Modified MMAS N:0.12 
Gatti et al 2009288 Pharmacy clients Cross-sectional 275 MMAS N: 0.03 C:-0.14 
Wileman et al 2011289 Renal dialysis patients Cross-sectional 76 MAQ + drug concentrationsd 
N: 0.25 C:-0.06 
NCD: 0.25 
Wileman et al 2014290 Renal dialysis patients 
Cross-sectional 
(baseline results of 
a longitudinal 
study) 
112 MARS 
N: 0.35 C:-0.15 
NCD: 0.34 
Horne et al 2001151 Renal dialysis patients Cross-sectional 47 1 item self-report N: 0.03 C:-0.39 
Neame &Hammond 2005150 Rheumatoid Arthritis Cross-sectional 331 1 item from RAI 
N:-0.02 C:-0.18 
NCD: 0.17 
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Study Condition Study design N Adherence measure 
Effect size 
correlation 
Treharne et al 2004146 Rheumatoid Arthritis Cross-sectional 85 
CQR + 2 items from RAM + 1 
study-specific item e 
N: 0.69 C:-0.13 
de Thurah et al 2010291 Rheumatoid Arthritis Longitudinal 91 CQR N: 0.29 C:-0.05 
van den Bemt et al 2009292 Rheumatoid Arthritis Cross-sectional 228 
CQR + MARS + 1 item 
interview question d 
N: 0.11 C:-0.05 
Zwikker et al 2014293 Rheumatoid Arthritis Cross-sectional 580 CQR 
N: 0.03 C: 0.00 NCD: 
0.03 
Iudici et al 2014154 Systemic Sclerosis Cross-sectional 92 MAQ 
N: 0.22 C:-0.19 
NCD: 0.37 
Butler et al 2004294 Transplant recipients Cross-sectional 58 Electronic monitoring N: 0.27 C: -0.12 
Chisholm-Burns et al 2012295 Transplant recipients Cross-sectional 512 ITAS 
N: 0.18 C:-0.12 
NCD: 0.18 
Griva et al 201291 Transplant recipients Cross-sectional 218 MARS + drug concentrations 
N: 0.48 C:-0.24 
NCD: 0.45 
Kung et al 2012186 Transplant recipients Cross-sectional 326 ITAS N: 0.13 C:-0.19 
Massey et al 2013296 Transplant recipients Longitudinal 106 BAASIS Interview N: 0.19 C:-0.18 
Moshkovska et al 2009297 Ulcerative Colitis Cross-sectional 169 
12 item self-report + drug 
concentrations 
N: 0.11 C:-0.09 
N = number of participants in study, N=Correlation between BMQ Specific necessity subscale and medication adherence, C= Correlation between BMQ Specific concerns subscale and medication adherence, 
NCD: Correlation between necessity-concerns differential and medication adherence. 
a Correlations between BMQ subscales and the first and second measure were included in the publication. Only the first measure, adherence to prophylactic frequency was used in the meta-analysis 
b Correlation between BMQ subscale and prescription refills was the only correlation included in the meta-analysis. Other data were not included in the publication 
c Correlation between BMQ subscale and MARS score was the only correlation included in the meta-analysis. Other data were not included in the publication 
d Correlation between BMQ subscales and MAQ was the only correlations included in the meta-analysis. Other data could not be calculated. 
e Correlation between BMQ subscale and CQR score was the only correlation included in the meta-analysis. Other data were not included in the publication 
f Correlations between BMQ subscales and MARS was the only correlation that was performed in the study. Other measure of adherence could not be calculated 
 
Abbreviations: ACS = Acute Coronary Syndrome; ACTG= Adherence to Combination Therapy Guide; BAASIS=Basel Assessment of Adherence to Immunosuppressive Medication Scale; BARS=Brief 
Adherence Rating Scale; BMQ=Brief Medication Questionnaire; CQR= Compliance Questionnaire Rheumatology; ITAS= Immunosuppressant Therapy Adherence Instrument; MAQ=4 item (Morisky) 
Medication Adherence Questionnaire MAR scale= Medication Adherence Reasons Scale; MARS=Medication Adherence Report Scale; MARS*= Medication Adherence Representation Questionnaire; MARS**= 
Medication Adherence Rating Scale; MASRI = Medication Adherence Self-Report Inventory; MEMS= Medication Event Monitoring Systems; MMAS=8 item Morisky Medication Adherence Scale; RAI= 
Rheumatology Attitudes Index; RAM= Reported Adherence to Medication; SECope= Side Effect Coping Questionnaire; SES= Service Engagement Scale; VAS= Visual Analogue Scale 
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 Overall Meta-Analysis 
All three variables in the meta-analysis showed significant associations with medication adherence 
as presented in Table 2.2. The necessity subscale was positively correlated with medication adherence 
and the concerns subscale was negatively correlated with adherence. The necessity-concerns 
differential was also positively correlated with medication adherence. There was significant 
heterogeneity with all Ԛ values being statistically significant and all I2 values indicated a large amount 
of heterogeneity between studies.  
Table 2.2: Meta-analysis results for the correlation between the necessity subscale, concern 
subscale and necessity-concern differential with medication adherence 
(k, number of studies; N, number of participants; COR, mean effect size correlation; CI, Confidence 
intervals for effect size; Q, Hedge’s Q statistic; I2, index of heterogeneity) 
*p<0.0001 
 
Figure 2.2, Figure 2.3 and Figure 2.4 show the forest plots for each variable, including the calculated 
overall effect size for each study. 
 
  
Variable k N COR 95% CI Q I2 
Necessity 91 22543 0.17* 0.14 ‒ 0.20 498.84* 82.00% 
Concern 89 22210 -0.18* -0.21 ‒ -0.15 441.62* 80.10% 
Necessity-Concerns 
Differential 
25 3874 0.24* 0.18 ‒ 0.30 104.74* 77.10% 
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Figure 2.2: Forest plot of the mean effect size for the necessity subscale (mean effect size 
correlation [COR], 95% confidence intervals [95% CI], percentage weight using the random 
effects model [W random]. 
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Figure 2.3: Forest plot of the mean effect size for the concerns subscale (mean effect size 
correlation [COR], 95% confidence intervals [95% CI], percentage weight using the random 
effects model [W random].  
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Figure 2.4: Forest plot of the mean effect size for the necessity-concerns differential (mean 
effect size correlation [COR], 95% confidence intervals [95% CI], percentage weight using the 
random effects model [W random]. 
 
Funnel plots were produced to test for publication bias (Figure 2.5, Figure 2.6 and Figure 2.7). Taking 
into account the large amount of study heterogeneity, all plots indicated acceptable plot symmetry, 
which suggests limited publication bias. Similarly Eggers test showed no indication of asymmetry 
for necessity (t (89) = -0.32, p=0.75) or concerns (t (87) = -0.38, p=0.70) effect sizes. Eggers test for 
necessity-concerns differential was significant (t(23) = 2.2, p=0.04) indicating asymmetry, however 
the small number of studies and large expected heterogeneity needs to be taken into account. 245 
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Figure 2.5: Funnel plot for correlation between necessity subscale and medication adherence 
 
 
Figure 2.6: Funnel plot for correlation between concerns subscale and medication adherence 
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Figure 2.7: Funnel plot for correlation between necessity-concerns differential and medication 
adherence 
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 Assessment of Risk of Bias within Studies 
Necessity 
There were no significant differences in effect size correlation for the necessity subscale when studies 
were stratified based on measure of adherence (p=0.39), power (p=0.31) or study design (p=0.47). 
Although effect sizes varied with each quality measure, as shown in Table 2.3, all remained 
significant at p<0.05 and had confidence intervals which crossed that of the overall effect size seen 
in the meta-analysis.  
Table 2.3: Overall mean effect size correlation for BMQ Necessity when stratified based on 
quality assessment measures  
(k, number of studies; COR, mean effect size correlation; CI, Confidence intervals for effect size; I2, 
index of heterogeneity) 
  
Quality assessment measure k 
BMQ Necessity 
effect size 
(COR) 
95% CI p-value I2 value 
Measure 
of 
adherence 
Objective 7 0.11 0.02 – 0.19 0.01 38.20% 
Validated self-report 62 0.17 0.13 – 0.21 <0.0001 83.50% 
Unvalidated self-report 15 0.20 0.11 – 0.28 <0.001 80.50% 
Mix 7 0.21 0.08 – 0.33 0.002 82.50% 
Power 
Low (n=<85) 16 0.22 0.13 – 0.30 <0.0001 38.70% 
High (n=≥85) 75 0.17 0.13 – 0.20 <0.0001 84.30% 
Study 
design 
Cross-sectional 79 0.17 0.14 – 0.21 <0.0001 83.20% 
Longitudinal 12 0.15 0.08 – 0.21 0.0001 56.90% 
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Concerns 
There was a significant difference in effect size correlation for the concerns subscale when studies 
were stratified based on measure of adherence (p=0.0002), with studies using objective measures of 
adherence having a significantly lower effect size correlation than any other measure of adherence 
(Table 2.4). There was no significant difference in effect size correlation when studies were stratified 
based on power (p=0.73) or study design (p=0.58). All other effect sizes remained significant at 
p<0.05 and had confidence intervals which crossed that of the overall effect size seen in the meta-
analysis.  
 
Table 2.4: Overall mean effect size correlation for BMQ Concern when stratified based on 
quality assessment measures  
(k, number of studies; COR, mean effect size correlation; CI, Confidence intervals for effect size; I2, 
index of heterogeneity) 
  
Quality assessment measure k 
BMQ 
Concern 
effect size 
(COR) 
95% CI p-value I2 value 
Measure 
of 
adherence 
Objective 7 -0.03 -0.10 – 0.04 0.37 21.30% 
Validated self-report 62 -0.20 -0.24 – -0.16 <0.0001 82.70% 
Unvalidated self-report 14 -0.17 -0.23 – -0.11 <0.0001 52.90% 
Mix 6 -0.13 -0.19 – -0.07 <0.0001 15.20% 
Power 
Low (n=<85) 15 -0.17 -0.25 – -0.09 <0.0001 21.90% 
High (n=≥85) 67 -0.19 -0.23 – -0.15 <0.0001 84.20% 
Study 
design 
Cross-sectional 78 -0.18 -0.22 – -0.15 <0.0001 82.00% 
Longitudinal 11 -0.17 -0.22 – -0.11 <0.0001 27.10% 
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 Stratifying by Condition 
Stratifying the analysis by condition showed that the correlation between necessity and concern 
subscale and medication adherence varied in some conditions. Table 2.5 provides the effect size 
correlations for each condition group. We assessed variability in effect sizes in each subscale by 
comparing the 95% confidence interval for the condition against 95% confidence interval of the 
aggregated results. Non-overlapping confidence intervals were observed for the necessity subscale in 
asthma and cardiovascular disease (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure). 
Specifically, the correlation was higher in studies conducted in asthma (COR=0.33) and lower in 
cardiovascular disease (COR=0.07), compared to the overall effect size for all included studies. No 
differences between different condition groups were observed in effect sizes for the concern subscale. 
A number of conditions did not have an enough studies to examine condition related differences and 
this limits our interpretation of the data. Similarly, for the necessity-concerns differential there were 
limited studies to make any condition specific conclusions.  
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Table 2.5: Meta-analysis results stratified by condition  
Condition 
Necessity Concerns Necessity-Concerns Differential 
k N COR 95% CI k N COR 95% CI k N COR 95% CI 
Asthma 7 1280 0.33 0.26 ‒ 0.41 6 1216 -0.19 -0.28 ‒ -0.08 2 268 0.39 0.28 – 0.48 
Cancer 3 329 0.21 0.10 ‒ 0.31 2 216 -0.29  -0.41 ‒ 0.16 1 40 0.18 -0.14 – 0.47 
Cardiovascular disease 
(ACS/Stroke/Coronary Artery 
Bypass Surgery/Heart Failure) 
8 2577 0.07 0.03 ‒ 0.11 8 2571 -0.14 -0.21 ‒ -0.06 2 925 0.14 0.07 – 0.20 
Cardiovascular disease 
(Hypercholesterolemia) 
2 834 0.11 -0.12 ‒ 0.32 2 834 -0.12 -0.47 ‒ 0.27 ‒ ‒ ‒ ‒ 
Cardiovascular disease 
(Hypertension) 
3 643 0.25 0.17 ‒ 0.32 4 967 -0.15 -0.21 ‒ -0.08 1 117 0.30 0.12 – 0.46 
Cardiovascular disease (Mixed) 2 1009 0.14 -0.11 ‒ 0.37 2 992 -0.12 -0.18 ‒ -0.06 1 122 0.28 0.13 – 0.42 
Chronic Obstructive Pulmonary 
Disease (COPD) 
1 188 0.03 -0.11 – 0.18 1 188 -0.44 -0.55 – 0.32 – – – – 
Diabetes (Type 2) 6 1566 0.11 0.03 ‒ 0.19 6 1556 -0.15 -0.30 ‒ 0.15 ‒ ‒ ‒ ‒ 
Epilepsy 2 109 -0.06 -0.31 ‒ 0.19 2 109 -0.16 -0.34 ‒ 0.03 ‒ ‒ ‒ ‒ 
Glaucoma 2 606 0.14 0.06 ‒ 0.22 2 606 -0.17  -0.24 ‒ -0.09 1 131 0.20 0.03 – 0.36 
Haemophilia 1 32 0.44 0.11 ‒ 0.68 1 32 -0.14 -0.47 ‒ 0.22 ‒ ‒ ‒ ‒ 
HIV 8 1373 0.17 0.12 ‒ 0.22 6 1023 -0.19 -0.27 ‒ 0.09 1 109 0.23 0.05 – 0.41 
Inflammatory Bowel Disease 3 2553 0.27 0.14 ‒ 0.39 3 2553 -0.13  -0.24 ‒ -0.02 ‒ ‒ ‒ ‒ 
Lupus ‒ ‒ ‒ ‒ 1 106 -0.23  -0.40 ‒ 0.041 ‒ ‒ ‒ ‒ 
Marfan syndrome II ‒ ‒ ‒ ‒ 1 174 -0.18 -0.32 ‒ -0.03 1 174 0.12 -0.03 – 0.26 
Mental Illness (Bipolar 
Disorder) 
2 247 0.14 -0.08 ‒ 0.34 2 247 -0.24  -0.36 ‒ 0.12 1 108 0.50 0.34 – 0.63 
Mental Illness (Depression) 7 1091 0.17 0.06 ‒ 0.28 7 1092 -0.29 -0.38 ‒ -0.18 1 85 0.24 0.03 – 0.43 
Mental Illness (Mixed) 4 516 0.18 -0.01 ‒ 0.35 4 516 -0.17 -0.26 ‒ -0.09 1 160 0.28 0.13 – 0.42 
Mental Illness (Schizophrenia) 1 150 0.23 0.07 ‒ 0.38 1 150 -0.15  -0.30 ‒ 0.01 ‒ ‒ ‒ ‒ 
Migraine 1 174 -0.08 -0.22 ‒ 0.07 1 174 -0.14  -0.28 ‒ 0.01 1 174 0.06 -0.09 – 0.21 
Non-malignant chronic pain 1 217 0.19 0.06 ‒ 0.32 1 217 -0.12 -0.25 ‒ 0.01 ‒ ‒ ‒ ‒ 
Osteoporosis 2 607 0.03  -0.14 – 0.21 1 244 -0.07 -0.20 – 0.05 1 244 0.00 -0.13 – 0.13 
Renal dialysis patients 3 235 0.24 -0.07 ‒ 0.40 2 123 -0.22 -0.51 ‒ 0.12 2 188 0.30 0.17 – 0.43 
Rheumatoid Arthritis 5 1271 0.23 -0.01 ‒ 0.43 5 1270 -0.08 -0.16 ‒ -0.00 2 849 0.09 -0.05 – 0.23 
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Condition 
Necessity Concerns Necessity-Concerns Differential 
k N COR 95% CI k N COR 95% CI k N COR 95% CI 
Systemic Sclerosis 1 92 0.22 0.02 – 0.41 1 92 -0.19 -0.38 – 0.02 1 92 0.37 0.18 – 0.54 
Transplant recipients 5 1208 0.25 0.11 ‒ 0.39 5 1207 -0.16 -0.22 ‒ -0.11 2 730 0.32 0.03 – 0.55 
Ulcerative Colitis 1 169 0.11 -0.04 – 0.26 1 169 -0.09 -0.24 ‒ 0.06 ‒ ‒ ‒ ‒ 
TOTAL 81 19076 0.17 0.14 ‒ 0.21 80 19817 -0.17 -0.20 – -0.14 22 4516 0.23 0.17 – 0.29 
(k, number of studies; N, number of participants; COR, mean effect size correlation; CI, confidence intervals for effect size) 
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 Discussion  
This chapter reports on a meta-analysis that investigated the relationship between beliefs about 
medicines and medication adherence. We found that both the necessity and concern subscales were 
significantly correlated with medication adherence on a population level. The small but significant 
correlations reported in this meta-analysis indicate that adherence to medication is positively 
correlated with necessity beliefs and negatively correlated with concern beliefs elicited from the 
BMQ. Those who believe their medication is necessary for their current and future health are more 
likely to be adherent to their medication than those who do not endorse these beliefs. Conversely, 
individuals who hold strong concern beliefs, such as beliefs about side effects, dependence on 
medicines and disruption to daily life are more likely to be non-adherent to their medication.  
Beliefs about medicines are one of many factors playing a role in medication adherence. This may be 
one reason for the small effect sizes. The magnitude of the effect sizes is comparable to the 
relationship between adherence and physician communication (r=0.19)69 as well as adherence and 
perceived illness severity (r=0.22)298 both of which are recognised as significant predictors of 
medication adherence.13 The significant correlations reported indicate that there is a consistent 
relationship between medication adherence and beliefs about medicines. In comparing the current 
study with previous meta-analyses, it can be seen that other documented predictors of adherence are 
not as strongly correlated to adherence (e.g. age and self-reported adherence [r=-0.04],299 objectively 
measured disease severity and self-reported adherence [r=0.00].298) This highlights the significance 
of the relationship between beliefs about medicines with medication adherence.  
The results of the meta-analysis also found that the necessity-concerns differential was positively 
correlated with medication adherence. Only 25 (27%) of the included studies in the meta-analysis 
reported using the necessity-concerns differential. The differential is an indicator of the relative 
importance of necessity and concern beliefs for an individual and a method of operationalising the 
cost-benefit analysis described by the Health Belief Model.107,109 The differential appears useful to 
understand the interplay between necessity and concern beliefs and the ‘cost-benefit’ decisions 
individuals are making with their medicines.109 Our study is the first to show that across many 
different conditions, the necessity-concern differential is significantly correlated with medication 
adherence. We suggest that the necessity-concerns differential should be used more in research as a 
way of presenting the cost-benefit analysis individuals are making. 
For the majority of conditions included in the meta-analysis, beliefs were related to adherence in a 
way that is consistent with the Beliefs about Medicines Framework. This in itself is striking given the 
wide variety of conditions included in the meta-analysis. The only two conditions that had 
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correlations in which their 95% confidence interval did not overlap with aggregated results was in 
asthma and the cardiovascular group (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure). 
In studies conducted in asthma, there was a stronger overall effect size between the necessity subscale 
and medication adherence. This suggests that for these individuals, having a high score on the 
necessity subscale is a stronger correlate of adherence than the overall population. Menckeberg and 
colleagues130 found that patients with asthma who had strong necessity beliefs reported the highest 
medication adherence, regardless of whether they had strong or weak concern beliefs. Adherence to 
asthma medicines may be dependent on patients believing in the necessity of their medicines for 
current and future health, given the chronicity and asymptomatic nature of asthma when it is well 
controlled. In comparison, the cardiovascular group (ACS/Stroke/Coronary Artery Bypass 
Surgery/Heart Failure) showed no correlation between the necessity subscale and adherence. Patients 
with more severe cardiovascular disease, such as those who have had a stroke often express concerns 
that they are prescribed too many medicines which give them side effects without any symptomatic 
benefit.253,300 It appears that the relationship between medication adherence and concerns beliefs is 
stronger than the relationship with necessity beliefs in patients with cardiovascular disease 
(ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure). This may mean that addressing 
concerns beliefs is a more important target for researchers to focus interventions on in order to support 
medication adherence in these patient populations.  
In comparing the results to the meta-analysis published at the time of submission of this manuscript 
for publication,156 there were some differences in the included studies. Nineteen studies included in 
the previous meta-analysis were not included in the present study because of different 
inclusion/exclusion criteria or being unable to calculate an effect size from available data. Conversely, 
we included an additional 21 studies that were not included in the previous meta-analysis. The 
majority of these studies were published after the previous meta-analysis. Despite these differences, 
our findings are in line with the meta-analysis conducted by Horne and colleagues.156 
An interesting finding of our quality assessment analysis is that in studies using an objective measure 
of adherence, there was a significantly lower mean concern effect size compared to other measures 
of adherence. This indicates that concern beliefs were not correlated to objectively measured 
adherence. It is noteworthy that objective measures not only included MEMS, but also prescription 
refills and drug concentrations in the body. The reason for the difference in effect size is not clear. 
There were a small number of studies included in this category (k=7); however, a number of these 
had large sample sizes. It may be that the statements/questions in self-report adherence questionnaires 
more closely align with the statements in the BMQ and therefore participants’ answers are likely to 
align and result in a stronger correlation. This is an interesting area to explore in future research.  
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A number of conditions such as migraine and ulcerative colitis had insufficient sample size. This 
limited our ability to make any inferences about differences in effect sizes. An inherent problem 
among many meta-analyses is that not all included studies reported results as the common effect size 
(i.e. correlation). While standard equations were used to convert individual study results into 
correlations, it is likely that the converted correlation is an underestimation of the true effect size. Our 
findings are conservative and as such, the true effect size for the three variables may be larger than 
reported.  
 Conclusion 
This meta-analysis supports the use of the Beliefs about Medicines framework for predicting 
medication adherence and the BMQ as an effective tool to elicit beliefs in the necessity and concerns 
of medications across diverse conditions. We found that for the majority of conditions, holding strong 
beliefs in the necessity of medication and weak concern beliefs were predictive of medication 
adherence. Although the necessity-concerns differential was not commonly used in the included 
studies, our analysis indicated that it was also a positive predictor of adherence. Stratification by 
condition was limited by some groups having small sample sizes; however, we identified that in 
asthma and in the cardiovascular group (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure), 
the relationship between necessity beliefs and medication adherence was different compared to the 
overall effect size.  
Given the multifactorial nature of adherence, our research suggests that necessity and concern beliefs 
about medicines are an important factor to consider when understanding reasons for non-adherence. 
The effect sizes reported were small in magnitude and because beliefs are thought to play a large role 
in medication-taking behaviour, these findings suggest there are other beliefs outside the Beliefs 
about Medicines Framework that are important in medication adherence. 
 Studies Published after Publication 
Since publication, a number of new manuscripts have been published. These includes studies in 
depression,301 epilepsy,302,303 HIV,304 hypertension,180 inflammatory bowel disease,305 heart failure306 
and rheumatoid arthritis.184,185 The necessity subscale was significantly associated with a measure of 
medication adherence in five studies.185,301,303-305 The concern subscale was significantly associated 
with a measure of medication adherence in four studies.185,301,303,304 These studies do not change the 
results or interpretation of our findings.  
 Chapter Summary 
In this chapter we have reported that beliefs about medicines are correlated to medication adherence 
and the effect size is consistent among most of the included conditions. The small effect size suggests 
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that factors outside the Beliefs about Medicines Framework may contribute to medication adherence. 
The next chapter will describe a study to explore how other beliefs associate with medication-taking 
behaviour.  
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  METHODS TO EXPLORE THE RELATIONSHIP BETWEEN 
HEALTH BELIEFS AND MEDICATION ADHERENCE IN INDIVIDUALS 
WITH ASTHMA 
 Introduction 
The literature review argued that health beliefs are associated with medication-taking behaviour 
across a number of different chronic conditions, but the exact way beliefs correlate to medication 
adherence in asthma is not well known. The most commonly elicited beliefs are beliefs about 
medicines and the meta-analysis conducted in Chapter 2 concluded that these were significantly 
correlated to medication adherence across the majority of included conditions. However, the effect 
sizes reported in the meta-analysis were small which implies other factors may also influence 
medication adherence. Other beliefs that may be associated with medication adherence are illness 
perceptions and locus of control beliefs. This chapter will describe the methodology of a study to 
explore the relationship between beliefs about medicines, illness perceptions and locus of control 
beliefs and self-reported medication adherence in individuals with asthma.  
  Aim 
The aim of the study is to investigate the relationship between beliefs about medicines, illness 
perceptions and locus of control beliefs with self-reported medication adherence in individuals with 
asthma. 
 Research Questions 
1. What do individuals with asthma believe about their asthma medicines, asthma and the 
controllability of their health as measured by the BMQ, B-IPQ and MHLCS respectively?  
2. What are the bivariate relationships between measures of health beliefs (BMQ, B-IPQ and 
MHLCS) and self-reported medication adherence in a sample of individuals with asthma?  
3. What multivariable model best predicts the relationship between patient characteristics, 
measures of health beliefs (BMQ, B-IPQ and MHLCS) and self-reported medication 
adherence in a sample of individuals with asthma? 
 Method 
 Research Design 
To explore an individual’s beliefs and medication-taking behaviour at one time point, a cross-
sectional study of participants with asthma using an inhaled preventative asthma medication was 
performed. Once consented to the study, participants completed a short survey to elicit their 
medication adherence and health beliefs, all using validated questionnaires.  
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 Ethics Approval 
Ethics approval was obtained for the study through the School of Pharmacy Human Research Ethics 
Committee, University of Queensland (Reference number: 2014/8). The ethics approval letter and 
additional amendment letters are provided in Appendix A.  
 Inclusion and Exclusion Criteria 
Participants were included in the study if they had been prescribed an ICS ± LABA for the treatment 
of asthma for at least three months, were 16 years of age or older and were responsible for 
administering their own medicine.  
Participants were excluded from the study if they were unable to complete the survey unaided (e.g. 
difficulty reading English). 
 Recruitment Strategies 
Participants were recruited through four different methods of recruitment and could only be involved 
in the study once. 
The first method of recruitment was a convenience sample of individuals attending one of two 
Brisbane community pharmacies. Patients who presented a prescription for an asthma medication 
when the researcher was present or were known to the pharmacy to be on a preventative asthma 
medication were approached by the researcher while their medication was being dispensed. The 
researcher introduced themselves and provided a brief description of the study. Pharmacy patients 
who were interested in the study were then asked questions to ensure they met the inclusion criteria. 
Following this, participants expressed their consent to participate by signing a written consent form. 
Participants completed the survey unassisted. The researcher was available if the participant sought 
clarification on a question.  
The second method of recruitment was through Asthma Australia. A short summary of the research 
project and a URL link to the online questionnaire was published by Asthma Australia on their 
website (http://www.asthmaaustralia.org.au/qld/research/participate-in-asthma-research) and social 
media sites (Facebook [https://www.facebook.com/AsthmaAustralia/] and Twitter 
[https://twitter.com/asthmaaus]) in July 2014. Participants who clicked on the URL were directed to 
an online version of the survey which was hosted by Checkbox Survey software. Participants were 
provided with the same participant information as method one and were asked to agree to an online 
consent form before they could be involved in the study survey. Only those who agreed that all of the 
inclusion criteria applied to them were able to access the survey. To further improve the participation 
rate, a paid advertisement on Facebook through Asthma Australia was also used. Asthma Australia 
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targeted the advertisement to individuals who have a specific interest in asthma. The link to the survey 
was the same as the original Asthma Australia promotion.  
It was expected that these two methods of recruitment would be sufficient to reach the required 
number of participants (200), as suggested by Asthma Australia staff. Recruitment was slower than 
expected and for this reason a further two methods of recruitment were used to improve participant 
numbers.  
Method three involved recruiting participants through an A6 advertisement card that was distributed 
to different community pharmacies in South East Queensland. The card contained a short summary 
of the study, a URL for participants to be able to complete the study online and the researcher’s email 
and mailing address where they could request a paper copy of the study if preferred. A total of 60 
cards were placed into each pharmacy and left for six weeks. The online survey for these participants 
had the same format as method two, with patients agreeing to an online consent form before they 
could access the survey. 
The final method was an advertisement in The University of Queensland weekly online newsletter 
(“UQ Update”) (http://www.uq.edu.au/update/) which is distributed to all University of Queensland 
staff and students via email. The advertisement ran for six weeks in total (two separate three-week 
blocks). The advertisement was a short summary of the study and a URL for participants to be able 
to complete the study online. Again, the online survey had the same format as method two and three. 
 Measuring Behavioural Constructs 
To elicit the constructs relevant to the Health Belief Model, Common Sense Model and Locus of 
Control Model from participants, validated questionnaires that relate to their corresponding theories 
were used. Each of these attitudinal measures were previously developed and validated using 
common approaches. 
This section provides a brief background into the development and validation of measures used to 
elicit adherence and belief constructs.  
The constructs used within questionnaires are commonly developed from literature reviews, focus 
groups and/or expert opinions. The BMQ, for example, was developed based on identifying 
commonly held beliefs about medicines in the literature and from interviews with individuals taking 
medication for a chronic condition.127 Once an item pool (questions or statements) has been 
generated, factor analysis is often used to assess whether there are similar patterns of response to 
some of the items, to determine whether they should be separated into multiple subscales or 
domains.307  
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Once the measure is developed, it is essential that it is validated.307 Content validity examines whether 
the tool is assessing the relevant parts of a larger construct. This is often done through using subject 
experts to examine the measure. A particularly important aspect of validation of behavioural measures 
is to assess whether the tool is actually measuring the underlying theory or model of what is meant to 
be measured, known as construct validity. Criterion validity assesses whether the questionnaire is 
related to a similar measure or outcome at the same time (concurrent validity) and/or whether the 
questionnaire is related to a similar measure or outcome at later time point (predictive validity). 
Convergent and discriminant validity assess how well the measures are associated with similar 
measures and different measures, respectively.  
The reliability of a measure refers to how well the scores are consistent from the same individuals 
over time (test-retest reliability). Internal consistency, often measured using Cronbach alpha, assesses 
how consistent an individual scores within the measure. Internal consistency however is sample 
dependent and can vary each time the measure is used. 
The following section describes each questionnaire used in this study and the evidence for validation 
and reliability.  
 Study Procedure 
Participants were asked to fill out the study survey once informed consent had been obtained. Surveys 
were self-completed to minimise the influence of social conformity when the researcher (that is, the 
patient saying what they believe the interviewer wants to hear to avoid possible disappointment or 
anger from their practitioner).54,308 
The first part of the survey elicited a number of patient characteristics. These were: age, gender, level 
of education, duration of asthma, peak flow measurement, hospital admissions in the past two years 
because of asthma, prescribed preventer and frequency of use, SABA use, concession card, other co-
morbidities and prescribed medication. Overall health rating was assessed using the widely used 
generic question developed for use in the health-rating short form (SF-36) questionnaire.309 Following 
this, participants completed validated questionnaires to measure medication adherence and elicit 
health beliefs. The full survey for the community pharmacy participants and online participants is 
provided in Appendix B and Appendix C, respectively. 
 
Measuring Medication Adherence 
Adherence to preventative asthma medication was determined through the five item self-report 
questionnaire, Medication Adherence Report Scale (MARS) (Table 3.1).51,165  
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In this study, we used a self-report measure of medication adherence to be able to elicit both 
medication-taking behaviour and to identify the possible reason(s) for non-adherence.25 MARS is 
easy to use, affordable, acceptable to participants and validated. MARS has been used previously to 
elicit adherence to asthma medication.130,132,248,310 In asthma, MARS correlates with objective 
measures of adherence such as prescription refills (r=0.46),130 MEMS (r=0.48)233 and pill counts 
(r=0.53).310 MARS has good test-retest reliability (r=0.74)310 and has shown good reliability in the 
way participants complete it (Cronbach’s alpha=0.75 – 0.83).132,248,310,311 
MARS consists of five statements regarding adherence to medication that are answered on a 5-point 
Likert scale, where 1= always, 2= often, 3= sometimes, 4=rarely and 5=never.51 For each participant, 
a summed MARS score was calculated ranging from 5 to 25. A high MARS score indicates better 
adherence.51 For the purpose of analysis, MARS remained on a continuous scale.  
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Table 3.1: Medication Adherence Report Scale (MARS)  
 
 
Many people find a way of using their medicines which suit them. 
 This may be different from the instructions on the label or from what their doctor has said. 
 We would like to ask you a few questions about how you use your medicines. 
 
 
 
 
For each statement please tick the box which best applies to you in regards to your preventative 
asthma medication. 
 
Your own way of using 
your medicines 
Always Often Sometimes Rarely Never 
M1 I forget to take them      
M2 I alter the dose      
M3 
I stop taking them for a 
while 
     
M4 I decide to miss a dose      
M5 
I take less than 
instructed 
     
 
© Robert Horne 
(Developed by Professor Rob Horne in the School of Pharmacy at the University of Brighton, 
United Kingdom) 
QUESTIONS ABOUT USING YOUR MEDICINES 
Here are some ways in which people have said that they use their 
medicines 
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Eliciting Stage of Change 
The Asthma Readiness to Change Questionnaire was developed to elicit the stage of change an 
individual is in with regards to being adherent to their asthma medication. It can be considered as an 
alternative self-report measure of medication adherence. In this study, individuals answered one 
question regarding how they currently use their asthma medication and if they intend on changing 
their behaviour (Table 3.2).226 Individuals were then placed into one of the five stages of change: pre-
contemplation (1), contemplation (2), preparation (3), action (4) or maintenance (5).226 
This questionnaire was designed for use in asthma and is yet to be applied to other illnesses.226 Test-
retest reliability was found to be satisfactory (>0.70).226 The questionnaire indicated satisfactory 
concurrent validity when compared to a measure of medication adherence (dose counts of metered 
dose inhalers) (r=0.72).226  
Table 3.2: Asthma Readiness to Change Questionnaire 
  
 
Please choose only one of the items below that best describes how you use your preventative 
asthma medication now 
 I have not been taking my asthma medication as prescribed in the past month, and do not 
intend to do so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but am 
thinking about doing so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but plan do 
so in the next month. 
 I am taking my medication as prescribed. 
 I have been taking my asthma medication as prescribed in the past month, and plan to 
continue doing so in the next month.  
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Eliciting Beliefs about Medicines 
The BMQ Specific, which contains the necessity and concerns subscales, was used to elicit a 
participants beliefs about their preventative asthma medication (Table 3.3). The necessity subscale 
(items 1, 3, 4, 7 and 10) elicits beliefs about medicines being protective of current and future health 
(e.g. improved quality of life, reduction in symptoms).107 The concerns (items 2, 5, 6, 8, 9) subscale 
elicits beliefs about the negative effects of medicines (e.g. disruption to daily life, side effects).107 
Participants indicated their level of agreement with each statement through a five-point Likert scale, 
where 1=strongly disagree, 2=disagree, 3=uncertain, 4= agree and 5= strongly agree. The scores from 
each subscale were summed to give a total subscale score. 
Substracting the necessity subscale score from the concern subscale score generates a necessity-
concerns differential.109 The differential is a single measure of how an individual weighs their beliefs 
in the necessity of their medicines against their concerns.107,109 Scores can range from -20 to +20.  
The BMQ was originally validated in six different chronic illness groups, including asthma.127 In 
asthma, the BMQ subscales had good internal consistency and test-retest reliability.127 For the 
necessity subscale, the Cronbach alpha coefficient was 0.80 and the test-retest correlation was 0.77. 
For the concerns subscale, the Cronbach alpha coefficient was 0.75 and the test-retest correlation was 
0.76. Criterion validity was demonstrated through positive correlations with similar subscales on the 
IPQ, Sensitivity Soma scale and the Reported Adherence to Medication scale.127 Discriminant 
validity was shown through BMQ scores being different in different illness and treatment groups.127 
For example, the asthma sample had significantly higher concern subscale scores (15.76) than the 
diabetes group (12.91) which is expected due to common concerns around the side effects of ICS.127 
The BMQ has now been widely used in the adherence literature. Scores from the BMQ have been 
associated with medication adherence across a number of different illnesses as described in Chapter 
1, Section 1.3.1.1. 
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Table 3.3: Beliefs about Medicines Questionnaire Specific 
Your views about your prescribed asthma preventer medication 
 We would like to ask you abou your personal views about your asthma and medicines 
prescribed for you 
 These are statements other people have made about their medicines  
 Please indicate the extent to which you agree or disagree with them by ticking the appropriate 
box  
 There are no right or wrong answers. We are interested in your personal views 
 
  
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
My health, at present, depends 
on my medicines 
     
Having to take asthma 
medication worries me 
     
My life would be impossible 
without my asthma medication 
     
Without my asthma medication 
I would be very ill 
     
I sometimes worry about the 
long term effects of my asthma 
medication 
     
My asthma medication is a 
mystery to me 
     
My health in the future will 
depend on my asthma 
medication 
     
My asthma medication disrupts 
my life 
     
I sometimes worry about 
becoming too dependent on my 
asthma medication 
     
My asthma medication protects 
me from becoming worse. 
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Eliciting Illness Perceptions 
The B-IPQ was used to elicit an individual’s illness perceptions (identity, timeline, consequences, 
cause, personal control, treatment control) (Table 3.4).161 In the questionnaire, the term ‘illness’ was 
replaced with ‘asthma’ and ‘treatment’ was replaced by ‘preventative inhaler’ as suggested by the 
authors to make it more relevant for participants.161 The questionnaire elicits an individual’s beliefs 
about the perceived consequences of their asthma, how long they expect their asthma to last 
(timeline), their ability to control their asthma (personal control) and treatment to control their asthma 
(treatment control), how many symptoms they perceive to be associated with their asthma (identity) 
perceived cause and perceived understanding of asthma. The B-IPQ also elicits an individual’s 
emotional illness representations, specifically how concerned (emotional representation 1) and 
emotionally affected (emotional representation 2) they are about their asthma. All subscales, except 
perceived cause, are measured on an 11-point scale (0-10), with each subscale having different 
endpoints (Table 3.4). Perceived cause is an open answer response, asking patients to list in order the 
three most important factors they believe caused their asthma.161 Responses were grouped into 
themes, for example hereditary causes.161 Themes were then categorised into ‘most cited overall’ as 
suggested by the authors.161 Responses were also weighted (by HF), depending on what order they 
had been listed in, where 3=ranked first, 2=ranked second and 1=ranked third.  
The B-IPQ has good test-retest reliability, with all subscales showing significant correlations at a 
three (r=>0.48) and six week time period (r=>0.42).161 Furthermore, it has shown satisfactory 
concurrent validity by having strong correlations with similar subscales of the BMQ, IPQ-R, validated 
self-efficacy scales and predicting patients HbA1c.
161 For example, patients with poorer metabolic 
control (higher HbA1c) had lower personal control scores and higher identity scores, as predicted. 
The B-IPQ was also able to distinguish between different illnesses, demonstrating discriminant 
validity.161 
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Table 3.4: Brief-Illness Perception Questionnaire  
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Eliciting Locus of Control Beliefs 
Form C of the MHLCS was used in this study to elicit an individual’s beliefs in the controllability of 
their health (Table 3.5). Throughout the questionnaire, the term ‘illness’ was replaced with ‘asthma’ 
as suggested by the authors.198 There are 18 items consisting of four different subscales: Internal (item 
1, 6, 8, 12, 13 and 17), Chance (item 2, 4, 9, 11, 15 and 16), Doctor (item 3, 5 and 14) and Other 
People (item 7, 10 and 18). The internal subscale elicits the degree to which an individual believes 
that their asthma becoming better or worse is their own responsibility and due to their own behaviour. 
The chance locus of control, doctor locus of control and other people locus of control subscales 
represent measures of external locus of control. The chance subscale elicits the degree to which an 
individual believes that chance controls whether their asthma gets better or worse. The doctor 
subscale elicits beliefs about the role of the doctor in controlling asthma-related problems. Lastly, the 
other people subscale elicits an individual’s beliefs about the role of other people, such as family and 
friends, in determining whether their asthma gets better or worse.  
Participants indicated their level of agreement on a 6-point Likert scale, where 1= strongly disagree, 
2= moderately disagree, 3= disagree, 4= agree, 5= moderately agree, 6= strongly agree. Each subscale 
was summed to give a total subscale score, as each subscale is independent of one another. Thus, the 
range of possible scores are 6 to 36 for the internal and chance subscales, and 3 to 18 for the doctor 
and other people subscale.  
Form C of the MHLCS displays good psychometric properties. In the original validation study, all 
subscales had a Cronbach alpha scores above 0.7 and the test-retest reliability was satisfactory for all 
subscales (r=>0.58) except for the other people subscale which had generally low stability in the 
initial development.198 Importantly, locus of control beliefs are thought to change over time, so a very 
high test-retest reliability is not expected. Form C correlated well with similar subscales of form B of 
the MHLCS and did not correlate with dissimilar subscales of form B indicating acceptable 
concurrent and discriminate validity.198 
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Table 3.5: Form C of the Multi-dimensional Health Locus of Control Scale 
 
  
 
Strongly 
agree 
Moderately 
agree 
Agree Disagree 
Moderately 
disagree 
Strongly 
disagree 
If my asthma worsens, it is my own 
behaviour which determines how soon I will 
feel better again. 
      
As to my asthma, what will be will be.       
If I see my doctor regularly, I am less likely 
to have problems with my asthma. 
      
Most things that affect my asthma happen 
to me by chance. 
      
Whenever my asthma worsens, I should 
consult a medically trained professional. 
      
I am directly responsible for my asthma 
getting better or worse. 
      
Other people play a big role in whether my 
asthma improves, stays the same, or gets 
worse. 
      
Whatever goes wrong with my asthma is 
my own fault. 
      
Luck plays a big part in determining how 
my asthma improves. 
      
In order for my asthma to improve, it is up 
to other people to see that the right things 
happen. 
      
Whatever improvement occurs with my 
asthma is largely a matter of good fortune. 
      
The main thing which affects my asthma is 
what I myself do. 
      
I deserve the credit when my asthma 
improves and the blame when it gets worse. 
      
Following doctor's orders to the letter is the 
best way to keep my asthma from getting 
any worse. 
      
If my asthma worsens, it's a matter of fate.       
If I am lucky, my asthma will get better.       
If my asthma takes a turn for the worse, it 
is because I have not been taking proper 
care of myself. 
      
The type of help I receive from other people 
determines how soon my condition 
improves. 
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 Summary of Health Belief Questionnaires  
The BMQ, B-IPQ and MHLCS have been summarised in Table 3.6. Each questionnaire has a number 
of subscales which elicit different health beliefs. For ease of interpretation, when discussing the 
results of this study in Chapter 4 and 5, a questionnaire subscale will be referred to in italics and the 
questionnaire it stems from in brackets, for example necessity (BMQ) subscale.  
Table 3.6: Summary of Questionnaires used in Survey to Elicit Health Beliefs 
Questionnaire Subscale Belief elicited by subscale 
Beliefs about 
Medicines 
(BMQ) 
Necessity subscale Necessity beliefs about asthma medicines 
Concerns subscale Concern beliefs about asthma medicines 
Brief Illness 
Perception 
Questionnaire 
(B-IPQ) 
Consequences subscale 
Beliefs about the consequences of asthma on 
the individual’s life 
Timeline subscale Beliefs about how long asthma will continue 
Personal Control subscale 
Beliefs about whether asthma can be controlled 
by the individual 
Treatment Control subscale 
Beliefs about whether treatment can control 
asthma 
Identity subscale 
How many symptoms are experienced from 
asthma 
Emotional representation 1 
subscale 
Concerns about asthma 
Emotional representation 2 
subscale 
Overall emotional impact of asthma 
Understanding subscale Perceived understanding of asthma 
Cause subscale Perceived cause of asthma 
Multi-
Dimensional 
Health Locus 
of Control 
Scale 
(MHLCS) 
Internal subscale Belief in oneself to control asthma outcomes 
Chance subscale 
Belief in chance/fate to control asthma 
outcomes 
Other People subscale 
Belief in other people to control asthma 
outcomes 
Doctor subscale Belief in the doctor to control asthma outcomes 
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 Data Analysis  
All data analysis was conducted using R Studio software version 3.1.244 All statistical tests used a 
significance cut-off of p<0.05. An exception to this was when testing the assumption of homogeneity 
of variance (Levene’s test) for independent t-tests and analysis of variance (ANOVA) which uses a 
strict significance cut-off of p<0.001.  
To address the research questions of the study shown in Section 3.3, the first step was to use 
descriptive statistics to describe the sample population and the beliefs they hold. Correlation analysis 
was then used to identify any significant correlations between subscales from the BMQ, B-IPQ and 
MHLCS and MARS score. The results of this analysis are presented in Chapter 4.  
To develop a predictive model of medication adherence, multivariable regression analysis was 
conducted. Multiple linear regression with interaction effects using backwards stepwise elimination 
was performed to identify a regression model that could predict MARS scores based on participants 
characteristics and scores on health belief questionnaires. The aim of this analysis was to use the 
simplest statistical method possible that could identify multivariable associations between health 
beliefs and medication adherence, including interactions between beliefs. This analysis is described 
in detail in Chapter 5.  
 Sample Size 
There are a number of methods to determine a minimum sample size for multivariable linear 
regression. A conservative estimate commonly used is to allow 10 participants per independent 
variable. Using this sample size estimate helps prevents model saturation (that is, the model may 
overfit the data).312,313 
Previous studies that have conducted regression analysis using the BMQ, B-IPQ and MHLCS 
separately, found at least one subscale from each questionnaire to be significant in the final regression 
model. Given the assumption that the final model could include up to 15 independent variables and 
not all participants would fill out all questions in the survey, a sample size of 200 participants was 
selected for the study.  
 Data Exploration 
Multivariable analysis using regression trees and random forests were conducted to further explore 
the data using a different method to multiple linear regression. Briefly, regression trees use recursive 
partitioning to develop a predictive model.314 Random forests are an ensemble of regression trees 
used to assess variable importance. Random forest analysis involves taking random subsets of the 
study sample and using them to construct a forest of regression trees, with the average taken from all 
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the trees. The variable that appears the most in the forest, (therefore occurring in the most regression 
trees) is classified as being the most important predictor of the outcome variable.  
A random forest for all variables (not including interaction effects) that were included in the final 
regression model from Chapter 5, Section 5.5.2 is shown in Appendix D for reference. It can be seen 
from this figure that findings were consistent with the regression model described in Chapter 5, 
Section 5.5.2. This supports the accuracy of the final regression model. The random forest analysis 
provided no additional insight into the data and for this reason is not included in the thesis. 
 Statistical Assumptions 
The statistical assumptions of independence, normal distribution and homogeneity were all examined 
before any statistical tests were conducted. The following methods were used to examine the 
independence, normality and homogeneity of the data. Specific model fit parameters were used in 
regression analysis and these are described in detail in Chapter 5, Section 5.4.  
Independence 
Independence was assumed for all statistical tests as variables were to the best of our knowledge, 
elicited from different individuals.  
Normality 
It is generally assumed that for samples with a size bigger than 30, statistical tests such as correlations, 
regression, t-tests and ANOVA are robust, regardless of whether the assumptions of normality are 
met (central limit theorem). Although the sample size of the present study was larger than 30, each 
variable was checked for normality. Histograms or boxplots were produced for all variables and these 
are presented in Chapter 4, Section 4.5. For correlation analysis, normality was checked through 
visual inspection of quantile-comparison plots and linearity was examined via scatterplots. Quantile 
comparison plots have not been presented in this thesis due to the large number of plots produced. 
Unless otherwise stated, these tests indicated that the data were normally distributed. 
Homogeneity of Variance 
For all categorical variables being analysed with t-tests or ANOVA, homogeneity of variance was 
checked through Levene’s test. A p-value <0.001 indicates significant differences between standard 
deviations and that there is extensive heterogeneity of variances. In all situations where t-tests or 
ANOVA were used, the p-value for Levene’s test was >0.001. This means that the null hypothesis 
can be accepted and homogeneity of variances can be assumed. 
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 Summary 
This chapter described the study design, participants, procedure and methods of analysis for a study 
that explores the relationship between health beliefs and medication adherence in a sample of 
individuals with asthma. The findings of this study are reported in Chapter 4 and 5 of the thesis.  
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 DEMOGRAPHICS, BELIEFS ANND ADHERENCE IN 
PARTICIPANTS WITH ASTHMA 
 Introduction 
This chapter describes the demographics, clinical characteristics, health beliefs and medication 
adherence of a sample of individuals with asthma and determines the bivariate relationship between 
these factors and medication adherence. As discussed in Chapter 1, Section 1.3, beliefs appear to be 
associated with medication adherence but the relationships between specific beliefs and adherence 
are inconsistent across different conditions. To explore how beliefs correlate to medication adherence 
in individuals with asthma, it was important to first describe the beliefs individuals with asthma 
commonly hold. Individuals with asthma are generally younger, more likely to be female, take less 
medicines and have fewer comorbidities than people with other chronic conditions, such as type 2 
diabetes and heart disease.3,4,315 These differences may affect the beliefs individuals hold and the way 
they related to medication adherence in asthma. This chapter contributes to the literature on 
medication adherence in asthma by describing the beliefs individuals have about their medicines, 
illness and the controllability of their health. It is hoped that an understanding of the commonly held 
beliefs and their relationship with medication adherence in this sample population can inform health 
professionals on better ways to support individuals in their medication-taking.  
 Aim 
The aim of this chapter is to: 
1. Describe the demographics, clinical characteristics, self-reported medication adherence, and 
health beliefs (beliefs about medicines, illness perceptions and locus of control beliefs) of a 
sample of individuals with asthma.  
2. Investigate the bivariate relationship between demographics, clinical characteristics, 
measures of health beliefs (BMQ, B-IPQ, MHLCS) with self-reported medication adherence 
in individuals with asthma. 
 Research Questions 
1. What do individuals with asthma believe about their asthma medicines, asthma and the 
controllability of their health as measured by the BMQ, B-IPQ and MHLCS respectively?  
2. What are the bivariate relationships between demographics, clinical characteristics, measures 
of health beliefs (BMQ, B-IPQ and MHLCS) and self-reported medication adherence in a 
sample of individuals with asthma?  
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 Method 
Data collected from participant questionnaires was first analysed using standard descriptive statistics. 
Individuals were not required to answer all questions and therefore the total sample size for each 
question varies. To examine any differences in MARS score between categorical variables (e.g. 
gender, level of education), independent t-tests (2 levels) and ANOVA (≥3 levels) were used.  
Pearson’s product-moment correlation (r) was used to examine relationships between MARS score 
and continuous variables (e.g. age, belief questionnaire subscale scores). Spearman’s rank correlation 
(ρ) was performed when subscales scores were not normally distributed.  
Cronbach’s alpha was used to determine internal consistency for MARS and each of the subscales of 
the BMQ and MHLCS. As the B-IPQ only had one question per subscale, Cronbach alpha was not 
calculated for this questionnaire.  
 Descriptive Results 
A total of 219 participants enrolled into the study survey between May 2014 and May 2015. The 
majority of participants were recruited through an Asthma Australia advertisement (n=147), 49 
participants were recruited through the University of Queensland Update newsletter advertisement 
and the remaining 23 participants were recruited in community pharmacy. Participants who did not 
complete the questionnaire beyond demographic questions were excluded (n=21). This left 198 
participants included in the study. 
For participants recruited in community pharmacies by the principal investigator (HF), two 
individuals declined to enter into the study and three individuals were recruited and then excluded as 
they did not meet the inclusion criteria. Reasons for declining were time and not wanting to be 
involved. This information was unable to be captured in the online setting, although online response 
rates have been estimated at around 30%.316 Out of the online participants who chose to be involved 
in the study, 29 participants did not meet the inclusion criteria. 
 Patient Demographics and Clinical Characteristics 
The characteristics of the sample are described in Table 4.1. The mean (± standard deviation [SD]) 
age of participants was 39.8 (±12.7) years, with a range of 19 – 74 years. One hundred and sixty-one 
participants (81.7%) were female.  
As shown in Table 4.1, participants had a mean (±SD) duration of asthma of 24.4 (±14.2) years, with 
the shortest duration being one year and the longest being 61 years. One hundred and sixty-three 
(83.6%) participants were on a combination preventer that contained an ICS and LABA 
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(fluticasone/salmeterol, fluticasone/eformoterol or budesonide/eformoterol). Seventy-seven (54.2%) 
participants were using their SABA three or more times per week.  
The most common concomitant medical conditions individuals had were depression (19.7%), Gastro-
Oesophageal Reflux Disease (GORD) (18.2%) and arthritis (14.1%). One hundred and thirteen 
(59.2%) individuals were on one or more other prescribed medications. Most participants perceived 
their overall health as good or higher (73%). 
Table 4.1: Demographics and clinical characteristics of study participants 
 
  
Characteristics Value 
Mean (±SD) age, years  
n=195 
39.8 (±12.7) 
Gender, n (%) 
Female 
Male 
 
161 (81.7) 
36 (18.3) 
Location, n (%) 
QLD 
NSW 
VIC 
SA 
WA 
TAS 
ACT 
NT 
 
113 (57.4) 
35 (17.8) 
20 (10.2) 
16 (8.1) 
5 (2.5) 
6 (3.1) 
1 (0.5) 
1 (0.5) 
Level of Education, n (%) 
Grade 10 
Grade 12 
Diploma/Certificate 
University 
Further Degree 
Other 
 
16 (8.2) 
29 (14.8) 
22 (11.2) 
81 (41.3) 
46 (23.5) 
2 (1.0) 
Concession card, n (%) 
n=189 
47 (24.2) 
82 
 
Table 4.1: Demographics and clinical characteristics of study participants (cont.) 
   
Characteristics Value 
Mean (±SD) asthma duration, years  
n=184 
24.4 (±14.2)  
Main prescribed ICS ± LABA, n (%) 
Fluticasone/salmeterol  
Budesonide/eformoterol  
Fluticasone 
Budesonide 
Fluticasone/eformoterol  
Others 
 
87 (44.6) 
72 (36.9) 
12 (6.2) 
7 (3.6) 
4 (2.1) 
13 (6.7) 
SABA, n (%) 
Salbutamol 
Terbutaline 
 
129 (65.2) 
22 (11.1) 
SABA use, n (%) 
< 3 times per week 
≥ 3 times per week 
 
65 (45.8) 
77 (54.2) 
Mean (±SD) peak flow measurement, L/min  
n=38 
346.6 (±113.7) 
Hospitalisation in last 2 years because of 
asthma 
No 
Yes 
 
 
153 (78.1) 
43 (21.9) 
Other medical conditions, n (%) 
Depression 
GORD 
Arthritis 
Hypertension 
Hypercholesterolemia 
Allergy-related conditions 
Diabetes 
Heart disease 
COPD 
Cancer 
 
39 (19.7) 
36 (18.2) 
28 (14.1) 
24 (12.1) 
16 (8.1) 
11 (5.6) 
9 (4.5) 
6 (3.1) 
4(2.0) 
3 (1.5) 
Other prescribed medicines, n (%) 
None 
1 – 4 
5 – 9 
≥10 
 
78 (40.8) 
97 (50.8) 
13 (6.8) 
3 (1.6) 
Perceived health, n (%) 
Excellent 
Very Good 
Good 
Fair 
Poor 
 
15 (7.7) 
48 (24.5) 
81 (41.3) 
41 (20.9) 
11 (5.6) 
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 Medication Adherence 
Self-reported adherence to asthma preventative medication was measured using MARS, with a high 
MARS score indicating better adherence. The Cronbach alpha coefficient for MARS was 0.81. 
The mean (±SD) MARS score of the sample population was 19.2 (±4.5) with the lowest score being 
7 and the highest score 25. Figure 4.1 shows that there was a spread of participants MARS scores, 
with both high and low MARS score being captured in the study. One hundred and twenty-six 
(72.4%) participants had a MARS score below 23.  
Figure 4.1: Histogram of participant’s MARS score (n=174) 
 
The percentage of participant responses for each statement is presented in Figure 4.2. Eighty (44.0%) 
participants reported that they always, often or sometimes “stop taking their asthma preventer for a 
while”. Ninety-seven (52.2%) participants reported that they always, often or sometimes “forget to 
take them” relating to their asthma preventer.  
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Figure 4.2: Relative percentage of participant’s responses for each MARS statement (n=198) 
 
 Stages of Change 
The Asthma Readiness to Change Questionnaire was used to evaluate which stage of change 
participants were in, in regards to adhering to their preventative asthma medication. Table 4.2 and 
Figure 4.3 show the distribution of participant answers, with the majority of participants (46.3%) 
reporting that they have been taking their asthma medication as prescribed and plan to do so in the 
next month (maintenance stage).  
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Table 4.2: Frequency of responses for each stage of change (n=175) 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Frequency of participant’s responses for each stage of change (n=175) 
  
Stage of change 
n=175 
N (%) 
Pre-contemplation 
I have not been taking my asthma medication as prescribed in the 
past month, and do not intend to do so in the next month. 
14 (8.0) 
Contemplation 
I have not been taking my asthma medication as prescribed in the 
past month, but am thinking about doing so in the next month. 
13 (7.4) 
Preparation  
I have not been taking my asthma medication as prescribed in the 
past month, but plan do so in the next month. 
22 (12.6) 
Action  
I am taking my medication as prescribed. 
45 (25.7) 
Maintenance 
I have been taking my asthma medication as prescribed in the past 
month, and plan to continue doing so in the next month.  
81 (46.3) 
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 Beliefs about Medicines 
Beliefs in the necessity and concerns of medicines were elicited using the BMQ. Each subscale 
(necessity and concerns) gives a summed score from 5 – 25. A higher score indicates stronger 
agreement with the subscale. The Cronbach alpha coefficient for the necessity (BMQ) subscale and 
concern (BMQ) subscale was 0.77 and 0.80 respectively.  
Participant Necessity Beliefs  
On the necessity (BMQ) subscale, the mean (±SD) summed score was 19.0 (±3.8) with the lowest 
being 8 and the highest being 25. Figure 4.4 shows that the data have a relatively normal distribution, 
with few participants reporting low scores. 
 
Figure 4.4: Histogram of participant’s necessity (BMQ) score (n=176) 
 
Examining the percentage of responses for each of the necessity (BMQ) statements ( Figure 4.5), it 
can be seen that 160 (88.4%) participants were in agreement (strongly agreed or agreed) with the 
statement “My asthma medication protects me from becoming worse” but only 108 (60.7%) with the 
statement “Without my asthma medication I would be very ill”. 
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 Figure 4.5: Relative percentage of participant’s responses for each necessity (BMQ) statement 
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Participant Concern Beliefs  
The mean (±SD) summed score for the concerns (BMQ) subscale was 12.9 (±4.7) with the lowest 
score being 5 and the highest being 23. Figure 4.6 shows that there are two peaks at scores of 5 and 9.  
Figure 4.6: Histogram of participant’s concerns (BMQ) score (n= 175) 
 
 
The percentage of responses for each concerns (BMQ) statement is shown in Figure 4.7. By looking 
at the individual statements, it can be seen that 101 (56.4%) participants were in agreement with the 
statement “I sometimes worry about the long term effects of my asthma medication” and 69 (39.0%) 
participants with the statement “I sometimes worry about becoming too dependent on my asthma 
medication”. 
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Figure 4.7: Relative percentage of participant’s responses for each concerns (BMQ) statement
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Necessity-Concerns Differential 
The mean (±SD) necessity-concerns (BMQ) differential score was 6.1 (±5.0) with the lowest score 
being -8 and the highest being 17. Figure 4.8 shows the necessity-concerns differential is normally 
distributed.  
Figure 4.8: Histogram of participant's necessity-concerns (BMQ) differential score (n=172) 
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 Illness Perceptions 
Participants’ illness perceptions were elicited using the B-IPQ which has 9 different items. All items 
except cause illness perception were measured on a 0–10 scale with each item using a different 
beginning and end point (Table 4.3). The cause (B-IPQ) responses were grouped into themes based 
on participant responses. Individuals were asked to rank what they believed caused their illness in 
order. Themes were then listed as most cited overall and as a weighted score, to be able to identify 
those themes that were more commonly placed as first perceived cause. These have been listed in 
Table 4.4. 
From the B-IPQ, the majority of the sample responded that their asthma will continue for a long time 
(timeline), their asthma preventer could help their asthma (treatment control) and that they understood 
their asthma (understanding). Most of the sample were not emotionally affected by their asthma 
(emotional representation 2). The most cited factor that participants believed caused their asthma was 
hereditary with many participants citing that they were just ‘born with it’ (n=85 [49.5%]). This was 
also cited most commonly as the number one cause of their asthma.  
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Table 4.3: Mean (±SD) scores for each B-IPQ subscale 
  
Illness perception Scale endpoints 
Mean (±SD) 
 (min – max) 
Consequences 
How much does your asthma affect your 
life? 
N=181 
No affect at all (0) to Severely 
affects my life (10) 
4.9 (±2.7) 
(0 – 10) 
Timeline  
How long do you think your asthma will 
continue? 
N=180 
A very short time (0) to 
Forever (10) 
9.2 (±1.7) 
(1 – 10) 
Personal Control 
How much control do you feel you have 
over your asthma? 
N=179 
Absolutely no control (0) to 
Extreme amount of control 
(10) 
6.4 (±2.2) 
(0 – 10) 
Treatment Control 
How much do you think your preventative 
inhaler can help your asthma? 
N=179 
Not at all (0) to Extremely 
helpful (10) 
7.9 (±2.2) 
(1 – 10) 
Identity  
How much do you experience symptoms 
from your asthma? 
N=180 
No symptoms at all (0) to 
Many severe symptoms (10) 
5.2 (±2.4) 
(0 – 10) 
Emotional representation 1 
How concerned are you about your 
asthma? 
N=180 
Not at all concerned (0) to 
Extremely concerned (10) 
5.0 (±2.8) 
(0 – 10) 
Emotional representation 2 
How much does your asthma affect you 
emotionally? 
N=180 
Not at all emotionally (0) to 
Extremely affected 
emotionally (10) 
3.8 (±3.1) 
(0 – 10) 
Understanding 
How well do you feel you understand your 
asthma? 
N=179 
Don’t understand at all (0) to 
Understand very clearly (10) 
7.2 (±2.4) 
(0 – 10) 
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Table 4.4: Frequency of most common responses for cause illness perception (n=172) 
Theme Overall frequency, n (%) *Ranked weighted frequency 
Hereditary 85 (49.4) 220 
Allergies 76 (44.2) 162 
Illness 44 (25.6) 88 
Smoking 38 (22.1) 87 
Environmental factors 33 (19.2) 61 
Weather 33 (19.2) 60 
Exercise induced 26 (15.1) 47 
Stress 13 (7.6) 31 
Weight 8 (4.7) 17 
*Score of 3 was given if participants ranked first, 2 for second and 1 for third perceived cause of 
asthma. 
 
As seen in Figure 4.9, the timeline (B-IPQ) illness perception is skewed to the left (negative skew), 
with most participants having high scores. Understanding and treatment control (B-IPQ) illness 
perceptions are also slightly skewed to the left. The remaining illness perception items show a more 
even distribution of responses.  
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Figure 4.9: Boxplot for each illness perception (B-IPQ) dimension  
(The solid line through the box represents the median, the box represents the interquartile range 
[middle 50% of scores], the whiskers represent the upper and lower 25% of scores and circles 
represent outliers) 
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 Locus of Control Beliefs 
Participants’ locus of control beliefs were elicited using the MHLCS. Participants indicate their level 
of agreement with each scale from 1 – 6. The internal and chance subscale have 6 statements and the 
doctor and other people subscales have 3 statements, giving different minimum and maximum scores 
(Table 4.5). Higher scores indicates stronger agreement. Cronbach’s alpha coefficient for each 
subscale was: internal (0.78), chance (0.75), doctor (0.71) and other people (0.74).  
The mean (±SD) scores for each subscale are presented in Table 4.5. The mean score was highest 
(relative to the number of statements) for the doctor (MHLCS) subscale, followed by internal, chance 
and other people (MHLCS) subscales. 
Table 4.5: Mean (±SD) scores for each MHLCS subscale 
 
The boxplot for each MHLCS subscale is presented in Figure 4.10, which has been standardised 
(score divided by number of questions in the subscale) to allow comparison between subscales. It can 
be seen that the internal, chance and other people (MHLCS) subscales are normally distributed. The 
doctor (MHLCS) subscale is skewed to the left, towards high scores.  
  
Subscale 
(min-max) 
Mean (±SD) 
(min – max) 
Internal (6-36) 
N=167 
19.4 (±4.5) 
(8 – 30) 
Chance (6-36) 
N=159 
16.8 (±5.2) 
(6 – 29) 
Doctor (3-18) 
N=168 
12.8 (±3.0) 
(5 – 18) 
Other People (3-18) 
N=167 
8.3 (±3.2) 
(3 – 18) 
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Figure 4.10: Boxplot for MHLCS subscales 
(The solid line through the box represents the median, the box represents the interquartile range 
[middle 50% of scores], the whiskers represent the upper and lower 25% of scores and circles 
represent outliers) 
 
The percentage of responses for each statement of the internal (MHLCS) scale are presented in Figure 
4.11. One hundred and thirty-two (76.3%) participants were in agreement with the statement (strongly 
agreed, moderately agreed or agreed) that if their asthma worsens, then it is their own behaviour that 
determines how soon they will feel better. Similarly, 131 (75.3%) participants were in agreement that 
they are directly responsible for their asthma getting better or worse. A total of 115 (66.9%) 
participants were in disagreement (strongly disagreed, moderately disagreed or disagreed) with the 
statement “Whatever goes wrong with my asthma is my own fault”.  
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Figure 4.11: Relative percentage of participant’s responses for each internal (MHLCS) statement
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The percentage of responses for each statement of the chance (MHLCS) scale can be seen in Figure 
4.12. Eighty-two (47.7%) participants were in agreement that most things that affect their asthma 
occur by chance and 23 (13.8%) participants with the statement that if their asthma worsens then it is 
a matter of fate.  
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Figure 4.12: Relative percentage of participant’s responses for each chance (MHLCS) statement
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The percentage of responses for each doctor (MHLCS) statement is presented in Figure 4.13. One 
hundred and thirty-eight (80.7%) participants were in agreement that following the doctor’s 
instructions was the best way to prevent their asthma worsening and 134 (78.4%) participants with 
the statement “whenever my asthma worsens, I should consult a medically trained professional”.  
 
 
Figure 4.13: Relative percentage of participant’s responses for each doctor (MHLCS) 
statement 
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The percentage of responses for each other people (MHLCS) statements is shown in Figure 4.14. 
There were 116 (67.4%) participants that were in disagreement with the statement that other people 
play a big role in their asthma improving, staying the same or getting worse. A total of 71 (42.3%) 
were in agreement that the type of help they receive from other people determines how soon their 
asthma improves.  
 
Figure 4.14: Relative percentage of participant’s responses for each other people (MHLCS) 
statement 
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 Discussion of Descriptive Results 
In this sample, there was a range of self-reported medication-taking behaviours, reflected in the 
distribution of MARS scores. In particular, the relatively low mean MARS score suggests that many 
participants may be non-adherent to their preventer. Using the BMQ, we found that this sample 
believed their preventer medication was necessary, and most did not have strong concern beliefs. 
According to responses on the B-IPQ, many participants viewed their asthma as a long-term condition 
and believed that their preventer could help their asthma. The MHLCS revealed that participants 
believed that their doctor was important in controlling their asthma. Few participants believed that 
luck played a role in their asthma improving or getting worse.  
The demographic and clinical characteristics of the group are representative of individuals with 
asthma in Australia.1,317,318 The sample was relatively young in age, with few elderly participants. 
This is in line with the average age of people with asthma in Australia3 and with participants included 
in a large systematic review of international studies examining adherence determinants in asthma.15 
One key difference in the sample is that the majority of participants were female. Although females 
are more likely to have asthma than males there was an overrepresentation in the sample, compared 
to previous studies in adults with asthma.129,133,165 This is most likely explained by online recruitment 
methods, with evidence that females are more likely to respond to online surveys compared to 
males.319,320  
Although participants were recruited online, their clinical characteristics were similar to participants 
recruited in asthma clinics in the community.165 Most participants had been diagnosed with asthma 
for over 10 years and had not been hospitalised in the last two years because of their asthma. Preventer 
medication most commonly consisted of an ICS and a LABA (‘combination therapy’) and this 
matches national prescribing patterns.1,317 Despite being on combination therapy, most participants 
reported using a SABA three or more times per week. This often indicates that asthma is not well 
controlled and one reason for this may be non-adherence to their ICS.4  
The mean MARS score reported is comparable to previous studies in asthma in the Netherlands130 
and Sweden,248 both reporting similar mean MARS scores for their sample. Conversely, in secondary 
preventative medication in stroke253 and in individuals with cancer,141 means MARS scores were 
much higher. This may suggest that non-adherence is more common in conditions where the 
perceived consequences are not as severe and/or there is more patient discretion involved in the choice 
of treatment and dosing regimen. Examining the individual MARS statements, there were many cases 
of individuals self-reporting that they alter their dose and frequency and/or stop their ICS 
intermittently. According to the taxonomy described by Vrijens29 and Gearing et al.,30 these 
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participants could be categorised as partially accepting treatment or intermittent treatment adopters. 
Our findings align with national reports that under-use of ICS medication is common in asthma.3 
The Asthma Readiness to Change Questionnaire was used as a second method of eliciting medication 
taking behaviour. The questionnaire was able to characterise participants, with regards to their 
readiness to adhere to their ICS. Most participants self-reported they were currently using their ICS 
as prescribed and plan to continue to use it in the following months (maintenance stage of change). 
This matches the findings observed in a small study of individuals with asthma.226 However; it does 
contrast with the relatively low MARS scores reported in the present study. Using a MARS score cut 
off of <23 to reflect non-adherence, and ≥23 reflecting adherence,27,136,251,285,321 72% of participants 
would fall into the ‘non-adherent’ category. Differences in MARS and the readiness to change 
classification may be because MARS is more sensitive at picking up any non-adherence. It appears 
that the Asthma Readiness to Change Questionnaire is identifying that most of the sample accept the 
importance of their medicines and intend on being adherent, but cannot identify those individuals 
who are ‘a little’ non-adherent. Using these tools in combination allow for the researcher to identify 
a sample’s intentions to adhere (the Asthma Readiness to Change Questionnaire) and actual 
adherence (MARS). An intervention to support adherence in individuals with the same MARS score, 
may be very different depending on what stage of change the individual is in (pre-contemplative 
versus maintenance). 
There was a high mean necessity (BMQ) score and a low concerns (BMQ) score in the sample. The 
high mean score on the necessity (BMQ) subscale for the sample was comparable to a previous study 
in asthma with participants with similar demographics,109 but higher than a study conducted in the 
Netherlands by Menckeberg and colleagues.130 Menckeberg et al. noted that their sample were 
sceptical of their medicines and suggested differences in symptom severity, duration of disease and 
comorbidity may influence an individual’s perspective of the benefit of their medicines.130 Other 
studies using the BMQ in participants with asthma do not report mean scores, making it difficult to 
compare across studies. Furthermore, because most studies do not report scores of the individual 
questions on the BMQ, it is difficult to determine whether the difference in mean scores between 
studies represents that this sample held more necessity beliefs about their ICS or stronger beliefs in 
the necessity of their ICS. 
While participants expressed some concerns about the long-term effects of their preventer, the mean 
concerns (BMQ) score was low compared to previous studies in asthma109,130 and in other chronic 
conditions (hypertension,322 type 2 diabetes263 and schizophrenia283). Concern beliefs have been 
shown to weaken over time in patients with asthma,111 possibly because of actual experience with the 
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treatment and side effects. In the study by Horne and colleagues, participants had a much shorter 
duration of asthma which may have been a reason for individuals holding strong concern beliefs.109 
Another factor that may have influenced the low concerns (BMQ) score is that participants may have 
a different level of health literacy. Health literacy has been shown to be associated with concern 
beliefs in COPD323 and older adults with asthma.324 Those who were considered to have adequate 
health literacy had a lower mean concern (BMQ) score compared to individuals with low health 
literacy.323,324 In the current study, most participants were members of Asthma Australia who are 
likely to be better informed about the side effects of their medicines, such as the difference between 
ICS and anabolic steroids. This may be due to regular educational campaigns and advocacy through 
Asthma Australia social media and website which may translate to better health literacy and the 
reason behind the relatively low concerns (BMQ) score seen in the sample.  
The mean score of each illness perception dimension and the most commonly cited causes of asthma 
were similar to the results in the asthma sample in the original B-IPQ validation study (except for 
consequences which was slightly higher in the present sample [4.9 versus 3.5]).161 The validation 
study included 309 people with asthma recruited from general practitioner clinics in the United 
Kingdom.161 Participants were of a similar age and had a similar duration of asthma to our sample. 
This suggests that our participants had illness perceptions in line with that seen ‘typically’ in people 
with asthma. 
The mean score for the treatment control (B-IPQ) subscale was higher than the personal control (B-
IPQ) subscale. This suggests that the group has a stronger belief in their ICS to help their asthma than 
themselves. Researchers have suggested there is a close relationship between beliefs about medicines 
and illness perceptions in asthma.164,165 Believing medication is necessary (necessity [BMQ] beliefs) 
and that it can help control asthma (treatment control [B-IPQ]) appear closely related and may both 
be measuring the same (or part of the same) construct. The mean score for the identity (B-IPQ) 
subscale was similar to another study in asthma,161 but higher than in completely asymptomatic 
conditions such as hypertension,325 and lower than symptomatic conditions such as COPD152and 
chronic pain.167 This suggests that individuals with asthma perceive some symptoms (possibly 
associated with asthma exacerbations) but less than conditions that are likely to have daily symptoms. 
There were many different perceived causes of asthma in the sample, with the most common cause 
being hereditary. Individuals appeared to view this question in two ways: cause of disease versus 
cause of asthma symptoms or exacerbations. There were many responses of smoking, weather, 
exercise and illness.  
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The last set of beliefs explored were locus of control beliefs elicited by the MHLCS. Looking at 
statements from the internal (MHLCS) subscale individually, it can be seen that individuals make a 
clear distinction about where responsibility for their asthma lies. Many believe they are directly 
responsible for their asthma getting better or worse but very few believe that it is their own fault when 
something goes wrong with their asthma. Initially, it was thought that internal locus of control beliefs 
would most logically relate to health behaviour and outcomes, and as such, little time was spent 
examining external factors (doctors, chance).196 Studies that examined external locus of control 
beliefs commonly used a MHLCS version that groups other people (e.g. family, friends) and health 
professionals together and therefore the individual impact of the doctor locus of control was not often 
investigated.134,197,213 In this study, the doctor (MHLCS) subscale had the highest mean score (relative 
to the number of statements). Many participants believed in the doctor to help control their asthma, 
and in particular that following the doctor’s orders is the best way to prevent their asthma getting 
worse, which reflects the beliefs held by other participants with asthma.200,201 Similar to previous 
studies conducted in asthma, few participants believed in chance and other people to help control 
their asthma.200,201 In conditions that are more difficult to treat, such as cancer, individuals tend to 
score higher on the chance (MHLCS) scale as many believe they have no control over the progression 
or the outcome of their condition.198 The majority of this sample did not believe that ‘luck’, ‘good 
fortune’ or ‘fate’ had a role in their asthma improving or getting worse or that it was up to ‘other 
people’ to see that their asthma improves, suggesting they perceive to have more control over their 
illness.  
This section has described the beliefs a group of individuals with asthma hold which has provided 
insight into the way the participants conceptualise their medicines, illness and the controllability of 
their health. Mean scores on the BMQ, B-IPQ and MHLCS were different to studies conducted in 
participants with other chronic conditions. Because of a lack univariate, descriptive literature in other 
chronic conditions, it is not clear whether our sample had stronger/weaker beliefs or they hold 
different beliefs about their medicines, illness and controllability of their health.  
In the following section, the relationship between demographics, clinical characteristics, beliefs about 
medicines, illness perceptions and locus of control beliefs with medication adherence will be 
investigated.  
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 Bivariate Results  
Levene’s test of homogeneity of variance was performed on all categorical and all groups were found 
to have similar variance (p>0.001), suggesting homogeneity of variances can be assumed. 
 Patient Demographics and Clinical Characteristics and Medication Adherence 
The relationship between patient characteristics and medication adherence in the sample are reported 
in Table 4.6. There was a significant positive correlation between age and MARS score, with older 
participants more likely to self-report that they adhere to their preventer (r=0.18, p=0.02). Those who 
reported they had been admitted to hospital in the last two years because of their asthma had a 
statistically significantly higher mean (±SD) MARS score (21.2 ± 3.8) than those who had not been 
to hospital (18.6 ± 4.6) (p=<0.001) (Figure 4.15). There were no other significant associations 
between patient characteristics and MARS score.  
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Table 4.6: Associations between demographic and clinical characteristics and MARS score  
 n (%) 
Mean (±SD)   
MARS score 
(5 – 25) 
Statistical test 
Age, years   r (170)=0.18 , p=0.02 
Gender 
Female 
Male 
 
139 (80.3) 
34(19.7) 
 
19.1 (±4.5) 
19.5 (±4.8) 
 
t (171)=-0.54, p=0.59 
Location 
QLD 
NSW 
VIC 
SA 
WA 
TAS 
ACT 
NT 
 
102 (59.0) 
28 (16.2) 
17 (9.8) 
14 (8.1) 
5 (2.9) 
5 (2.9) 
1 (0.6) 
1 (0.6) 
 
19.5 (±4.4) 
18.1 (±5.2) 
19.5 (±4.5) 
18.9 (±4.4) 
18.6 (±5.4) 
16.8 (±3.7) 
25.0 
25.0 
F (7, 165) =1.0, p=0.44 
Level of Education 
Grade 10 
Grade 12 
Diploma/Certificate 
University 
Further Degree 
Other 
 
10 (5.8) 
26 (15.0) 
20 (11.6) 
74 (42.8) 
42 (24.3) 
1 (0.6) 
 
21.2 (±3.7) 
20.2 (±4.5) 
18.9 (±4.2) 
18.7 (±4.9) 
19.0 (±4.2) 
18.0 
F (5,167)=0.89, p=0.49 
Concession card 
Yes 
No 
 
40 (24.0) 
127 (76.0) 
 
20.3 (±4.2) 
18.8 (±4.6) 
t (165)=-1.8, p=0.07 
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Table 4.6: Associations between demographic and clinical characteristics and MARS score 
(cont.) 
  
 n (%) 
Mean MARS score 
 (±SD) 
(5 – 25) 
Statistical test 
Asthma duration, years r (162) =-0.10, p=0.19 
Main prescribed ICS ± 
LABA 
Fluticasone/salmeterol  
Budesonide/eformoterol  
Fluticasone 
Budesonide 
Fluticasone/eformoterol  
Others 
 
 
78 (45.1) 
63 (36.4) 
11 (6.4) 
7 (4.0) 
4 (2.3) 
10 (5.8) 
 
 
18.9 (±4.6) 
19.6 (±4.3) 
16.5 (±5.6) 
19.7 (±4.4) 
20.8 (±2.9) 
20.2 (±4.8) 
F (5, 167) = 1.2, p=0.33 
SABA use 
< 3 times per week 
≥ 3 times per week 
 
59 (45.7) 
70 (54.3) 
 
19.2 (±4.7) 
19.2 (±4.4) 
t (127) = 0.04, p=0.97 
Hospitalisation in last 2 
years because of asthma 
No 
Yes 
 
 
136 (78.6) 
37 (21.4) 
 
 
18.6 (±4.6) 
21.2 (±3.8) 
t(171) = -3.26, p=0.001 
Other prescribed 
medicines 
None 
1 – 4 
5 – 9 
≥10 
 
72 (41.9) 
86 (50.0) 
12 (7.0) 
2 (1.2) 
 
18.5 (±4.6) 
19.3 (±4.6) 
21.2 (±3.6) 
23.0 (±2.8) 
F (3, 168) = 1.7, p=0.16 
Perceived health 
Excellent 
Very Good 
Good 
Fair 
Poor 
 
15 (8.6) 
42 (24.1) 
74 (42.5) 
35 (20.1) 
8 (4.6) 
 
18.5 (±5.3) 
19.6 (±3.8) 
18.2 (±4.9) 
20.3 (±3.5) 
22.0 (±5.0) 
F (4, 169) = 2.6, p=0.40 
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Figure 4.15: Differences in mean MARS scores and 95% confidence intervals for individuals 
being hospitalised in last two years because of asthma (n=173)  
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 Stages of Change and Medication Adherence 
There was a significant difference in the mean MARS score across each stage of change (F (4, 154) 
= 26.7, p=<0.0001) as presented in Table 4.7. Tukey’s pairwise comparison using a familywise alpha 
of 0.01 indicated that participants in the action or maintenance stage of change had a significantly 
higher MARS score than participants in the pre-contemplation, contemplation or preparation stage of 
change. Those in preparation stage of change also had significantly higher MARS score than those in 
the pre-contemplation stage of change. As shown in Figure 4.16, MARS score increases with each 
stage of change.  
Table 4.7: Number of participants (n), mean MARS score and standard deviation (±SD) for 
each stage of change 
Stage of change n mean ±SD 
Pre-contemplation 13 12.1 3.9 
Contemplation 13 14.9 4.0 
Preparation  20 17.7 3.3 
Action  38 21.9 3.0 
Maintenance 75 20.4 3.6 
 
Figure 4.16: Differences in mean MARS scores and 95% confidence intervals for individuals 
in different stages of change (n=159) 
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 Beliefs about Medicines and Medication Adherence 
The necessity and concerns (BMQ) subscale and the necessity-concerns differential showed 
significant correlations with MARS score. Specifically, there was a positive correlation between 
necessity (BMQ) scores and MARS scores (r (159) = 0.17, p=0.03), a negative correlation between 
concerns (BMQ) scores and MARS scores (r (159) = -0.19, p=0.02) and positive correlation between 
the necessity-concerns differential and MARS scores (r (156) = 0.32, p=<0.0001).  
 Illness Perceptions and Medication Adherence 
The relationship between the different illness perceptions (B-IPQ) subscales and MARS are shown 
in  Table 4.8. There was a positive correlation between treatment control (B-IPQ) scores and MARS 
scores (r(160)=0.16, p=0.04) and understanding (B-IPQ) scores and MARS scores (r(160)=0.20, 
p=0.01). All other correlations were not significant.  
 Table 4.8: Correlations between B-IPQ subscales and MARS 
*Spearman’s rank correlation (ρ) 
  
Illness perception subscale Pearson correlation (r) P-value 
Consequences 
n=164 
-0.01 0.88 
Timeline  
n=163 
-0.05* 0.55 
Personal Control 
n=162 
0.08 0.29 
Treatment Control 
n=162 
0.16 0.04 
Identity  
n=163 
-0.06 0.42 
Emotional representation 1 
n=163 
0.06 0.48 
Emotional representation 2 
n=163 
-0.06 0.44 
Understanding 
n=162 
0.20 0.01 
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 Locus of Control Beliefs and Medication Adherence 
The correlations between each locus of control subscale and MARS are shown in Table 4.9. There 
was a significant positive correlation between doctor (MHLCS) scores and MARS scores (r (152) = 
0.41, p= <0.0001). There was no other significant correlations. 
Table 4.9: Correlations between MHLCS subscales and MARS 
 
 Discussion of Bivariate Results 
The results have shown that a number of different types of health beliefs were correlated with 
medication adherence in a predictable manner. From the BMQ, belief in the necessity of medicines 
was positively correlated with medication adherence and concern beliefs were negatively correlated 
with medication adherence. Treatment control illness perceptions from the B-IPQ were positively 
correlated with medication adherence. These findings are consistent with previous literature in 
individuals with asthma.155,164 Perceived understanding from the B-IPQ and doctor locus of control 
beliefs from the MHLCS were also both positively correlated with medication adherence. This has 
not been previously reported and makes a unique contribution to the literature.  
MARS score significantly increased from pre-contemplation, where the participants self-reported that 
they have no intention on adhering, through to contemplation, preparation, action and then 
maintenance, where participants reported that they are currently taking their preventer as prescribed. 
The significant relationship indicates that higher MARS scores are associated with later stages of 
change (action and maintenance) and this aligns with findings of another study in asthma.326 
Increasing age was the only demographic variable associated with medication adherence in this study 
and this has been reported previously in asthma15,164,327 This contradicts some literature suggesting 
older age is associated with non-adherence in individuals with chronic conditions.13 This may be 
because in asthma, there is generally a younger age group, compared to other chronic conditions such 
as heart disease, where the mean age is usually significantly older, and this may have influenced the 
finding.  
Locus of Control Subscale Pearson correlation P-value 
Internal 
n=154 
-0.11 0.16 
Chance 
n=147 
-0.06 0.45 
Doctor 
n=154 
0.41 <0.0001 
Other People 
n=154 
0.02 0.76 
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Individuals who had been hospitalised in the last two years because of their asthma had better 
adherence than those who had not. The Health Belief Model and Common Sense Model both suggest 
that individuals who perceive strong consequences of the illness are likely to act in a way that aims 
to reduce the health threat.17,157 In this situation, hospitalisation may demonstrate to the individual 
that asthma has serious consequences and this motivates them to adhere to their medication. This is 
further supported by a meta-analysis that found that in patients with less serious conditions (including 
asthma) those who had objectively-defined poor health were more adherent than patients with the 
same conditions in better health.298 Importantly, there is evidence in other conditions that non-
adherence can decline significantly 6–12 months after hospital discharge, suggesting this relationship 
may only be temporary.328 A limitation is that we did not ask participants to specify exact time since 
hospitalisations and therefore cannot examine this relationship further. Despite expectations, there 
was no relationship between SABA use and medication adherence. One would expect that those who 
do not adhere to the preventer would need to use their SABA more; however, results did not 
corroborate this finding. There are many possible reasons for this finding. It may be that participants 
are using their SABA (appropriately) prior to exercise or that they had been acutely unwell which 
would also increase the need for quick-acting medication.  
There was a significant correlation between the necessity and concern (BMQ) subscales and MARS 
score. Individuals who believed their preventer was necessary to help control their current and future 
health were more likely to adhere than those that did not. Individuals who had few concerns about 
taking their preventer, its side effects and long-term effects were also more likely to adhere to their 
preventer. It has been reported that in asthma, necessity beliefs had a stronger relationship with 
adherence compared to concern beliefs.15,155 This was not observed in this study, as the strength and 
direction of the association in this sample were comparable to the population level values in the meta-
analysis reported in Chapter 2, Section 2.4.3. The necessity-concerns differential was also positively 
correlated with medication adherence and this relationship appears stronger than necessity or 
concerns alone, a finding that has been reported previously.109 The differential is useful to understand 
the interplay between necessity and concern beliefs and the ‘cost-benefit’ decisions individuals are 
making with their medicines, as described by the Health Belief Model.109 
From the B-IPQ, treatment control and perceived understanding subscales were significantly 
correlated to MARS score. Believing that your preventer can help your asthma (treatment control) 
and that you understand your asthma (understanding), were associated with better medication 
adherence. Treatment control perceptions has been previously reported to be a predictor of adherence 
in asthma164 and other chronic conditions.80,169,172,173,178,179,181 These beliefs appear particularly 
important for adherence in asymptomatic conditions because the treatment may not cause any 
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noticeable changes in the condition (e.g. symptom relief) and this may lead the individual to believe 
there is no need for their medication. Recognising that their treatment is necessary to prevent long-
term complications appears essential. Perceived understanding of illness has not been widely 
investigated in the literature, but was positively correlated to adherence in the sample. A previous 
systematic review found no correlation between perceived understanding and medication adherence, 
but the review did not have any studies conducted in asthma.158 Individuals who can make sense of 
their asthma, its symptoms and treatment, and therefore have a better overall understanding of their 
asthma are more likely to adhere to their medication. This perception is said to represent a ‘meta-
cognition’ where the patient evaluates their understanding of their illness and is thought to be 
important for long-term adjustment and responding to symptoms.128 This finding suggests that 
exploring an individuals perceived understanding of their asthma is an important factor to consider 
when understanding their medication-taking behaviour.  
There was no significant correlation between the timeline (B-IPQ) subscale and MARS score which 
may have been due to the severely skewed data, making it difficult to show a correlation. Previous 
studies have reported that people with asthma often adopt an acute view of asthma, rather than 
considering it as a chronic condition and this can discourage long-term adherence.163,187 This was not 
observed in the sample, probably because most participants had asthma for a long duration already, 
which would have provided them with the knowledge that their condition is not short-term.  
A strong belief in the doctor to control health outcomes (doctor [MHLCS] subscale) was positively 
correlated to MARS score. This relationship was stronger than any other correlation found in the 
study (r=0.41). Individuals with strong doctor locus of control beliefs may be more receptive to the 
advice and recommendations given by the doctor compared to internally orientated individuals. It 
seems predictable that if an individual believes that their doctor can help control their asthma then 
they are more likely to take their medication prescribed by that doctor, as previously shown in 
asthma.326 This finding contributes to the literature as the relationship between doctor locus of control 
beliefs and medication adherence is rarely investigated. Other facets of the patient-doctor relationship 
have been found to be important for medication adherence. These include physician 
communication,16,69 patient attitudes towards doctors203 and trust in the doctor.70,71 Across different 
chronic diseases, negative attitudes towards doctor were the most important factor associated with 
medication adherence.203 In patients with bipolar disorder, trust in the advice of the doctor was shown 
to form one dimension of participants’ necessity (BMQ) beliefs70 and has also been found to moderate 
the relationship between cost of medicines and adherence.329 The doctor locus of control construct 
may also relate to treatment control (B-IPQ) illness perceptions. Given necessity (BMQ), treatment 
control (B-IPQ) and doctor (MHLCS) subscales were all positively correlated with adherence, it is 
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possible that they are measuring the same (or part of the same) construct. This suggests that positive 
beliefs around the healthcare team are critical for adherence to medication.  
 Limitations 
There are some limitations to consider when generalising the results of the study to all individuals 
with asthma. The majority of participants were recruited online through an asthma advocacy group. 
The benefits of online recruitment are reaching a wider population, including participants that are 
geographically isolated and participant anonymity.330 However; a limitation of this method of 
recruitment is it is not known whether online recruitment captures a more motivated group of 
individuals, whether these individuals hold different beliefs and/or report different levels of 
medication adherence. There were differences in the beliefs that were correlated to medication 
adherence in the sample compared to the literature. Unfortunately, not all studies describe the patient 
population well and this limits our ability to compare participant characteristics with other studies. 
This study has described the spread of adherence scores captured, representing different medication-
taking behaviours in the sample. This is not reported frequently in the literature, which makes it 
difficult to conclude whether this study captured different medication-taking behaviours compared to 
other studies using a self-report measure of medication adherence. Differences in medication-taking 
could influence how beliefs associated with medication adherence in patient populations.  
This study did not elicit all the beliefs that are likely to influence medication-taking behaviour in this 
sample. The focus on beliefs derived from the Health Belief Model, Common Sense Model and Locus 
of Control Model was based on empirical support and ability to measure beliefs related to the models 
in a convenient way. Patient characteristics that were not elicited may have influenced our results. 
Disease severity was not objectively measured in the study. People with severe asthma may have very 
different reasons for holding certain beliefs, compared to someone who has never had a bad 
experience with their asthma. Disease severity is also thought to be positively correlated with 
medication adherence in less serious diseases such as asthma.298 Indirect measures of severity used 
in the study were asthma-related hospitalisations in the last two years, number of prescribed ICS 
medication and SABA use. Peak flow measurements were recorded but there was a very small 
response rate for this survey question, which may indicate most individuals do not rely on peak flow 
monitoring. Responses to the indirect measures were typical for an asthma population and did not 
reflect a group of individuals with severe asthma. In the future it would be useful to elicit oral 
corticosteroid use in participants as a better indication of asthma severity, including previous asthma 
exacerbations.  
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 Conclusion 
There was a range of beliefs and medication-taking behaviours reported in this sample of individuals 
with asthma. We found that the mean scores on BMQ, B-IPQ and MHLCS subscales were different 
compared to other chronic conditions, suggesting that interventions to support medication adherence 
in asthma may need to be different to interventions used in other chronic conditions. Increasing age, 
being hospitalised because of asthma, strong necessity beliefs and few concern beliefs elicited from 
the BMQ, belief in treatment to help asthma and perceived understanding of asthma from the B-IPQ 
and belief in doctor to help control asthma from MHLCS were all found to be correlated with 
medication adherence. These findings indicate that beliefs play an important role in medication-taking 
behaviour and that further work is warranted to explore whether these beliefs can predict medication 
adherence in a multivariable model.  
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 MULTIVARIABLE MODEL OF MEDICATION ADHERENCE 
IN PARTICIPANTS WITH ASTHMA 
 Introduction 
Attempting to explain adherence behaviour using only one belief scale relies on an oversimplified 
model of adherence. This approach to adherence cannot account for the interrelationships between 
beliefs about medicines, illness perceptions and locus of control beliefs, and the ways in which these 
interrelationships may better predict adherence behaviour when compared to bivariate models. 
Adherence decisions are likely to be made through the interplay of an individual’s beliefs, leading 
the individual to make a decision about whether they should adhere to their medication.  
Studies examining the relationships between the BMQ, B-IPQ and MHLCS suggest that the 
constructs examined by these scales are interrelated, but little work has been done to investigate 
whether these relationships meaningfully relate to medication adherence. Scores from the BMQ have 
been found to correlate with scores from the IPQ107,165,167 and MHLCS.134 Specifically, the necessity 
(BMQ) subscale positively correlates with the consequences (B-IPQ) subscale and timeline (B-IPQ) 
subscale in asthma.165 In chronic pain, the necessity (BMQ) subscale was likewise correlated with 
consequences (B-IPQ) but researchers also reported that the concerns (BMQ) subscale was correlated 
with consequences (B-IPQ) and illness emotion (B-IPQ).167 In individuals taking lipid-lowering 
medication, the powerful others (MHLCS) subscale was correlated with both the necessity (BMQ) 
and concerns (BMQ) subscale.134  
Relationships between beliefs may change the way each ‘type’ of belief is associated with medication 
adherence.164,165,196 A study examining the interaction effect of locus of control subscales on 
objectively measured medication adherence (HbA1c in patients with diabetes) found that the way in 
which the chance (MHLCS) subscale scores correlated with HBA1c depended on the individual’s 
internal (MHLCS) score.196 Specifically, HbA1c levels were only correlated to chance (MHLCS) 
scores in individuals who also had low internal (MHLCS) scores. In individuals with a high internal 
locus of control (MHLCS) score, there was no significant correlation between chance (MHLCS) 
scores and HbA1c. This study concluded that locus of control beliefs meaningfully interrelate to affect 
medication adherence.196 It appears critical for individuals who have strong beliefs in chance to 
control their diabetes that they also believe in their own ability to follow their diabetic treatment 
regimen, to prevent poor HbA1c levels. It is proposed that beliefs about medicines, illness perceptions 
and locus of control beliefs may interrelate in a similar way and may explain the observed 
inconsistency in the relationships between different belief subscales and measures of medication 
adherence when evaluated through bivariate analysis. 
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Regression analysis is one approach to exploring the complex relationship between scales measuring 
beliefs about medicines, illness perceptions and locus of control beliefs and medication adherence. 
Regression analysis is capable of describing associations between beliefs and medication adherence, 
exploring relationships between beliefs as well as predicting an individual’s medication adherence 
based on a number of variables.331 This can help reveal important associations between variables and 
prediction can help health professionals identify individuals who are likely to be at risk of non-
adherence.  
This chapter describes the methods and results of a regression analysis that can be used to predict 
self-reported medication adherence from participant characteristics and subscales eliciting health 
beliefs in a sample of individuals with asthma.  
 Aim  
The aim of this chapter is to develop a multivariable regression model that can be used to predict 
medication adherence in individuals with asthma.  
 Research Questions 
1. What multivariable model best predicts the relationship between patient characteristics, 
measures of health beliefs (BMQ, B-IPQ and MHLCS) and self-reported medication 
adherence in a sample of individuals with asthma? 
2. How do measures of health beliefs (BMQ, B-IPQ, and MHLCS) interrelate to predict self-
reported medication adherence? 
 Methods 
A multiple linear regression line was calculated to predict self-reported medication adherence (MARS 
score) based on participant demographics, clinical variables and scores from the BMQ, B-IPQ and 
MHLCS, using backwards stepwise elimination. Backwards stepwise elimination was used to 
sequentially remove variables that made the smallest contribution to the model one at a time. This 
process continued until the best fitting model was obtained. Variables considered important for model 
prediction can be forced to stay in the model during this process. Stepwise elimination is useful in 
exploratory research where there is no a priori reason for entering variables into the model in a 
particular order. Alternative methods are preferred when there are clear a priori reasons to include 
specific variables in the model. However; in this study, backwards stepwise elimination was used.  
Identification of significant independent predictors was conducted in two steps. First, demographic 
variables, clinical variables and belief questionnaire subscales were entered into separate regression 
models to identify significant predictors from each group of variables. Then, any variable that 
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remained in this step was added into the final regression model. Variable and model selection for the 
preliminary and final model was based on the Akaike Information Criterion (AIC) measure.332 The 
AIC selects the model which maximises prediction while minimising model complexity. The AIC 
gives a relative indication of the fit of the model to the data.333 There is no statistical test of the AIC, 
but a smaller AIC indicates a better fit.333 
An interaction effect occurs when a variable effects the direction and/or strength of the relationship 
between another predictor variable and the dependent variable.334 Identification of significant 
interaction effects between subscales was conducted in two steps. Firstly, interactions were explored 
between different questionnaire subscales (e.g. necessity [BMQ] and doctor [MHLCS] subscales) and 
between belief subscales, demographics and clinical characteristics. Significant interactions (p-value 
of the t-statistic <0.05) were then added into the preliminary model and backwards stepwise linear 
regression was used to identify the final model. All predictor variables and interaction terms were 
standardised (z scoring) and centred (subtracted the data mean score from the individual data point, 
then divide each point by the standard deviation from all data points) to reduce multi-collinearity 
problems associated with interaction effects.335,336 In this situation, predictor and interaction terms 
are often strongly correlated as the interaction terms are a product of two predictor variables.336 
Standardising variables significantly reduces the correlation between the two terms.333,337 
Categorical variables (e.g. gender) were dummy-coded so that each category was entered in as a 
dichotomous variable (e.g. female = 1, male = 0). All variables were checked for normal distribution 
and multi-collinearity.  
Effect sizes for each predictor variable were reported as β-coefficients. β-coefficients correspond to 
the unit increase (decrease if negative) in MARS score for every one unit increase in the predictor 
variable. As each variable is measured on a different scale, the value of the β-coefficient does not 
necessarily indicate the importance of that variable. Standardised β-coefficients correspond to the 
unit increase (decrease if negative) in MARS score for every one standard deviation change in the 
predictor variable. Standardised β-coefficients are therefore comparable to each other. Unadjusted β-
coefficients represent the effect of the predictor variable on MARS score, without controlling for the 
other factors. Adjusted β-coefficients represent the effect of the predictor variable on MARS score, 
in the presence of all other variables in the model; therefore adjusted β-coefficients provide an 
independent association of each factor with self-reported medication adherence. Semi-partial 
correlations (squared) were reported as a method of assessing the relative importance of each variable 
in determining the MARS score.333 For the final model with interaction effects, all variables were 
standardised before model testing, therefore, the β-coefficient (unstandardised) for each variable was 
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not calculated. Variance Inflation Factors (VIF) were used as an index of multi-collinearity between 
variables.333 Generally, if a variable has a VIF larger than 10, the variable is considered to have 
significant multi-collinearity (strongly correlated to each other) which is problematic in regression 
analysis as it leads to large standard error of regression estimates.333 
Model fit parameters were examined through visual inspection of four different graphs. A Residuals 
vs Fitted plot and Scale-Location plot was produced to check the assumption of homoscedasticity. A 
Q-Q plot was produced to examine the distribution of residuals and inspect for outliers in the data. A 
Residuals vs Leverage plot was produced to identify any data points that may have a large influence 
on the model fit.338 Regression analysis fits a line that passes through the data, seeking to minimise 
the vertical distances between a data point and the line. The further away a data point is from the line, 
the more leverage (that is, more influence) they will have on the regression model.338,339 Leverage 
also increases if data points are isolated, therefore leverage reflects both distance from the regression 
line and isolation of the point. To evaluate whether any data points are driving the results of the 
regression (i.e. have a lot of leverage), Cook’s distance was calculated.339 This distance is how far a 
predicted value would move if the model was fitted without the data point. Any values outside of 
Cook’s distance (Residual vs Leverage plot) are considered problematic.  
 Results 
The preliminary model and final model with interactions effects are presented in section 5.5.1 and 
5.5.2, respectively. When checking the assumptions of normal distribution, the timeline (B-IPQ) 
subscale was found to be severely skewed towards higher scores (see Chapter 4, Section 4.5.5) and 
for this reason, scores were dichotomised into forever (10) and not forever (<10). Also, asthma 
duration was positively associated with concession card (p=0.035) and age (p<0.001), which could 
cause multicollinearity if all were added into the model. To avoid this, these were not all added in to 
the same model. Age was found to be the strongest predictor of MARS score and was the only one 
of these variables entered in the final model.  
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 Preliminary Model 
A significant regression equation, F (7,131) = 9.75, p=<0.001 with an adjusted R2 =0.31. MARS score 
was found to be predicted by the following equation: 
𝑴𝑨𝑹𝑺 𝒔𝒄𝒐𝒓𝒆 = 11 + (0.06 × 𝐴𝑔𝑒 ) + (2.25 × 𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛)
+ (0.18 × 𝑁𝑒𝑐𝑒𝑠𝑠𝑖𝑡𝑦 (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒) + (0.53 × 𝐷𝑜𝑐𝑡𝑜𝑟 (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒)
+ (1.13 × 𝑇𝑖𝑚𝑒𝑙𝑖𝑛𝑒 (𝐵-𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒) − (0.23 × 𝐶𝑜𝑛𝑐𝑒𝑟𝑛𝑠 (𝐵𝑀𝑄)𝑠𝑐𝑜𝑟𝑒)
− (0.11 × 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙 (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒) + 𝑈 
Where hospitalisation has been dummy-coded and is coded 1 for yes and 0 for no and timeline (B-IPQ) score has been coded 1 for not forever (score 
of <10) and 0 for forever (score of 10). 
 U is an error term that represents variables that were not measured.  
 
Table 5.1 shows the effect of each predictor variable on MARS score. The effect plots for each 
predictor variable on MARS score is presented in Figure 5.1. 
Table 5.1: Unadjusted, adjusted β-coefficient and standardised β-coefficient, standard error 
(SE) and p-value for each predictor variable on MARS score (n=139) 
Variables entered but not retained in final model: Prescribed more than 1 preventer, Understanding (B-IPQ) subscale, 
Other People (MHLCS) subscale. 
 
 
 
 Unadjusted Adjusted 
Variable β SE p-value β Standardised β SE p-value 
Age 0.08 0.03 0.005 0.06 0.16 0.03 0.03 
Hospitalisation –
Yes 
2.8 0.97 0.004 2.25 0.19 0.86 0.01 
Timeline (B-IPQ) – 
Not forever 
0.62 0.88 0.48 1.13 0.11 0.74 0.13 
Necessity (BMQ)  0.20 0.09 0.03 0.18 0.16 0.09 0.04 
Concern (BMQ)  -0.17 0.07 0.02 -0.23 -0.24 0.07 0.002 
Doctor (MHLCS) 0.64 0.11 <0.001 0.53 0.36 0.11 <0.001 
Internal (MHLCS) -0.10 0.08 0.21 -0.11 -0.11 0.07 0.15 
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Figure 5.1: Effect plots for predictor variables in preliminary model, with 95% confidence intervals
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 Final Model: Main Effects with Interaction Terms 
There were two variables that were found to have significant two-way interaction effects. These were 
the concerns (BMQ) subscale with the chance (MHLCS) subscale and the treatment control (B-IPQ) 
subscale with the understanding (B-IPQ) subscale. These variables were entered into the preliminary 
regression model described above to test whether model prediction could be improved.  
The final regression model with main effects and interaction terms produced an improvement in 
prediction, F (8,121) = 11.35, p=<0.001 with an adjusted R2 =0.39. This model explained 39% of the 
variance in MARS score using the following variables: age, hospitalisation in the last two years 
because of asthma, timeline (B-IPQ) subscale, necessity (BMQ) subscale, concern (BMQ) subscale, 
doctor (MHLCS) subscale and the two interaction effects (concern (BMQ) subscale moderated by 
chance (MHLCS) subscale and treatment control (B-IPQ) subscale moderated by understanding (B-
IPQ) subscale. See Table 5.2 for effect sizes.  
The regression equation is: 
𝑴𝑨𝑹𝑺 𝒔𝒄𝒐𝒓𝒆 = 19.0 + (0.82 × 𝐴𝑔𝑒 )  + (1.56 × 𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛) + (1.18 
× 𝑇𝑖𝑚𝑒𝑙𝑖𝑛𝑒 (𝐵-𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒)  + (0.52 × 𝑁𝑒𝑐𝑒𝑠𝑠𝑖𝑡𝑦 (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒)
+  (1.61 × 𝐷𝑜𝑐𝑡𝑜𝑟 (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒) − (0.90 × 𝐶𝑜𝑛𝑐𝑒𝑟𝑛 (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒)
− (1.02 × 𝐶𝑜𝑛𝑐𝑒𝑟𝑛 (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒 ∗ 𝐶ℎ𝑎𝑛𝑐𝑒 (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒 )
− (0.56 × 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐵-𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒 ∗ 𝑈𝑛𝑑𝑒𝑟𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔 (𝐵-𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒)
+ 𝑈 
Where hospitalisation has been dummy-coded and is coded 1 for yes and 0 for no and timeline (B-IPQ) score has been coded 1 for not forever (score 
of <10) and 0 for forever (score of 10).  
U is an error term that represents variables that were not measured.  
* represents an interaction effect 
 
As seen in Table 5.2, the doctor (MHLCS) subscale uniquely accounts for 12% of the variance in 
MARS score (semi-partial correlation squared=0.12). All variables in the model had a VIF of less 
than 2, indicating little evidence of multi-collinearity. Although the predictor variables, 
hospitalisation, timeline (B-IPQ) subscale and necessity (BMQ) subscale, had p-values (which is 
determined by the t-statistic) >0.05, they remained in the model because the method of removing 
variables from the model was using the AIC. 
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Table 5.2: Adjusted standardised β-coefficient, standard error (SE), p-value, semi-partial 
correlation squared and variance inflation factor (VIF) for each predictor variable and 
interaction effects on MARS score (n=130) 
 Adjusted 
Variable 
Standardised 
β 
SE p-value 
Semi-partial 
correlation 
squared 
VIF 
Age 0.82 0.30 0.01 0.032 1.04 
Hospitalisation- 
Yes 
1.56 0.89 0.08 0.015 1.16 
Timeline (B-IPQ) subscale– 
Not forever 
1.18 0.74 0.11 0.012 1.06 
Necessity (BMQ) subscale 0.52 0.34 0.13 0.011 1.25 
Doctor (MHLCS) subscale 1.61 0.32 <0.001 0.12 1.10 
Concern (BMQ) subscale -0.90 0.34 0.008 0.034 1.23 
Concerns (BMQ) subscale 
*Chance (MHLCS) subscale 
-1.02 0.30 <0.001 0.055 1.07 
Treatment control (B-IPQ) 
subscale * Understanding (B-
IPQ)subscale 
-0.56 0.24 0.02 0.026 1.11 
Variables entered but not retained in final model: Prescribed more than 1 preventer and Other People (MHLCS) subscale. 
Figure 5.2 describes four different model fit parameters for the regression model. Overall, model fit 
graphs showed that the final model fits the data well and that the assumptions of homoscedasticity 
(variance in residuals does not change with different values of the predictor variables) and normally 
distributed residuals are met. 
The Residuals vs Fitted plot (Figure 5.2a) and Scale-Location plot (Figure 5.2c) showed no particular 
trend in the data, with data points being randomly distributed around the horizontal line. This suggests 
we can make the assumption of homoscedasticity.338 The Q-Q plot (Figure 5.2b) shows that most of 
the data points are lying within the red dashed lines (95% confidence intervals) and only a few data 
points are varying from the centre at the ends. This suggests normal distribution of residuals, with 
minimal outliers. Lastly, The Residuals vs Leverage plot (Figure 5.2d) shows that that the red line 
stays close to the horizontal dashed line and there are no points outside Cook’s distance (>0.5). This 
indicates that no single observation is heavily influencing the regression model.  
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Figure 5.2: Model Fit parameters: a) Residuals vs Fitted plot, b) Q-Q plot, c) Scale-Location plot and d) Residuals vs Leverage plot 
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An effect plot for each of the independent predictors in the final model is shown in Figure 5.3. The 
effect plot for the concerns subscale is not shown as it is discussed in detail with interaction effects 
in Figure 5.4. Continuous predictor variables have been standardised and therefore values on each x-
axis describe standard deviation units away from the mean.  
 
127 
 
 
 
Figure 5.3: Effect plots for predictor variables (standardised) on MARS score, with 95% confidence intervals 
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The interaction terms that were found to be significant in the model were the concerns (BMQ) 
subscale being moderated by the chance (MHLCS) subscale and treatment control (B-IPQ) subscale 
being moderated by the understanding (B-IPQ) subscale.  
The relationship between MARS scores and concerns (BMQ) scores at different scores on the chance 
(MHLCS) subscale is presented in Figure 5.4. When an individual has a score of the mean or above 
(≥16.8) on the chance (MHLCS) subscale (long dashed, dotted and solid line), there is a significant 
negative correlation between the concern (MHLCS) subscale score and MARS score (Pearson’s 
correlation= -0.46, p=<0.001). Conversely, when an individual scores lower than the mean (<16.8) 
on the chance (MHLCS) subscale (dot-dash and dashed line), there is no statistically significant 
correlation between the concern (BMQ) subscale and MARS score (Pearson’s correlation= -0.001, 
p=0.99). This indicates that the chance (MHLCS) subscale is moderating the correlation between 
concerns (BMQ) score and MARS score. 
 
 
Figure 5.4: Effect plot for concerns (BMQ) score on MARS score being moderated by chance 
(MHLCS) subscale. Each line on the graph represents a different standard deviation away 
from the mean score (mean [±SD] = 16.8 [±5.2]) for the chance (MHLCS) subscale. 
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The second significant interaction observed was between the treatment control (B-IPQ) subscale and 
understanding (B-IPQ) subscale. Figure 5.5 shows that the relationship between treatment control 
(B-IPQ) scores and MARS scores is different depending on the score of the understanding (B-IPQ) 
subscale. Specifically, for those who have a score lower than the mean (<7.2) on the understanding 
(B-IPQ) subscale (long dashed, dot-dash and dashed line), there is a positive correlation between 
treatment control (B-IPQ) scores and MARS scores (Pearson’s correlation=0.29, p=0.01). For those 
with a score of the mean or higher (≥7.2) on the understanding (B-IPQ) subscale (dotted and solid 
line), there is no statistically significant correlation between treatment control (B-IPQ) scores and 
MARS scores (Pearson’s correlation= -0.06, p=0.57). This indicates that the understanding (B-IPQ) 
subscale is moderating the correlation between treatment control (B-IPQ) scores and MARS scores 
in this population.   
 
Figure 5.5: Effect plot for treatment control (B-IPQ) score on MARS score being moderating 
by understanding (B-IPQ) subscale. Each line on the graph represents a different standard 
deviation away from the mean score (mean [±SD] = 7.2 [±2.4]) on the understanding (B-IPQ) 
subscale. 
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  Discussion 
A multivariable model was developed to identify factors that can predict self-reported medication 
adherence in a sample of individuals with asthma. Age, hospitalisation in the last two years because 
of asthma, necessity and concern beliefs, timeline illness perceptions and doctor locus of control 
beliefs all predicted medication adherence in the final model. When interaction effects were 
introduced into the model, there were two significant interactions between scales measuring health 
beliefs: concerns (BMQ) subscale interacting with chance (MHLCS) subscale and understanding (B-
IPQ) subscale interacting with treatment control (B-IPQ) subscale. These interactions suggest that 
the regression of each of the predictors on MARS score depends on the value of the other predictor.333 
Both of these interaction terms were a better predictor of MARS score than either predictor alone. 
Including these interactions into the model improved the prediction of MARS score by eight percent. 
The final model accounted for 39% of the variance seen in participants’ self-reported medication 
adherence. These findings confirm that adherence is a multifaceted behaviour, with many factors 
predicting adherence. 
In common with previous research, beliefs were a predictor of medication adherence.13,73,165 Belief 
that the doctor can control asthma outcomes (elicited by the doctor [MHLCS] scale) accounted for 
the most variance (12%) in the regression model. This was ten times greater than the predictive power 
of the necessity (BMQ) subscale and nearly five times greater than the concerns (BMQ) subscale. 
This confirms the findings from Chapter 4 that for this sample, belief in the doctor to control asthma 
outcomes, is a key factor associated with participants’ medication adherence.  
The overall model prediction was better than those reported in studies using only the BMQ and IPQ 
(Aflakseir [R2=0.25],168 Rajpura and Nayak [R2=0.21]322 and Morgan et al. [R2=0.20]185) and the 
BMQ and MHLCS (Berglund et al. [R2=0.06]134). In another study of individuals with asthma, a 
regression model predicted 36% of the variance in MARS score, using only illness perceptions and 
beliefs about medicines.165 The strongest predictors were beliefs about medicines.165 However, the 
BMQ used in this study incorporated an additional six asthma-specific items, which may have 
attributed to the improved prediction of medication adherence in the sample as the beliefs were more 
specific to medication-taking behaviour in asthma.165 
Interactions effects have not been widely explored in the adherence literature or described in 
theoretical models, but were important predictors in the final model and provided deeper insight into 
understanding the interplay of beliefs and their relationship with adherence. As with previous 
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research, scores on the concerns (BMQ) subscale were a significant predictor of medication 
adherence in the total sample.155,156 However, the significant interaction term found suggests that the 
relationship is more complex, with different scores on the chance (MHLCS) scale moderating the 
relationship.  
In individuals with a high score on the chance (MHLCS) subscale, there was a strong negative 
correlation between concern (BMQ) subscale scores and MARS scores. On the other hand, in 
individuals with a low score on the chance (MHLCS) subscale, concern (BMQ) subscale scores were 
not significantly correlated to MARS score. These findings suggest that an individual’s chance locus 
of control beliefs changes the way their concern beliefs about medicines relate to their medication 
adherence. This interaction effect may explain the weak correlations previously reported in the 
literature between concern (BMQ) subscale scores and measures of medication adherence. Two meta-
analyses have shown that concern (BMQ) subscale scores are associated with measures of medication 
adherence on a population level 155,156; however, the association is weak.155 By examining interaction 
effects, we found that the correlation for individuals with high chance (MHLCS) subscale scores was 
significantly stronger (r=-0.46, p=<0.001) compared to the correlation found in bivariate analysis (r= 
-0.19, p=0.02). By combining these sub-populations, researchers may be diluting the effect of concern 
beliefs on medication adherence. If this finding is a true effect, it suggests that chance locus of control 
beliefs should be taken into account when considering the relationship between concern beliefs and 
medication adherence. 
The interaction between the concerns (BMQ) and chance (MHLCS) subscale is consistent with the 
literature. Subscales of the MHLCS have been found to interact and moderate the relationship with 
objectively measured medication adherence (HbA1c).196 Another study has found locus of control 
beliefs (elicited using a different locus of control questionnaire) moderated the correlation between 
medication barriers and self-reported medication adherence.213 One suggestion is that chance locus 
of control beliefs changes the way individuals react when they experience concerns, such as perceived 
side effects of their medicine.191 Individuals who believe their health outcomes are ultimately due to 
chance may be less likely to endure concerns regarding the side effects of medication and therefore 
stop taking their medication.191 Conversely, individuals who do not believe that chance controls their 
asthma may be more likely to continue to take their medicines even when they have concerns, as they 
may believe it is the only way to control their asthma. Although concerns (BMQ) score alone was a 
significant predictor in the regression model, eliciting chance locus of control beliefs appears to 
provide a method of targeting individuals who would benefit most from an intervention aimed at 
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reducing concern beliefs about medicines. In our study population of individuals with asthma, this 
suggests that addressing concern beliefs may be more relevant in those individuals who also have a 
strong belief in chance to control their illness. Particular concern beliefs that may be relevant to 
individuals who also hold concomitant beliefs that their asthma is due to chance, may be around 
potential long-term side effects and dependence on their ICS. Addressing beliefs about the concerns 
of a medication to improve medication adherence may be less effective in those individuals with weak 
chance locus of control beliefs. This is a testable hypothesis. 
The second interaction showed that an individual’s score on the understanding (B-IPQ) subscale 
moderated the correlation between the treatment control (B-IPQ) subscale and MARS scores. 
Although both variables were positively correlated with MARS score in bivariate analysis, neither 
emerged as independent predictors in the final regression model. The two subscales together as an 
interaction were a significant predictor in the multivariable model. In individuals with low scores on 
the understanding (B-IPQ) subscale, treatment control (B-IPQ) scores were positively correlated to 
MARS scores. This means that only in individuals who self-reported a poor understanding of asthma, 
were beliefs about treatment to control their asthma correlated to medication adherence.  
In individuals with a high score on the understanding (B-IPQ) subscale, there was no correlation 
between treatment control (B-IPQ) scores and MARS scores. There is no literature describing this 
observation and the health behaviour models do not provide any theory on this interaction. While 
holding strong beliefs in treatment to control asthma (elicited by the treatment control (B-IPQ) 
subscale) has been previously correlated with different measures of medication adherence in 
asthma164 and other chronic conditions,80,169,172,173,175,178-181 this is the first study to find that the 
relationship is moderated by perceived understanding of asthma. This suggests that addressing 
treatment control beliefs is likely to be more effective in individuals with poor understanding than 
those with a good understanding of asthma.  
It would be valuable to investigate the role of interaction effects in other chronic diseases to explore 
whether these findings are illness specific or if they can be translated across different chronic 
conditions.  
The findings of this study should be tested in a larger asthma population to ensure findings are robust 
and test the predictability of the regression model. In particular, it would be important to validate the 
negative association between timeline (B-IPQ) perceptions and MARS score as this was an 
unexpected finding. The timeline (B-IPQ) subscale was not a significant correlate of MARS in the 
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bivariate analysis and previous work suggests that believing a chronic illness will last forever is 
associated with better adherence.164 Our findings are limited by the skewed results and having to 
dichotomise the timeline (B-IPQ) subscale which may have influenced the findings. Therefore, this 
finding needs to be validated in another sample of individuals with asthma.  
 Conclusion 
Using regression analysis with interaction effects, health beliefs elicited from validated 
questionnaires were found to predict self-reported medication adherence. Older age, hospitalisation 
in the last two years, beliefs about the necessity and concerns of medicines, perceptions about the 
timeline of asthma and belief in the doctor to control health outcomes were all predictors of 
medication adherence. 
Prediction of medication adherence was improved by interaction effects between different health 
belief scales. Chance locus of control beliefs were found to be moderating the relationship between 
concern beliefs about medicines and medication adherence. Also, understanding illness perceptions 
were found to moderate the relationship between treatment control illness perceptions and medication 
adherence. These interaction terms suggest that the relationship is changed in certain sub-populations 
and the final regression model was able to account for these differences through the incorporation of 
the two interaction terms in the regression equation. Interactions between beliefs may be one reason 
for the low correlations reported between scales eliciting beliefs and measures of medication 
adherence. The findings of this study contribute to a better understanding of the role of beliefs in 
medication adherence in individuals with asthma. Certain beliefs meaningfully interrelate with each 
other and change the relationship they have with medication adherence. If these beliefs are causally 
related to medication adherence and can be intervened upon, the findings of this study are useful for 
providing targets to better personalise adherence support to the individual’s requirements. In doing 
so, we propose that this would lead to population level improvements in medication adherence.  
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 EXPLORING THE CAUSAL RELATIONSHIP BETWEEN 
BELIEFS AND MEDICATION ADHERENCE 
 Introduction 
The results of the correlation and regression analysis have contributed to and improved our 
understanding of the relationships between health beliefs and medication-taking behaviour in 
individuals with asthma. This research opens up new avenues of inquiry for understanding medication 
adherence and developing interventions to better support medication-taking behaviour. This chapter 
aims to explore the degree to which the regression model identified in Chapter 5 represents causal 
relationships among the variables.  
One way to identify interventions that may improve medication adherence is to assess the degree to 
which the variables present in the regression model can be given a causal interpretation.331 There are 
several accounts of causality in the literature. Judea Pearl340 and James Woodward331 are leading 
protagonists of the interventionist account of causation. In the interventionist account of causation, 
the focus is on the effect of changes in one set of variables on an outcome variable. According to this 
account, the claim that “A causes B” is interpreted to mean that, other things being equal, if you 
intervene to cause a change in the value of A, you will see a change in the value of B. The assumptions 
that need to hold for the relationships between the variables in a regression model to be interpreted in 
a causal manner are specified in the interventionist account of causality — see Pearl340,341 and 
Woodward339 for further detail.  
The relationships between variables provided in a regression model can be interpreted in a number of 
ways. The model can be given a descriptive interpretation, a predictive interpretation or a causal 
interpretation.342 Each step from description, prediction to causation makes additional assumptions 
on the data. With additional assumptions there is increased risk for error. The trade-off, however, is 
that on the proviso that the assumptions hold, you can do much more with causal knowledge opposed 
to descriptive or predictive knowledge. In much of the medical literature, including in the medication 
adherence literature, the interpretation given to regression models is left implicit. Most regression 
models presented in the medication adherence literature appear to be interpreted as either descriptions 
or predictions based on observed data. Describing a body of data shows associations between 
variables in the sample without making claims about the stability of the model over time or in a 
different sample. To interpret a regression model as predictive is to suggest that should the same data 
be collected in a different sample or at a different time, you would expect to see relationships in the 
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data like those represented in the model.342 Causal inference is different because it describes what 
will happen to an dependent variable if you change one or more independent variables.342 In broad 
terms, to interpret a regression model as causal within the interventionist account is to suggest that if 
you intervene on one of the independent variables in the model in a population, you would expect to 
see a change in the dependent variable equivalent to that estimated by the model.  
To demonstrate the difference between interpretations, consider a study that is investigating whether 
umbrella use (independent variable) is related to rainfall (dependent variable). Data are collected from 
a city centre. The proportion of people carrying an umbrella at a busy central intersection between 
8am and 9am is calculated. Rainfall from 9am to 10pm that day is also collected. The data are 
analysed and a regression model is produced which shows that there is an association between the 
proportion of people carrying umbrellas in the city centre in the morning and rainfall later that day. 
The descriptive interpretation of this model suggests that umbrella use is associated with rainfall in 
this sample of data. The predictive interpretation of this model suggests that this association would 
be observed in another city centre or at a different point in time. The causal interpretation of this 
model suggests increasing umbrella use will increase rainfall. Clearly, for this model, the descriptive 
and predictive interpretation can be defended, but the causal interpretation cannot. Intervening to 
increase or decrease the proportion of people carrying umbrellas is not going to affect rainfall. The 
regression model may be descriptive and predictive but there is no causal relationship — umbrella 
use does not cause rainfall.  
The regression model in Chapter 5 found that the sample’s MARS score can be described by a number 
of health belief scales and we have given this a descriptive and predictive interpretation. To be able 
to inform interventions, the next step is to identify which of these variables may be amenable to an 
intervention to improve medication adherence. This requires giving the regression model a causal 
interpretation.  
For reference, the regression equation that was identified in Chapter 5, Section 5.5.2 is shown below. 
Timeline illness perceptions have not been included in this discussion, because of the severely skewed 
distribution in the sample making it difficult to conclude the actual relationship, as discussed in 
Chapter 5, Section 5.6.  
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𝑴𝑨𝑹𝑺 𝒔𝒄𝒐𝒓𝒆 = 19.0 + (0.82 × 𝐴𝑔𝑒 )  + (1.56 × 𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛) + (1.18 
× 𝑇𝑖𝑚𝑒𝑙𝑖𝑛𝑒 (𝐵 − 𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒)  + (0.52 × 𝑁𝑒𝑐𝑒𝑠𝑠𝑖𝑡𝑦  (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒)
+  (1.61 × 𝐷𝑜𝑐𝑡𝑜𝑟 (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒) − (0.90 × 𝐶𝑜𝑛𝑐𝑒𝑟𝑛  (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒)
− (1.02 × 𝐶𝑜𝑛𝑐𝑒𝑟𝑛  (𝐵𝑀𝑄) 𝑠𝑐𝑜𝑟𝑒 ∗ 𝐶ℎ𝑎𝑛𝑐𝑒  (𝑀𝐻𝐿𝐶𝑆) 𝑠𝑐𝑜𝑟𝑒 )
− (0.56 × 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  (𝐵 − 𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒
∗ 𝑈𝑛𝑑𝑒𝑟𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔  (𝐵 − 𝐼𝑃𝑄) 𝑠𝑐𝑜𝑟𝑒) + 𝑈 
Where hospitalisation has been dummy-coded and is coded 1 for yes and 0 for no and timeline (B-IPQ) score has been coded 1 for not forever (score 
of <10) and 0 for forever (score of 10).   
U is an error term that represents variables that were not measured.  
* represents an interaction effect 
In this chapter I explore the degree to which the observed relationships between beliefs and 
medication adherence in the regression model can be provided with a causal interpretation, given my 
data, the theory behind the BMQ, B-IPQ and MHLCS and the available literature. I will describe how 
the theory, the literature and the results of the regression model have been used to develop a causal 
diagram and provide several hypotheses that can be tested in the future.  
 Causal Interpretation of the Regression Model  
The hypothesised causal relationships between beliefs and adherence are presented in Figure 6.1. In 
this figure, a single-headed arrow represents a direct link from cause to effect. A bidirectional dashed 
arrow is used to indicate that the variables may have overlap in the constructs they represent. 
Moderator effects are represented by an arrow on the connecting arrow between two variables. These 
representations align with formal representation of causal diagrams in the literature (see, for instance, 
Pearl343).  
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Figure 6.1: Hypothesised causal relationships between beliefs and medication adherence in a 
sample of individuals with asthma 
 
In developing this causal diagram I have made a number of assumptions about the scales we have 
used to measure health beliefs. The first assumption is that the BMQ, B-IPQ and MHLCS are 
measuring the important constructs described by the Health Belief Model, Common Sense Model and 
Locus of Control Model. We are relying on the validation of these scales (Chapter 3, Section 3.4.6) 
and that they are measuring the relevant constructs in individuals. Also, although it is plausible that 
these scales are robust over time (test-retest reliability), this is an assumption being made.  
We are assuming that the constructs measured by the BMQ, B-IPQ and MHLCS are based on specific 
beliefs than an individual holds and that, to some extent, modifying these specific beliefs will cause 
a corresponding change in the scale score. The BMQ, B-IPQ and MHLCS subscales alone do not 
provide enough detail to inform interventions. To support medication-taking, interventions would 
need to be aimed at the specific beliefs and not the scales measuring the beliefs. Identifying these 
specific beliefs would need to be done at the ‘individual level’. For example, there is likely to be 
many different beliefs contributing to the way an individual responds on the BMQ scales and these 
are likely to differ between individuals. To be able to modify an individual’s BMQ score, it would be 
necessary to understand the specific beliefs they hold about their medicines. This would need to be 
done through an individualised, tailored approach. If the right beliefs are modified in individuals, we 
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assume we will see a change in the scales measuring those beliefs and, if the causal assumptions are 
correct, we will see a change in adherence behaviour as measured by mean MARS score. 
With these assumptions in mind, I will describe how the theory behind the BMQ, B-IPQ and MHLCS, 
the available literature and the results of the regression model were used to inform four specific 
testable hypotheses described by Figure 6.1.  
Hypothesis 1: Improving necessity beliefs and reducing concern beliefs about medicines will 
improve medication adherence. 
The Health Belief Model proposes that the perceived benefits and costs of a behaviour influence 
whether that behaviour is chosen (as described in Chapter 1, Section 1.3.1).18 This suggests a causal 
relationship and, therefore, that changing the way an individual perceives the benefits and costs of 
their medication-taking behaviour is expected to change their behaviour.18  
The regression model found that high necessity (BMQ) scores and low concerns (BMQ) scores 
predicted better self-reported medication adherence in the sample. These results are consistent with 
the Health Belief Model theory and aligns with a large amount of literature that has demonstrated a 
relationship between beliefs about medicines and medication adherence, including two meta-analyses 
of over 100 different studies.155,156 Interventions in patients with chronic disease have shown changes 
in BMQ scores followed by changes in medication adherence235,237 and improved clinical outcomes 
(blood pressure control).235 
Given the theoretical support of a causal relationship, the significant associations reported in the 
literature and some interventional support, I hypothesise that necessity and concern beliefs have a 
direct causal influence on medication adherence, as shown in Figure 6.1, in the way described by the 
Health Belief Model. Targeting interventions towards improving necessity beliefs and reducing 
concern beliefs may be an appropriate strategy to improve adherence in individuals with asthma who 
do not perceive their ICS to be necessary and/or have strong concerns.  
Figure 6.1 also describes the moderator effect of chance locus of control beliefs on concern beliefs 
about medicines. Discovery of this moderator effect has contributed to our understanding on the way 
beliefs interact. Although the concerns (BMQ) subscale was an independent predictor of MARS 
score, our moderator analysis found that the relationship was stronger in individuals who also had 
high chance (MHLCS) subscale scores. As described in Chapter 5, Section 5.6, a possible explanation 
for this interaction effect is that individuals who are more likely to believe their health outcomes are 
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due to chance may be more likely to act on concerns regarding the side effects of medication and 
reduce the amount they take of their medicines.191 In summary, concerns about ICS appear to be 
causally related to medication adherence and addressing concerns should improve adherence. A 
group in whom addressing concerns may be especially effective are those who believe that chance 
plays a strong influence on their health outcomes.  
Hypothesis 2: Improving treatment control illness perceptions will improve medication 
adherence in individuals with poor perceived understanding of their asthma. 
Unlike the Health Belief Model, the Common Sense Model is not clear on the casual relationship 
between illness perceptions and health behaviour. The model does not specify how illness perceptions 
may influence a behaviour such as medication adherence and does not commit to the view that 
changing these beliefs will change a behaviour.  
The literature exploring the relationship between illness perceptions and medication adherence 
(Chapter 1, Section 1.3.2.1) is not consistent, particularly across different conditions. Without guiding 
theory, consistent associations in the literature or intervention studies, it is more difficult to propose 
the expected causal relationship between each illness perception elicited by the B-IPQ and medication 
adherence. 
The findings from the regression model suggest that treatment control (B-IPQ) scores predict 
medication adherence in individuals with low understanding (B-IPQ) scores. We have described this 
a causal relationship as represented in Figure 6.1. This figure also has a bidirectional dashed arrow 
between treatment control (B-IPQ) and necessity (BMQ). This represents that these beliefs are likely 
to be measuring similar constructs and is discussed in hypothesis 4. 
One interpretation of this finding is that in individuals who have good understanding of their asthma, 
the other health beliefs they hold, such as beliefs about whether they believe their ICS can help their 
asthma (as measured by the treatment control (B-IPQ) subscale) may become less relevant to the 
individual’s medication-taking behaviour. Presumably, this could be because these individuals 
understand they need to use their ICS to control their asthma. This aligns with the notion that 
understanding illness perceptions can be considered a meta illness perception which represents 
whether the individual has a coherent understanding of their asthma.128 In individuals with poor 
perceived understanding, who may not have a coherent understanding of their asthma, I propose that 
improving treatment control beliefs is a strategy to improve their adherence.  
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Hypothesis 3: Improving doctor locus of control beliefs will improve medication adherence but 
may be difficult to change. 
The Locus of Control Model describes the relationship between perceived controllability of health 
and behaviour. The model suggests that those who believe their health is controlled by themselves 
(an internal locus of control) are more likely to take steps to improve their health (e.g. adhere to their 
medicines), compared to individuals who belief their health is controlled by external forces.19 Locus 
of control beliefs are thought to stem from relatively permanent factors, such as personality traits, 
which may be difficult to modify.189  
There is limited literature exploring the relationship between locus of control beliefs and medication-
taking behaviour. A small number of studies have reported a negative association between external 
locus of control beliefs and medication adherence203,208,210,211,218 and this aligns with the theory. 
However, most of these studies use a different measure of locus of control beliefs which does not 
consider doctor locus of control beliefs as a separate subscale. When considering medication 
adherence in individuals with chronic conditions, doctor locus of control beliefs may have a different 
relationship to medication adherence, compared to chance and other people locus of control beliefs. 
Some studies have reported positive associations between doctor locus of control beliefs and 
measures of medication adherence.200,204,207,216  
In this sample of individuals with asthma, the regression model found that the doctor (MHLCS) 
subscale was a strong predictor of medication adherence. In individuals with asthma, a strong belief 
in the doctor to control health may lead individuals to be more trusting in their doctor, satisfied with 
their advice and accept their recommendations. I propose that doctor locus of control beliefs cause 
the individual to be adherent to their medication, as they have been recommended to do so by their 
doctor. This has been described in Figure 6.1, with a direct causal relationship between doctor locus 
of control beliefs and medication adherence.  
One challenge in developing an intervention is that locus of control beliefs may not be easily 
modifiable, being a personality-related concept.189,344 Here I suggest that although a causal 
relationship exists, these beliefs may not be amenable to an intervention aimed at improving 
medication adherence.  
Hypothesis 4: There is overlap in the constructs measured by the BMQ, B-IPQ and MHLCS.  
The last hypothesis describes the bidirectional dashed arrows between doctor (MHLCS), necessity 
and concerns (BMQ) and treatment control (B-IPQ) shown in Figure 6.1. These arrows have been 
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used to specify that these beliefs may be interrelated and there may be overlap in the beliefs 
underpinning these constructs or in the constructs themselves.  
The BMQ and B-IPQ are interdependent on each other’s development, which is likely to have led to 
some overlap in the constructs they measure. In the original IPQ160 there was no distinction between 
treatment control and personal control. The BMQ was then developed with the idea that if individuals 
have beliefs about their illness, then they are also likely to have beliefs about their medicines that 
inform decisions about taking their medicines.127 The IPQ-R and B-IPQ were then developed based 
on the IPQ and to make the distinction between treatment and personal control. This distinction was 
made because of the growing interest into beliefs about medicines.128 The overlap between the BMQ 
and treatment control (B-IPQ) subscales is therefore expected. 
Examining the individual statements in the necessity (BMQ) subscale, it can be seen that “my health, 
at present, depends on my medicines” and “without my asthma medication I would be very ill” is 
eliciting similar beliefs to the treatment control (B-IPQ) subscale, “How much do you think your 
preventative inhaler can help your asthma?”. Similarly, subscales of the BMQ have been found to 
relate to the doctor (MHLCS) subscale, where patients who believe in their doctor to control their 
health may also hold stronger (or more) beliefs around the necessity and concerns of their 
medicines.134 Given, beliefs about medicines relate to a medication prescribed by the doctor, it is 
plausible that the doctor (MHLCS) subscale may be eliciting beliefs that relate to beliefs about 
medicines. This presents a challenge to be able to identify the cause of a change in adherence. It may 
not be possible to modify one set of beliefs without modifying the other interrelated beliefs. The 
extent to which these beliefs are related requires further research.  
 Conclusion 
This chapter has provided an opportunity to generate four hypotheses about the potential for beliefs 
about medicines, illness perceptions and locus of control beliefs to be amenable to an intervention 
that will improve adherence. I suggest that improving necessity beliefs and reducing concern beliefs 
about medicines, as measured by the BMQ is a strategy to improve medication adherence. In 
individuals who believe in chance to control their asthma (MHLCS) reducing concerns may have a 
stronger impact on adherence. Improving treatment control beliefs in individuals with poor 
understanding of their asthma is another strategy to improve medication adherence. Doctor locus of 
control beliefs appear to be causally related to adherence, but these beliefs may difficult to change.  
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In giving a regression model a causal interpretation, we have made a number of assumptions around 
the scales used to measure the constructs and we have not discussed possible confounders or 
unmeasured constructs. This chapter used the theoretical frameworks available and the literature 
exploring beliefs and medication adherence, to explore the degree to which relationships observed in 
the regression model may represent causal relationships. This is preliminary work and requires 
validation. This chapter however has allowed us to identify promising strategies for improving 
medication adherence.  
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 DISCUSSION 
 Introduction  
This thesis explored the relationship between beliefs about medicines, illness perceptions and locus 
of control beliefs with self-reported medication-taking in a sample of individuals with asthma. 
Medication non-adherence remains a barrier to improved health outcomes in individuals with chronic 
conditions. To support individuals in taking their medicines, a better understanding of the role of 
beliefs in medication-taking behaviour is needed. Models of health behaviour provide a theoretical 
framework for describing how beliefs may influence medication adherence. The Health Belief Model, 
Common Sense Model and Locus of Control Model have all been used to describe the type of beliefs 
that influence medication-taking behaviour. From these models, the beliefs an individual holds about 
their medicines, illness and controllability of their health have been identified as important factors to 
consider when understanding medication-taking behaviour. The literature review conducted in 
Chapter 1 identified that most researchers only examined the way one belief scale relates to a measure 
of medication adherence. Attempting to explain adherence behaviour using only one belief scale 
relies on an oversimplified model of adherence. Based on the available research across different 
chronic conditions, the way beliefs about medicines, illness perceptions and locus of control beliefs 
associate with medication adherence is often unclear and inconsistent. The application of multiple 
health behaviour models may improve our understanding of the role of health beliefs in medication-
taking behaviour.  
 Key Findings  
 Beliefs about Medicines Correlate to Medication Adherence on a Population Level 
Beliefs about medicines have been widely explored in the adherence literature, although studies vary 
in terms of illness population, measures of medication adherence and statistical methods used. This 
made it difficult to conclude from the individual studies whether both necessity and concern beliefs 
were significantly correlated with medication adherence on a population level. To address this, I 
conducted a meta-analysis that was published in Patient Education and Counseling (Chapter 2). 
Necessity and concern beliefs were both significantly correlated to medication adherence in the meta-
analysis, although the effects sizes were small but comparable to other barriers to medication 
adherence. When findings were stratified by condition, the effect size was similar for the majority of 
included conditions. Although a number of conditions consisted of only a few studies, that available 
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data suggests that necessity and concerns beliefs have a small but relatively consistent influence on 
adherence across different medical conditions.  
The findings of the meta-analysis were important for informing the development of the study design 
reported in Chapter 3. Necessity and concerns beliefs are one set of beliefs that are correlated with 
medication adherence. Other beliefs outside the Beliefs about Medicines Framework may also be 
important, but there is little work exploring their role.  
 Beliefs and Self-Reported Medication Adherence in Individuals with Asthma 
Chapter 3 of the thesis describes the design of a study that explored the association between scales 
eliciting beliefs about medicines, illness perceptions and locus of control beliefs with self-reported 
medication adherence in individuals with asthma. The results of this study were reported in Chapter 
4 and 5.  
In the 198 participants included in the study, there was a range of medication-taking behaviours 
reported. Many individuals reported that they alter their dose and frequency and/or stop their ICS 
intermittently. The relatively low mean MARS score indicated that most participants had poor ICS 
adherence. Medication adherence in the sample was similar to other studies conducted in 
asthma,130,248 and less than more serious conditions such as cancer141 and stroke.253 To better 
understand medication-taking behaviour in asthma, the beliefs individuals held about their medicines 
(beliefs about medicines [BMQ]), their illness (illness perceptions [B-IPQ]) and the controllability of 
their asthma (locus of control beliefs [MHLCS]) were elicited. From these questionnaires, the 
necessity and concerns (BMQ) subscales, treatment control and understanding (B-IPQ) subscales 
and the doctor (MHLCS) subscale were all correlated with self-reported medication adherence 
(MARS score). This confirmed that exploring beliefs outside the Beliefs about Medicines Framework 
is important, as different kinds of beliefs were associated with medication adherence in the sample. 
In particular, there was a very strong relationship between the doctor (MHLCS) subscale and MARS 
score (r=0.41) in the sample compared to other beliefs elicited in this study (Section 4.7). The 
correlation between doctor (MHLCS) subscale and MARS score was also stronger than other 
correlates of adherence reported in the literature (e.g. [beliefs about medicines [necessity=0.17, 
concerns= -0.18],155 age [r=-0.04],299 objectively measured disease severity [r=0.00]298). The 
relationship between doctor locus of control beliefs and medication adherence is yet to be widely 
explored in the literature but may be another important facet of the doctor-patient that should be 
explored further in future studies investigating medication-taking behaviour.  
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To further explore the associations between beliefs and medication adherence and the relationships 
between beliefs, a multivariable regression model was developed and presented in Chapter 5. Eliciting 
beliefs using the BMQ, IPQ and MHLCS better predicted adherence as measured by MARS when 
compared to studies using the BMQ and IPQ168,185,322 or the BMQ and MHLCS.134 Our findings 
further support eliciting multiple beliefs to improve prediction of medication adherence as beliefs 
about medicines, illness perception and locus of control beliefs all made unique contributions to 
model prediction.  
Important interactions were identified between subscales from the BMQ, B-IPQ and MHLCS and 
with self-reported adherence. The interaction between the concerns (BMQ) subscale and the chance 
(MHLCS) subscale suggest that only in individuals with strong chance locus of control beliefs, were 
concerns significantly correlated to medication adherence. Conversely, in individuals who did not 
believe in chance to control their asthma, there was no significant relationship between concern 
beliefs and medication adherence. A second interaction between the understanding (B-IPQ) subscale 
and treatment control (B-IPQ) subscale suggests that only in individuals with poor understanding 
illness perceptions, were treatment control illness perceptions positively associated with medication 
adherence. These findings have not been reported in the literature previously and I suggest that by 
overlooking these interactions, researchers may be diluting the relationship between beliefs and 
medication adherence reflecting the small effect sizes often observed in the literature.  
These two interaction effects suggest that there are important differences in the way beliefs associate 
with medication adherence, which bivariate analyses are not able to detect. If these findings can be 
replicated in a larger asthma population, it suggests that the way in which beliefs relate to medication 
adherence is changed depending on the other beliefs individuals hold. The results of the multivariable 
model provide two testable hypotheses. These were that addressing concern beliefs in an individual 
is likely to be more effective if that individual also holds a strong chance locus of control belief and 
that addressing treatment control illness perceptions in an individual is likely to be more effective if 
that individual also has poor understanding illness perceptions. 
 Causal Interpretation of the Regression Model 
In Chapter 6 of the thesis I explored the degree to which the regression model could be given a causal 
interpretation. Despite strong evidence that beliefs are correlated to medication adherence across 
different chronic conditions, there is very little discussion on whether these relationships are expected 
to be causal. Because of a tendency in science towards making conservative claims, many researchers 
provide a regression model as a description of the data and leave any further interpretation up to the 
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reader. This makes it difficult to differentiate between variables that are hypothesised to have causal 
and non-causal associations with medication adherence. To be able to progress the adherence 
literature, it was important to explore the possible causal relationships in the data to be able to inform 
future interventions to support medication adherence.  
Using the theory from models of health behaviour, the available literature and the results of the 
regression model, I developed a diagram to describe the possible causal associations between beliefs 
and medication adherence in my sample. This preliminary work contributes to the literature by 
proposing several causal hypotheses, which can be tested.  
These were:  
1. Improving necessity beliefs and reducing concern beliefs about medicines will improve 
medication adherence. 
2. Improving treatment control illness perceptions will improve medication adherence in 
individuals with poor perceived understanding of their asthma. 
3. Improving doctor locus of control beliefs will improve medication adherence but may be 
difficult to change. 
4. There is overlap in the constructs measured by the BMQ, B-IPQ and MHLCS. 
 Future Direction 
 Testing the Causal Model 
Moving forward with this research, the next step is to formally test the causal hypotheses generated 
in Chapter 6. An established method of testing a proposed causal structure is to use Structural 
Equation Modelling (SEM). SEM is a type of multivariate modelling which allows researchers to 
simultaneously test multiple dependent and independent variables on one or more outcomes.345 Like 
any statistical method, SEM cannot confirm whether a causal relationship exists, but can describe 
whether the data follows the suggested structure. In the future, we aim to use a different sample of 
individuals with asthma to explore whether these hypotheses remain consistent across different 
individuals. In doing so, we aim to better understand the causal relationships to be able to better 
support individuals in the taking their medicines. 
 Potential Strategies to Change Beliefs in Individuals with Asthma 
Once the causal structure is better understood, the next step is to identify potential strategies to modify 
beliefs to be able to prove/disprove the hypothesised causal relationships.  
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One technique that has shown to modify the beliefs, attitudes and knowledge of individuals is 
motivational interviewing.346 When considering an adherence intervention, one approach would be 
to employ aspects of motivational interviewing into a discussion with an individual about their 
adherence. The principle of motivational interviewing is that behaviour change cannot occur if it is 
inconsistent with an individual’s own beliefs.346 Instead of instructing the individual that they must 
be adherent, those using motivational interviewing techniques explore the cause or reason behind 
holding certain beliefs associated with non-adherence.347 This has led to improved medication 
adherence in individuals with hypertension.348 
Other techniques that used similar approaches to motivational interviewing include health coaching 
and “adherence therapy”.235,349 All these techniques cannot be standardised. Rather, the content of 
each intervention would need to be tailored to the individual and their specific reasons for non-
adherence. For example, individual scores on the BMQ, B-IPQ and MHLCS can provide some broad 
insight in to the reasons for non-adherence, but the reason individuals hold these beliefs cannot be 
determined through these questionnaires alone. Only through further discussion around the answers 
to the statements, could you identify the underlying specific beliefs and tailor the discussion to 
explore and modify these beliefs. A recent randomised controlled trial in individuals with chronic 
conditions, used this tailored approach and was able to modify beliefs to improve adherence and 
maintain these changes for at least six months.350  
Developing an intervention that incorporates these aspects for non-adherent individuals with asthma, 
may be one method of changing beliefs to improve medication adherence.  
 Conclusion  
Beliefs about medicines, illness perceptions and locus of control beliefs elicited by the BMQ, B-IPQ 
and MHLCS, respectively, are all important beliefs to consider when understanding medication-
taking behaviour in individuals with asthma. This thesis contributes to the literature by determining 
the relationship between beliefs about medicines and medication adherence across multiple patient 
populations, describing the beliefs held by individuals with asthma, discovering a multivariable 
model to predict medication adherence and hypothesising the possible causal relationships among 
beliefs and medication adherence.  
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APPENDIX B: Participant Information, Consent Form and Survey for 
Community Pharmacy Participants 
Participant Information Sheet (V2 19/05/2014) 
 
Full Project Title: Exploring the relationship between health beliefs and medication adherence 
Lay Title: Exploring how people’s beliefs affect their medication taking behaviour 
 
Principal Researcher: Ms Holly Ross, PhD candidate, School of Pharmacy, The University 
of Queensland. 
Associate Researcher(s): Dr Neil Cottrell, Associate Professor, School of Pharmacy, The 
University of Queensland. 
Dr Adam La Caze, Lecturer, School of Pharmacy, The University of 
Queensland. 
Dr Gina Gujral, Lecturer, School of Pharmacy, The University of 
Queensland. 
Dr Peter Baker, Senior Lecturer, School of Population Health, The 
University of Queensland. 
 
This Participant Information and Consent Form are 4 pages long. Please make sure you have all the 
pages.  
 
1. Your Consent 
You are invited to participate in this research project because you are presenting a prescription for a 
medicine used to treat asthma.  
 
This Participant Information Sheet contains detailed information about the research project. Its 
purpose is to explain to you as openly and clearly as possible all the procedures involved in this 
project before you decide whether or not to take part in it.  
 
Please read this Participant Information carefully. Feel free to ask questions about any information in 
the document. You may also wish to discuss the project with a relative or friend or your local health 
worker. Feel free to do this. 
 
Participation in any research project is voluntary. If you do not wish to take part, you are not obliged 
to. Your decision whether to take part or not to take part, or to take part and then withdraw, will not 
affect your routine treatment or your relationship with the pharmacy staff who dispense your 
medicines.  
 
Once you understand what the project is about and if you agree to take part in it, you will be asked to 
sign the Consent Form. By signing the Consent Form, you indicate that you understand the 
information and that you give your consent to participate in the research project. 
 
You will be given a copy of the Participant Information and Consent Form to keep as a record. 
 
2. Purpose and Background 
The purpose of this project is to help understand the how people’s beliefs can influence how they take 
their medicines. A total of 500 people will participate in this project. 
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People with asthma often use an inhaled preventer for a long period of time. For a variety of reasons, 
people in this situation may choose not to take their medicine as recommended. One of the reasons 
people don’t take their medicines is related to how they view their illness and the beliefs they have 
towards the medicines they take. Research suggests that people who report positive views of their 
illness or hold beliefs in the necessity of their medicines are more likely to take their medicines. This 
project will use questionnaires to elicit a person’s health beliefs to see how this impacts on whether 
a person takes their medicines as agreed. We hope to better understand the choices people make about 
their medicines. 
  
The results of this research may be used to help the researcher, Holly Ross, to obtain a degree. Results 
of this research may also be published and presented at conferences and information will be reported 
in such a way that you cannot be identified.  
 
3. Procedures 
Participation in this project will involve completion of a survey that will last for about twenty to thirty 
minutes. The survey involves a number of statements on your views about medicines, asthma and 
your health. You will be asked to record your level of agreement or disagreement with each statement. 
There are no right or wrong answers to any of the questions in the interview; it is your view and 
opinion that is important. 
 
4. Possible Benefits and Risks 
Possible benefits of this project include a better understanding of how beliefs can affect medication 
adherence which may help develop strategies in the future to better help people to take their 
medicines. There may be no direct benefit to you from participating in the survey. 
The study involves completing a survey and there is no foreseeable added risk to you above the risks 
of everyday living. If, at any time during the survey, you are not sure or do not have any opinion on 
a question asked, feel free to leave it blank. This will not affect the outcome of the survey or project. 
 
5. Privacy, Confidentiality and Disclosure of Information 
All data collected in this study will be stored securely. No identifying information will be collected 
in this study which means your answers will not be able to be linked back to you.  
 
Access to data is important for checking and reproducing good science. Non-identifiable data from 
this research will be maintained and stored in accordance to a data management plan. Non-identifiable 
data will be available to the scientific community upon request and therefore may be reused in the 
future by a different researcher. 
 
6. Results of the Project 
You may request a report on the study when it is completed. If you wish to have a report, please 
provide an address that the report can be sent to. If you decide at a later date that you would like a 
report on the study, please contact Holly Ross at the above address. Your name and address will not 
be linked to your survey response. 
 
7. Reimbursement for your costs 
You will not be paid for your participation in this project.  
 
8. Further Information or Any Problems 
If you require further information or if you have any problems concerning this project, you can contact 
the researcher responsible for this project on:  
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Dr Neil Cottrell  Tel: 3346 1977 
 
This study has been cleared by one of the human ethics committees of the University of Queensland 
in accordance with the National Health and Medical Research Council's guidelines. If you would like 
to speak to an officer of the University not involved in the study, you may contact the Ethics Officer 
on 3365 3924.  
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Participant Consent Form 
 
Full Project Title: Exploring the relationship between health beliefs and medication adherence 
Lay Title: Exploring how people’s beliefs affect their medication taking behaviour 
 
Principal Researcher: Ms Holly Ross, PhD candidate, School of Pharmacy, The University 
of Queensland, QLD 4072 
Associate Researcher(s): Dr Neil Cottrell, Associate Professor, School of Pharmacy, The 
University of Queensland. 
Dr Adam La Caze, Lecturer, School of Pharmacy, The University of 
Queensland. 
Dr Gina Gujral, Lecturer, School of Pharmacy, The University of 
Queensland. 
Dr Peter Baker, Senior Lecturer, School of Population Health, The 
University of Queensland. 
 
 
I have read, and I understand the Participant Information version 2 dated 19/05/2014. 
I freely agree to participate in this project according to the conditions in the Participant Information.  
I will be given a copy of the Participant Information and Consent Form to keep.  
The researcher has agreed not to reveal my identity and personal details if information about this 
project is published or presented in any public form.  
I understand that I may withdraw from the study at anytime during the survey, with or without 
stating a reason, without penalty, and without affecting my relationship with the research team or 
the staff in the pharmacy. 
I understand that I may not benefit directly from participation in the survey. 
 
Participant’s Name (printed) …………………………………………………… 
Signature        Date 
 
 
Researcher’s Name (printed) …………………………………………………… 
Signature        Date 
 
 
Note: All parties signing the Consent Form must date their own signature. 
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1. Have you previously completed this survey online through the Asthma foundation’s website 
or social media sites? Yes/No 
If you answered yes to this question, unfortunately you are not eligible to participate in the 
study. 
2. What is your gender? 
 Male   Female 
3. In which year were you born? _______________ 
4. Highest formal education completed? 
 Grade 10  Grade 12  University  Further degree(s)  
 Other______________ 
5. a) How long have you been diagnosed with asthma for?  
________________________________________________________________________________
_____________________________________________________________________ 
b) What was your most recent peak flow meter measurement (if known)? 
________________________________________________________________________________
______________________________________________________________________ 
c) Have you been admitted to hospital in the last 2 years because of your asthma? If yes, how 
many times? 
________________________________________________________________________________
_____________________________________________________________________ 
 
6.a) Please list all your PREVENTATIVE asthma medications (e.g. Seretide, Symbicort, 
Flixotide) prescribed for asthma and tick how often you use the medication. 
Preventer name 
Frequency 
Once daily Twice daily 
More than 
twice daily 
When 
required 
Occasionally 
      
      
      
      
 
b) Please select the RELIEVER asthma medication(s) you are currently taking and how often, 
on average, you use your reliever asthma medication.  
Please leave blank if you do not use a reliever medication. 
Reliever name 
Frequency 
More than 3 
times per week 
3 times per 
week 
Less than 3 
times per week 
Never 
Salbutamol (Ventolin, 
Asmol, Airomir) 
    
Terbutaline (Bricanyl) 
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7. Do you have a concession or pensioner card for your medicines? 
 
Yes   No 
 
 
8. Please list any other medical condition(s) and length of time since diagnosis:  
 
Other medical conditions 
 
 
 
 
 
 
 
 
9. How many other regular medications (excluding your asthma medication) do you take? 
 
 
 
 
 
10. In general would you say your health is (please circle): 
Excellent Very Good Good Fair Poor 
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Many people find a way of using their medicines which suit them. 
 This may be different from the instructions on the label or from what their 
doctor has said. 
 We would like to ask you a few questions about how you use your medicines. 
 
 
 
 
 
For each statement please tick the box which best applies to you in regards to your 
preventative asthma medication. 
 
 Your own way of 
using your medicines 
Always Often Sometimes Rarely Never 
M1 I forget to take them      
M2 I alter the dose      
M3 I stop taking them for 
a while 
     
M4 I decide to miss a dose      
M5 I take less than 
instructed 
     
 
© Robert Horne 
(Developed by Professor Rob Horne in the School of Pharmacy at the University of Brighton, 
United Kingdom) 
 
 
  
QUESTIONS ABOUT USING YOUR MEDICINES 
Here are some ways in which people have said that they use their 
medicines 
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Your views about your prescribed asthma preventer medication 
 We would like to ask you abou your personal views about your asthma and medicines 
prescribed for you 
 These are statements other people have made about their medicines  
 Please indicate the extent to which you agree or disagree with them by ticking the 
appropriate box  
 There are no right or wrong answers. We are interested in your personal views 
 
  
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
My health, at present, depends on 
my medicines 
     
Having to take asthma medication 
worries me 
     
My life would be impossible 
without my asthma medication 
     
Without my asthma medication I 
would be very ill 
     
I sometimes worry about the long 
term effects of my asthma 
medication 
     
My asthma medication is a mystery 
to me 
     
My health in the future will depend 
on my asthma medication 
     
My asthma medication disrupts my 
life 
     
I sometimes worry about becoming 
too dependent on my asthma 
medication 
     
My asthma medication protects me 
from becoming worse. 
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Each item below is a belief statement about your asthma with which you may agree or disagree. For 
each item we would like you to tick the box that represents the extent to which you agree or 
disagree with that statement. This is a measure of your personal beliefs; obviously, there are no 
right or wrong answers. 
  
 Strongly 
agree 
Moderately 
agree 
Agree Disagree Moderately 
disagree 
Strongly 
disagree 
If my asthma worsens, it is my own behaviour 
which determines how soon I will feel better 
again. 
      
As to my asthma, what will be will be.       
If I see my doctor regularly, I am less likely to 
have problems with my asthma. 
      
Most things that affect my asthma happen to 
me by chance. 
      
Whenever my asthma worsens, I should 
consult a medically trained professional. 
      
I am directly responsible for my asthma 
getting better or worse. 
      
Other people play a big role in whether my 
asthma improves, stays the same, or gets 
worse. 
      
Whatever goes wrong with my asthma is my 
own fault. 
      
Luck plays a big part in determining how my 
asthma improves. 
      
In order for my asthma to improve, it is up to 
other people to see that the right things 
happen. 
      
Whatever improvement occurs with my 
asthma is largely a matter of good fortune. 
      
The main thing which affects my asthma is 
what I myself do. 
      
I deserve the credit when my asthma improves 
and the blame when it gets worse. 
      
Following doctor's orders to the letter is the 
best way to keep my asthma from getting any 
worse. 
      
If my asthma worsens, it's a matter of fate.       
If I am lucky, my asthma will get better.       
If my asthma takes a turn for the worse, it is 
because I have not been taking proper care of 
myself. 
      
The type of help I receive from other people 
determines how soon my condition improves. 
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Please choose only one of the items below that best describes how you use your preventative asthma 
medication now. 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this survey 
 
QUESTIONS ABOUT USING YOUR MEDICINES 
 I have not been taking my asthma medication as prescribed in the past month, and 
do not intend to do so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but am 
thinking about doing so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but 
plan do so in the next month. 
 I am taking my medication as prescribed. 
 I have been taking my asthma medication as prescribed in the past month, and plan 
to continue doing so in the next month.  
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APPENDIX C: Participant Information, Consent Form and Study Survey for 
Online Participants 
Thank you for taking the time to complete our survey. Please read the following information 
about the study before continuing. 
 
Full Project Title: Exploring the relationship between health beliefs and medication adherence 
Lay Title: Exploring how people’s beliefs affect their medication taking behaviour 
Principal Researcher: Ms Holly Ross, PhD candidate, School of Pharmacy, The University of 
Queensland. 
Associate Researchers: Dr Neil Cottrell, Associate Professor, School of Pharmacy, The University 
of Queensland. 
Dr Adam La Caze, Lecturer, School of Pharmacy, The University of Queensland. 
Dr Gina Gujral, Lecturer, School of Pharmacy, The University of Queensland. 
Dr Peter Baker, Senior Lecturer, School of Population Health, The University of Queensland. 
 
Your Consent 
You are invited to participate in this research project because you are a member of the asthma 
foundation. This Participant Information form contains detailed information about the research 
project. Its purpose is to explain to you as openly and clearly as possible all the procedures involved 
in this project before you decide whether or not to take part in it. Please read this Participant 
Information carefully. Feel free to discuss the project with a relative or friend or your local health 
worker. Participation in any research project is voluntary. If you do not wish to take part, you are not 
obliged to. Your decision whether to take part or not to take part, or to take part and then withdraw, 
will not affect your routine treatment or your relationship with the Asthma Foundation. Once you 
understand what the project is about and if you agree to take part in it, you will be asked to agree to 
an online Consent Form. By agreeing to the Consent Form, you indicate that you understand the 
information and that you give your consent to participate in the research project. 
 
Purpose and Background 
The purpose of this project is to help understand the how people’s beliefs can influence how they take 
their medicines. A total of 500 people will participate in this project. People with asthma often use 
an inhaled preventer for a long period of time. For a variety of reasons, people in this situation may 
choose not to take their medicine as recommended. One of the reasons people don’t take their 
medicines is related to how they view their illness and the beliefs they have towards the medicines 
they take. Research suggests that people who report positive views of their illness or hold beliefs in 
the necessity of their medicines are more likely to take their medicines. This project will use 
questionnaires to elicit a person’s health beliefs to see how this impacts on whether a person takes 
their medicines as agreed. We hope to better understand the choices people make about their 
medicines. The results of this research may be used to help the researcher, Holly Ross, to obtain a 
degree. Results of this research may also be published and presented at conferences and information 
will be reported in such a way that you cannot be identified. 
 
Procedures 
Participation in this project will involve completion of a survey that will last for about twenty to thirty 
minutes. The survey involves a number of statements on your views about medicines, asthma and 
your health. You will be asked to record your level of agreement or disagreement with each statement. 
There are no right or wrong answers to any of the questions in the survey; it is your view and opinion 
that is important. If you prefer you can have the survey posted out to you and returned to the 
researcher’s address once completed. If you would prefer this, please email Holly at 
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h.ross1@uq.edu.au with your name and postal address. Your name and address will not be linked to 
your survey response. 
 
Possible Benefits and Risks 
Possible benefits of this project include a better understanding of how beliefs can affect medication 
adherence which may help develop strategies in the future to better help people to take their 
medicines. There may be no direct benefit to you from participating in the survey. The study involves 
completing a survey and there is no foreseeable added risk to you above the risks of everyday living. 
If, at any time during the survey, you are not sure or do not have any opinion on a question asked, 
feel free to leave it blank. This will not affect the outcome of the survey or project. 
 
Privacy, Confidentiality and Disclosure of Information 
All data collected in this study will be stored securely. No identifying information will be collected 
in this study which means your answers will not be able to be linked back to you. Access to data is 
important for checking and reproducing good science. Non-identifiable data from this research will 
be maintained and stored in accordance to a data management plan. Non-identifiable data will be 
available to the scientific community upon request and therefore may be reused in the future by a 
different researcher. 
 
Results of the Project 
You may request a report on the study when it is completed. If you wish to have a report, please send 
a request to the email address provided at the end of the survey and provide a postal address that the 
report can be sent to. If you decide at a later date that you would like a report on the study, please 
contact Holly Ross at the above address. Your name and address will not be linked to your survey 
response. 
 
Reimbursement for your costs 
You will not be paid for your participation in this project. 
 
Further Information or Any Problems 
If you require further information or if you have any problems concerning this project, you can contact 
the researcher responsible for this project on: 
Dr Neil Cottrell Tel: (07) 3346 1977 
 
This study has been cleared by one of the human ethics committees of the University of Queensland 
in accordance with the National Health and Medical Research Council's guidelines. If you would like 
to speak to an officer of the University not involved in the study, you may contact the Ethics Officer 
on 3365 3924. 
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* I have read, and I understand the Participant Information above. I freely agree to participate 
in this project according to the conditions in the Participant Information. 
 
The researcher has agreed not to reveal my identity and personal details if information about 
this project is published or presented in any public form. 
 
I understand that I may withdraw from the study at any time during the survey, with or without 
stating a reason, without penalty, and without affecting my relationship with the research team 
or the Asthma Foundation. 
 
I understand that I may not benefit directly from participation in the survey. 
 
□ I agree to participate in this study 
□ I do not wish to participate in this study 
 
*To be included in the study you must be: 
 
1. 16 years or older 
2. Prescribed an inhaled preventative asthma medication (e.g. Seretide, Symbicort, Flixotide,  
Alvesco, Pulmicort) for at least 3 months and; 
3. Be responsible for your own medicines 
 
Do all THREE of these apply to you? 
□ Yes 
□ No 
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1. Have you previously completed this survey at a Brisbane community pharmacy? 
If you answered yes to this question, unfortunately you are not eligible to participate in the 
study. 
2. What is your gender? 
 Male   Female 
3. In which year were you born? _______________ 
 
4. What state or territory are you currently living in? 
 QLD  NSW  VIC  TAS  N.T  S.A  W.A 
5. Highest formal education completed? 
 Grade 10  Grade 12  University  Further degree(s)  
 Other______________ 
 
6. a) How long have you been diagnosed with asthma for?  
________________________________________________________________________________
_____________________________________________________________________ 
b) What was your most recent peak flow meter measurement (if known)? 
________________________________________________________________________________
______________________________________________________________________ 
c) Have you been admitted to hospital in the last 2 years because of your asthma? If yes, how 
many times? 
________________________________________________________________________________
_____________________________________________________________________ 
 
7.a) Please select the preventative asthma medication(s) you are currently taking and how 
often you take this medication(s)?. 
Preventer name 
Frequency 
Once daily Twice daily 
More than 
twice daily 
When 
required 
Occasionally 
Seretide      
Flixotide      
Symbicort      
Serevent      
Qvar      
Pulmicort      
Alvesco      
Flutiform      
Other      
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b) Please select the RELIEVER asthma medication(s) you are currently taking and how often, 
on average, you use your reliever asthma medication.  
Please leave blank if you do not use a reliever medication. 
Reliever name 
Frequency 
More than 3 
times per week 
3 times per 
week 
Less than 3 
times per week 
Never 
Salbutamol (Ventolin, 
Asmol, Airomir) 
    
Terbutaline (Bricanyl) 
    
 
 
8. Do you have a concession or pensioner card for your medicines? 
 
Yes   No 
 
 
9. Please select any other medical conditions you have been diagnosed with:  
 
Other medical conditions 
Diabetes 
High Blood Pressure 
High Cholesterol 
Heart Disease 
Depression 
COPD 
Cancer 
Arthritis 
Reflux/Indigestion/Heartburn  
Other (please state): 
 
10. How many other regular medications (excluding your asthma medication) do you take? 
 
 
 
 
 
11. In general would you say your health is (please circle): 
Excellent Very Good Good Fair Poor 
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Many people find a way of using their medicines which suit them. 
 This may be different from the instructions on the label or from what their 
doctor has said. 
 We would like to ask you a few questions about how you use your medicines. 
For each statement please tick the box which best applies to you in regards to your 
preventative asthma medication. 
 
 Your own way of 
using your medicines 
Always Often Sometimes Rarely Never 
M1 I forget to take them      
M2 I alter the dose      
M3 I stop taking them for 
a while 
     
M4 I decide to miss a dose      
M5 I take less than 
instructed 
     
 
© Robert Horne 
(Developed by Professor Rob Horne in the School of Pharmacy at the University of Brighton, 
United Kingdom) 
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Your views about your prescribed asthma preventer medication 
 We would like to ask you abou your personal views about your asthma and medicines 
prescribed for you 
 These are statements other people have made about their medicines  
 Please indicate the extent to which you agree or disagree with them by ticking the 
appropriate box  
 There are no right or wrong answers. We are interested in your personal views 
 
  
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
My health, at present, depends on 
my medicines 
     
Having to take asthma medication 
worries me 
     
My life would be impossible 
without my asthma medication 
     
Without my asthma medication I 
would be very ill 
     
I sometimes worry about the long 
term effects of my asthma 
medication 
     
My asthma medication is a mystery 
to me 
     
My health in the future will depend 
on my asthma medication 
     
My asthma medication disrupts my 
life 
     
I sometimes worry about becoming 
too dependent on my asthma 
medication 
     
My asthma medication protects me 
from becoming worse. 
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Each item below is a belief statement about your asthma with which you may agree or disagree. For 
each item we would like you to tick the box that represents the extent to which you agree or 
disagree with that statement. This is a measure of your personal beliefs; obviously, there are no 
right or wrong answers. 
  
 Strongly 
agree 
Moderately 
agree 
Agree Disagree Moderately 
disagree 
Strongly 
disagree 
If my asthma worsens, it is my own behaviour 
which determines how soon I will feel better 
again. 
      
As to my asthma, what will be will be.       
If I see my doctor regularly, I am less likely to 
have problems with my asthma. 
      
Most things that affect my asthma happen to 
me by chance. 
      
Whenever my asthma worsens, I should 
consult a medically trained professional. 
      
I am directly responsible for my asthma 
getting better or worse. 
      
Other people play a big role in whether my 
asthma improves, stays the same, or gets 
worse. 
      
Whatever goes wrong with my asthma is my 
own fault. 
      
Luck plays a big part in determining how my 
asthma improves. 
      
In order for my asthma to improve, it is up to 
other people to see that the right things 
happen. 
      
Whatever improvement occurs with my 
asthma is largely a matter of good fortune. 
      
The main thing which affects my asthma is 
what I myself do. 
      
I deserve the credit when my asthma improves 
and the blame when it gets worse. 
      
Following doctor's orders to the letter is the 
best way to keep my asthma from getting any 
worse. 
      
If my asthma worsens, it's a matter of fate.       
If I am lucky, my asthma will get better.       
If my asthma takes a turn for the worse, it is 
because I have not been taking proper care of 
myself. 
      
The type of help I receive from other people 
determines how soon my condition improves. 
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Asthma Readiness to Change Questionnaire 
Please choose only one of the items below that best describes how you use your preventative asthma 
medication now. 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this survey 
 
  
 I have not been taking my asthma medication as prescribed in the past month, and 
do not intend to do so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but am 
thinking about doing so in the next month. 
 I have not been taking my asthma medication as prescribed in the past month, but 
plan do so in the next month. 
 I am taking my medication as prescribed. 
 I have been taking my asthma medication as prescribed in the past month, and plan 
to continue doing so in the next month.  
 
Here are some ways in which people have said that they use their 
medicines 
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